[
  {
    "id": 1,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "mhGAP Intervention Guide\nfor mental, neurological and substance use disorders\nin non-specialized health settings\nVersion 2.0\nMental Health Gap Action Programme\n\nWHO Library Cataloguing-in-Publication Data The mention of specific companies or of certain manufacturers’\nproducts does not imply that they are endorsed or recommended\nmhGAP intervention guide for mental, neurological and sub- by the World Health Organization in preference to others of\nstance use disorders in non-specialized health settings: mental a similar nature that are not mentioned. Errors and omissions\nhealth Gap Action Programme (mhGAP) – version 2.0. excepted, the names of proprietary products are distinguished by\ninitial capital letters. 1.Mental Disorders - prevention and control. 2.Nervous System\nDiseases."
  },
  {
    "id": 2,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ction Programme (mhGAP) – version 2.0. excepted, the names of proprietary products are distinguished by\ninitial capital letters. 1.Mental Disorders - prevention and control. 2.Nervous System\nDiseases. 3.Psychotic Disorders. 4.Substance-Related Disorders. All reasonable precautions have been taken by the World\n5.Guideline. I.World Health Organization. Health Organization to verify the information contained in this\npublication. However, the published material is being distributed\nISBN 978 92 4 154979 0 (NLM classification: WM 140) without warranty of any kind, either expressed or implied. The\nresponsibility for the interpretation and use of the material lies\nwith the reader."
  },
  {
    "id": 3,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "d\nISBN 978 92 4 154979 0 (NLM classification: WM 140) without warranty of any kind, either expressed or implied. The\nresponsibility for the interpretation and use of the material lies\nwith the reader. In no event shall the World Health Organization\n© World Health Organization 2016 be liable for damages arising from its use. All rights reserved. Publications of the World Health Organization Printed in Italy\nare available on the WHO website (http://www.who.int) or can\nbe purchased from WHO Press, World Health Organization, 20\nAvenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791\n3264; fax: +41 22 791 4857; email: bookorders@who.int)."
  },
  {
    "id": 4,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ttp://www.who.int) or can\nbe purchased from WHO Press, World Health Organization, 20\nAvenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791\n3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO\npublications –whether for sale or for non-commercial\ndistribution– should be addressed to WHO Press through the\nWHO website (http://www.who.int/about/licensing/copyright_\nform/index.html). The designations employed and the presentation of the material\nin this publication do not imply the expression of any opinion\nwhatsoever on the part of the World Health Organization\nconcerning the legal status of any country, territory, city or area\nor of its authorities, or concerning the delimitation of its frontiers\nor boundaries."
  },
  {
    "id": 5,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "r on the part of the World Health Organization\nconcerning the legal status of any country, territory, city or area\nor of its authorities, or concerning the delimitation of its frontiers\nor boundaries. Dotted and dashed lines on maps represent\napproximate border lines for which there may not yet be full\nagreement."
  },
  {
    "id": 6,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "or of its authorities, or concerning the delimitation of its frontiers\nor boundaries. Dotted and dashed lines on maps represent\napproximate border lines for which there may not yet be full\nagreement. wire possition\n\nmhGAP Intervention Guide\nfor mental, neurological and substance use disorders\nin non-specialized health settings\nVersion 2.0\nMental Health Gap Action Programme\n\nii\nmhGAP-IG 2.0 Table of Contents\nPreface iii ECP Essential Care & Practice 5\nAcknowledgements iv MC Master Chart 16\nIntroduction 1 DEP Depression 19\nHow to use the mhGAP-IG Version 2.0 3\nPSY Psychoses 33\nEPI Epilepsy 51\nCMH Child & Adolescent Mental & Behavioural Disorders 69\nDEM Dementia 93\nSUB Disorders due to Substance Use 105\nSUI Self-harm / Suicide 131\nOTH Other Significant Mental Health Complaints 141\nImplementation of mhGAP-IG 151\nGlossary 159\n\nmhGAP-IG 2.0 Preface\nMental, neurological and substance use (MNS) disorders are highly prevalent, interventions in non-specialized health-care settings."
  },
  {
    "id": 7,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "41\nImplementation of mhGAP-IG 151\nGlossary 159\n\nmhGAP-IG 2.0 Preface\nMental, neurological and substance use (MNS) disorders are highly prevalent, interventions in non-specialized health-care settings. Since its release in 2010, mhGAP-IG\naccounting for a large burden of disease and disability globally. There remains a has been widely used by a range of stakeholders including ministries of health, academic\nwide gap between available health systems capacity and resources, what is urgently institutions, NGOs and other philanthropic foundations and researchers to scale-up\nneeded, and what is available to reduce the burden. Nearly 1 in 10 people have a mental health services."
  },
  {
    "id": 8,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "is urgently institutions, NGOs and other philanthropic foundations and researchers to scale-up\nneeded, and what is available to reduce the burden. Nearly 1 in 10 people have a mental health services. mhGAP-IG Version 1.0 is being used in more than 90 countries in\nmental health disorder, but only 1% of the global health workforce provides mental all WHO regions and mhGAP materials were translated into more than 20 languages,\nhealth care. MNS disorders interfere, in substantial ways, with the ability of children to including the six UN official languages. learn and the ability of adults to function in families, at work, and in society at large."
  },
  {
    "id": 9,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ders interfere, in substantial ways, with the ability of children to including the six UN official languages. learn and the ability of adults to function in families, at work, and in society at large. Five years after the initial launch of the guide, updates to the mhGAP guidelines\nRecognizing the imperative to provide services for people with MNS disorders and their based on emerging literature was performed and revised mhGAP guidelines were\ncarers, and to bridge the gap between available resources and the large need for these published in 2015."
  },
  {
    "id": 10,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "sorders and their based on emerging literature was performed and revised mhGAP guidelines were\ncarers, and to bridge the gap between available resources and the large need for these published in 2015. We are now pleased to present mhGAP-IG Version 2.0 which not only\nservices, the WHO Department of Mental Health and Substance Abuse launched the reflects these updates but also extensive feedback from the field to enhance the guide\nMental Health Gap Action Programme (mhGAP) in 2008. The key objectives of mhGAP in its clarity and usability."
  },
  {
    "id": 11,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "the reflects these updates but also extensive feedback from the field to enhance the guide\nMental Health Gap Action Programme (mhGAP) in 2008. The key objectives of mhGAP in its clarity and usability. are to reinforce the commitment of governments, international organizations and other\nstakeholders to increase the allocation of financial and human resources for care It is our hope that this guide will continue to be a key technical tool to deliver\nof MNS disorders and to achieve much higher coverage with key interventions in low- care for people with MNS disorders around the world and lead us closer to achieving\nand middle-income countries. Through these objectives, mhGAP provides evidence-based the goal of Universal Health Coverage."
  },
  {
    "id": 12,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "r people with MNS disorders around the world and lead us closer to achieving\nand middle-income countries. Through these objectives, mhGAP provides evidence-based the goal of Universal Health Coverage. guidance and tools to advance toward achieving the targets of the Comprehensive\nMental Health Action Plan 2013-2020. Shekhar Saxena\nIn 2010, the mhGAP Intervention Guide (mhGAP-IG) for MNS disorders for non- Director, Department of Mental Health and Substance Abuse\nspecialized health settings was developed to assist in implementation of mhGAP. A World Health Organization\nsimple technical tool based on the mhGAP guidelines, mhGAP-IG presents integrated\nmanagement of priority MNS conditions using protocols for clinical decision-making."
  },
  {
    "id": 13,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "mhGAP. A World Health Organization\nsimple technical tool based on the mhGAP guidelines, mhGAP-IG presents integrated\nmanagement of priority MNS conditions using protocols for clinical decision-making. There is a widely shared but false notion that all mental health interventions are complex\nand can only be delivered by highly specialized staff."
  },
  {
    "id": 14,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nditions using protocols for clinical decision-making. There is a widely shared but false notion that all mental health interventions are complex\nand can only be delivered by highly specialized staff. Research in recent years has\ndemonstrated the feasibility of delivery of pharmacological and psychosocial\niii\n\niv\nmhGAP-IG 2.0 Acknowledgements\nVision and Conceptualization WHO Regional and Country Offices Technical Reviewers\nNazneen Anwar, Regional Office for South East Asia; Inputs and feedback were received from the following\nShekhar Saxena, Director, Department of Mental Health Florence Baingana, WHO Sierra Leone; Andrea Bruni, Regional international experts for the development of updated mhGAP\nand Substance Abuse, WHO."
  },
  {
    "id": 15,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "g\nShekhar Saxena, Director, Department of Mental Health Florence Baingana, WHO Sierra Leone; Andrea Bruni, Regional international experts for the development of updated mhGAP\nand Substance Abuse, WHO. Office for Americas; Anderson Chimusoro, WHO Zimbabwe; Guidelines and/or mhGAP-IG Version 2.0."
  },
  {
    "id": 16,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "drea Bruni, Regional international experts for the development of updated mhGAP\nand Substance Abuse, WHO. Office for Americas; Anderson Chimusoro, WHO Zimbabwe; Guidelines and/or mhGAP-IG Version 2.0. Manuel de Lara, WHO Turkey; Bahtygul Karriyeva, WHO\nTurkmenistan; R Kesavan, WHO Liberia; Devora Kestel, Regional\nAlbert Akpalu, College of Health Sciences, University of Ghana\nOffice for Americas; Lars Foddgard Moller, Regional Office for\nProject Coordination and Editing and Epilepsy Society of Ghana, Ghana; Sophia Achab*, WHO\nEurope; Maristela Goldnadel Monteiro, Regional Office for\nCollaborating Centre, University of Geneva/Hôpitaux Universitaires\nAmericas; Matthijs Muijen, Regional Office for Europe; Julius\nde Genève (HUG), Geneva, Switzerland; Emiliano Albanese*,\nTarun Dua, Nicolas Clark, Neerja Chowdhary, Alexandra Muron, WHO Liberia; Sebastiana Da Gama Nkomo, Regional\nWHO Collaborating Centre, University of Geneva/HUG, Geneva,\nFleischmann, Fahmy Hanna, Chiara Servili, Mark van Ommeren."
  },
  {
    "id": 17,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "erja Chowdhary, Alexandra Muron, WHO Liberia; Sebastiana Da Gama Nkomo, Regional\nWHO Collaborating Centre, University of Geneva/HUG, Geneva,\nFleischmann, Fahmy Hanna, Chiara Servili, Mark van Ommeren. Office for Africa; Jorge Jacinto Rodriguez, Regional Office for\nAmericas; Khalid Saeed, Regional Office for Eastern Mediterranean; Switzerland; Robert Ali*, Drug and Alcohol Services South Australia\nCaroline Saye, WHO Liberia; Yutaro Setoya, WHO Fiji; Xiao (DASSA), WHO Collaborating Centre for the Treatment of Drug and\nSobel, Regional Office for Western Pacific; Saydah Taylor, Alcohol Problems, University of Adelaide, Australia; Fredrick Altice,\nContribution\nWHO Liberia; Salma Tlili, WHO Guinea; Xiangdong Wang, Yale University School of Medicine and School of Public Health,\nRegional Office for Western Pacific; Eyad Yanes, WHO Syria."
  },
  {
    "id": 18,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "k Altice,\nContribution\nWHO Liberia; Salma Tlili, WHO Guinea; Xiangdong Wang, Yale University School of Medicine and School of Public Health,\nRegional Office for Western Pacific; Eyad Yanes, WHO Syria. New Haven, USA; José Ayuso-Mateos, Universidad Autonoma de\nValuable material, help and advice was received from technical\nMadrid and CIBER, Spain; Corrado Barbui*, WHO Collaborating\nstaff at WHO headquarters, staff from WHO regional and country\nKey International Experts\nCentre for Research and Training in Mental Health and Service\noffices and many international experts."
  },
  {
    "id": 19,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "aborating\nstaff at WHO headquarters, staff from WHO regional and country\nKey International Experts\nCentre for Research and Training in Mental Health and Service\noffices and many international experts. These contributions have\nLindsey America-Simms, Kenneth Carswell, Elizabeth Centeno-\nEvaluation, University of Verona, Italy; Gretchen Birbeck, Michigan\nbeen vital to the update of mhGAP Guidelines and/or develop-\nTablante, Melissa Harper, Sutapa Howlader, Kavitha Kolappa,\nment of the mhGAP-IG Version 2.0. State University, Michigan, USA; Anja Busse, United Nations Office\nLaura Pacione, Archana A. Patel, Allie Sharma, Marieke van\non Drugs and Crime, Vienna, Austria; Vladimir Carli*, National\nRegteren Altena."
  },
  {
    "id": 20,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "University, Michigan, USA; Anja Busse, United Nations Office\nLaura Pacione, Archana A. Patel, Allie Sharma, Marieke van\non Drugs and Crime, Vienna, Austria; Vladimir Carli*, National\nRegteren Altena. WHO Headquarters Centre for Suicide Research and Prevention of Mental Ill-Health\nValentina Baltag, John Beard, Alexander Butchart, Dan Chisholm, Administrative Support (NASP), Karolinska Institute, Stockholm, Sweden; Sudipto Chatterjee*,\nNathalie Drew, Jane Ferguson, Berit Kieselbach, Nicola Magrini, Adeline Loo, Cecilia Ophelia Riano."
  },
  {
    "id": 21,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "isholm, Administrative Support (NASP), Karolinska Institute, Stockholm, Sweden; Sudipto Chatterjee*,\nNathalie Drew, Jane Ferguson, Berit Kieselbach, Nicola Magrini, Adeline Loo, Cecilia Ophelia Riano. Parivartan Trust and Sangath, India; Dixon Chibanda, University\nChris Mikton, Eyerusalem Kebede Negussie, Alana Officer, of Zimbabwe, Friendship Bench Project, Harare, Zimbabwe;\nAnne Margriet Pot, Vladimir Poznyak, Geoffrey Reed, Dag Rekve, Interns Janice Cooper, Carter Center, Liberia; Wihelmus (Pim) Cuijpers*,\nDavid Ross, Jotheeswaran Amuthavalli Thiyagarajan, Farnoosh Ali, Lakshmi Chandrasekaran, Paul Christiansen, Vrije University, Amsterdam, Netherlands; Gauri Divan, Sangath,\nWilson Were."
  },
  {
    "id": 22,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Pim) Cuijpers*,\nDavid Ross, Jotheeswaran Amuthavalli Thiyagarajan, Farnoosh Ali, Lakshmi Chandrasekaran, Paul Christiansen, Vrije University, Amsterdam, Netherlands; Gauri Divan, Sangath,\nWilson Were. Anais Collin, Aislinne Freeman, Anna Fruehauf, Ali Haidar, Goa, India; Christopher Dowrick*, Institute of Psychology,\nHuw Jarvis, Steven Ma, Emma Mew, Elise Paul, Charlotte Phillips, Health and Society, University of Liverpool, Liverpool, UK; Joshua\nPooja Pradeeb, Matthew Schreiber."
  },
  {
    "id": 23,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Dowrick*, Institute of Psychology,\nHuw Jarvis, Steven Ma, Emma Mew, Elise Paul, Charlotte Phillips, Health and Society, University of Liverpool, Liverpool, UK; Joshua\nPooja Pradeeb, Matthew Schreiber. Duncan, Building Back better Project, CBM, Sierra Leone; Julian\nEaton*, CBM International, Togo and London School of Hygiene\nand Tropical Medicine, UK; Rabih El Chammay, Ministry of Health,\n\nBeirut, Lebanon; Peter Hughes, Institute of Psychiatry Psychology of Medical Sciences, New Delhi, India; Vandad Sharifi Senejani, Jordan; Raul Ayala, Mexico; Namsenmoh Aymar, Central African\nand Neuroscience King’s College, London, UK; Asma Humayun*, Tehran University of Medical Sciences, Tehran, Islamic Republic of Republic; Madhur Basnet, Nepal; Gertrude Bayona, Uganda; Rose\nMeditrina Health Care, Islamabad, Pakistan; Gabriel Ivbijaro*, Iran; Kolou Simliwa Dassa*, Ministry of Health, Lome, Togo; Leslie Beaugrand, Sierra Leone; Tadu Bezu, Ethiopia; Gaurav Bhattarai,\nWood Street Medical Centre, London, UK; Nathalie Jette*, Snider, Peace in Practice, Amsterdam, Netherlands; Chhit Sophal, Nepal; Jihane Bou Sleiman, Lebanon; Brian Byekwaso, Uganda;\nHotchkiss Brain Institute and O’Brien Institute for Public Health, Ministry of Health, Cambodia; Jessica Maria-Violanda Spagnolo, Jules Claude Casumba, South Sudan; Alice Clement, Nigeria;\nUniversity of Calgary, Canada; Lynne Jones, National Health School of Public Health, University of Montreal, Montreal, Canada; Gretel Acevedo de Pinzon, Panama; Barkon Dwah, Liberia;\nService, UK; Marc Laporta, Department of Psychiatry, McGill Emmanuel Streel, Public Mental Health and Substance Use Mufumba Emmanuel, Uganda; Olivia Gabula, Uganda; Kamal\nMontreal, WHO PAHO Collaborating Center for Research and Consultant, Belgium; Scott Stroup, Columbia University College of Gautam, Nepal; Renee Gerritzen, Nepal; Shree Ram Ghimire,\nDouglas Mental Health University Institute, Montreal, Canada; Physicians and Surgeons, New York State Psychiatric Institute, New Nepal; Sudip Ghimre, Nepal; Ijeh Ter Godwin, Nigeria; Kebeh\nAnita Marini, Cittadinanza NGO, Rimini, Italy; Farrah Mateen, York, USA; Athula Sumathipala, Keele University, UK; Kiran Thakur, Selma Gorpudolo, Liberia; Teen K."
  },
  {
    "id": 24,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "epal; Ijeh Ter Godwin, Nigeria; Kebeh\nAnita Marini, Cittadinanza NGO, Rimini, Italy; Farrah Mateen, York, USA; Athula Sumathipala, Keele University, UK; Kiran Thakur, Selma Gorpudolo, Liberia; Teen K. Grace, Nigeria; Georgina\nMassachusetts General Hospital, Harvard Medical School, USA; Johns Hopkins Hospital, Baltimore, USA; Rangaswamy Thara, Grundy-Campbell, UK and Turkey; Esubalew Haile, South Sudan;\nZhao Min, Shanghai* Drug Abuse Treatment Centre, Shanghai Schizophrenia Research Foundation, India; Graham Thornicroft* Tayseer Hassoon, Syria; Mahmoud Hegazy, Turkey; Zeinab Hijazi,\nJiaotong University School of Medicine, Shanghai, China; Charles Institute of Psychiatry, Psychology and Neuroscience, King’s Lebanon; Fred Kangawo, Uganda; Sylvester Katontoka, Zambia;\nNewton*, Kenya Medical Research Institute, Kilifi, Kenya; Olayinka College London, UK; Mark Tomlinson, Stellenbosch University, Fred Kiyuba, Uganda; Humphrey Kofie, Ghana; Moussa Kolie,\nOmigbodun*, Centre for Child and Adolescent Mental Health South Africa; Nyan Tun, Yangon General Hospital, Myanmar; Guinea; Samer Laila, Turkey; Richard Luvaluka, Uganda; Paul\n(CCAMH), University College Hospital, Ibadan, Nigeria; Akwasi Carmen Valle, CBM, Freetown, Sierra Leone; Pieter Ventevogel, Lwevola, Uganda; Scovia Makoma, Uganda; João Marçal-Grilo,\nOsei*, Ministry of Health, Accra, Ghana; Amrita Parekh, Dasra, United Nations High Commissioner for Refugees, Geneva, UK; Soo Cecilia Mbaidoove, Nigeria; Colette McInerney, Laos;\nMumbai, India; Alfredo Pemjean*, Departamento de Salud Mental, Switzerland; Inka Weissbecker*, International Medical Corps, Saeed Nadia, UK; Ruth Nakachwa, Uganda; Juliet Namuganza,\nMinisterio de Salud, Santiago, Chile; Hemamali Perera, Faculty of Washington, USA; Mohammad Taghi Yasamy, Geneva, Switzerland; Uganda; Emily Namulondo, Uganda; Margaret Namusobya,\nMedicine, University of Colombo, Sri Lanka; Michael Phillips, Lakshmi Vijayakumar*, SNEHA, Suicide Prevention Centre, Chennai, Uganda; Amada N."
  },
  {
    "id": 25,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nd; Uganda; Emily Namulondo, Uganda; Margaret Namusobya,\nMedicine, University of Colombo, Sri Lanka; Michael Phillips, Lakshmi Vijayakumar*, SNEHA, Suicide Prevention Centre, Chennai, Uganda; Amada N. Ndorbor, Liberia; Sheila Ndyanabangi, Uganda;\nSuicide Research and Prevention Center and Research Methods India; Abe Wassie, Department of Psychiatry, Faculty of Medicine Joel Ngbede, Nigeria; Fred Nkotami, Uganda; Zacharia Nongo,\nConsulting Center, Shanghai Mental Health Center, Shanghai Addis Ababa University and Amanuel Hospital, Ethiopia."
  },
  {
    "id": 26,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "iatry, Faculty of Medicine Joel Ngbede, Nigeria; Fred Nkotami, Uganda; Zacharia Nongo,\nConsulting Center, Shanghai Mental Health Center, Shanghai Addis Ababa University and Amanuel Hospital, Ethiopia. Nigeria; Emeka Nwefoh, Nigeria; Philip Ode, Nigeria; Mary Ogezi,\nJiaotong University School of Medicine and WHO Collaborating Nigeria; Martha Okpoto, Nigeria; Sagun Ballav Pant, Nepal;\nCenter for Research and Training in Suicide Prevention, Beijing * mhGAP Guideline Update Development Group Members Monica Peverga, Nigeria; Mapa H Puloka, Kingdom of Tonga;\nHuilongguan Hospital, Beijing, China; Martin Prince*, Institute of Muhannad Ramadan, Jordan; Nick Rose, UK; Brigid Ryan, Australia;\nPsychiatry, Psychology and Neuroscience, King’s College, London, Joseph s."
  },
  {
    "id": 27,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "gguan Hospital, Beijing, China; Martin Prince*, Institute of Muhannad Ramadan, Jordan; Nick Rose, UK; Brigid Ryan, Australia;\nPsychiatry, Psychology and Neuroscience, King’s College, London, Joseph s. Quoi, Liberia; Nidhal Saadoon, Turkey; Latifa Saleh,\nUK; Atif Rahman,* Institute of Psychology, Health & Society, Additional inputs were provided by following reviewers Kingdom of Saudi Arabia; Dawda Samba, Gambia; Nseizere\nUniversity of Liverpool, Liverpool, UK; Richard Rawson*, University through contributing to pilot testing, feedback or focus Mitala Shem, Uganda; Michel Soufia, Lebanon; Shadrach J."
  },
  {
    "id": 28,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": ", Gambia; Nseizere\nUniversity of Liverpool, Liverpool, UK; Richard Rawson*, University through contributing to pilot testing, feedback or focus Mitala Shem, Uganda; Michel Soufia, Lebanon; Shadrach J. of California at Los Angeles Integrated Substance Abuse Programs, group discussions: Suborzu II, Liberia; Wafika Tafran, Syria; Angie Tarr Nyankoon,\nCalifornia, USA; Tahilia Rebello, Columbia University, USA; Rajesh Liberia; Lilas Taqi, Turkey; Yanibo Terhemen C., Nigeria; Nongo\nSagar, All India institute of Medical Sciences, New Delhi, India; Ley Helal Uddin Ahmed, Bangladesh; Suzan Akwii Otto, Uganda; Terseer, Nigeria; Samnieng Thammavong, Laos; Manivone\nSander, UCL Institute of Neurology, London, UK; Alison Schafer, Robinah Alambuya, Uganda; Latifa Saleh Al Harbi, Saudi Arabia; Thikeo, Laos; Joshua Tusaba, Uganda; Chanthala Vinthasai, Laos;\nWorld Vision, Nairobi, Kenya; Kunnukattil S Shaji, Government Alaa Iddin Al Masri, Jordan; Laila Alnawaz, Turkey; Ebtisam Al Anna Walder, Sierra Leone; Abdulwas Yusufi, Ethiopia."
  },
  {
    "id": 29,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "hala Vinthasai, Laos;\nWorld Vision, Nairobi, Kenya; Kunnukattil S Shaji, Government Alaa Iddin Al Masri, Jordan; Laila Alnawaz, Turkey; Ebtisam Al Anna Walder, Sierra Leone; Abdulwas Yusufi, Ethiopia. Medical College, Thrissur, India; Pratap Sharan*, All India Institute Rowdhan, Saudi Arabia; Roseline Aposu, Nigeria; Manar Awwad,\nv\n\nvi\nThe following experts contributed to reviewing the University, Netherlands; Mark Keezer, University College London, Production Team\nupdated mhGAP guidelines as external reviewers: UK; Nicole Lee, Turning Point, Australia; Valentina Lemmi,\nLondon School of Economics, UK; Harriet MacMillan, McMaster Graphic design and layout: Erica Lefstad\nAtalay Alem, Addis Ababa University, Ethiopia; Laura Amato, University, Canada; Carlos Martinez, Ministry of Health, Printing Coordination: Pascale Broisin, Frédérique Claudie\nCochrane Collaborative Drugs and Alcohol Review Group, Italy; Argentina; Daniel Maggin, University of Illinois, USA; Silvia Rodin, WHO, Geneva."
  },
  {
    "id": 30,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "inting Coordination: Pascale Broisin, Frédérique Claudie\nCochrane Collaborative Drugs and Alcohol Review Group, Italy; Argentina; Daniel Maggin, University of Illinois, USA; Silvia Rodin, WHO, Geneva. Satinder Aneja, Lady Hardinge Medical College, India; Pierre Minozzi, Cochrane Collaborative Drugs and Alcohol Review\nBastin, Clinique Beaulieu, Switzerland; Gayle Bell, Institute of Group, Italy; Zuzana Mitrova, Cochrane Collaborative Drugs and\nNeurology, University College London, UK; Donna Bergen, Rush Alcohol Review Group, Italy; James Mugisha, National Financial support\nUniversity Medical Centre, Illinois, USA; José Bertolote, Botucatu Association for Suicide Prevention, Uganda; Adesola Ogunniy,\nMedical School, Brazil; Irene Bighelli, Verona University, Italy; University College Hospital, Nigeria; Denis Padruchny,\nThe following organizations contributed financially to the\nStephanie Burrows, Centre hospitalier de l’université de Montréal, Information and Training Centre of Psychiatry and Narcology,\ndevelopment and production of the Intervention Guide:\nCanada; Erico Castro-Costa, FIOCRUZ (Oswaldo Cruz Foundation), Belarus; Amrita Parekh, Public Health Foundation of India; Khara\nBrazil; Tony Charman, Institute of Psychiatry Psychology and Sauro, University of Calgary, Canada; Shoba Raja, Basic Needs, Autism Speaks, USA; CBM; Fountain House Inc.; Government\nNeuroscience King’s College, UK; Marek Chawarski, Yale School India; Brian Reichow, Child Study Centre, Yale School of of Japan; Government of the Republic of Korea; Government of\nof Medicine, USA; Vera da Ros, Rede Brasileira de Redução de Medicine, USA; Maria Luisa Scattoni, Istituto Superiore di Sanità, Switzerland; National Institute of Mental Health, USA; Syngenta."
  },
  {
    "id": 31,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ment of\nof Medicine, USA; Vera da Ros, Rede Brasileira de Redução de Medicine, USA; Maria Luisa Scattoni, Istituto Superiore di Sanità, Switzerland; National Institute of Mental Health, USA; Syngenta. Danos e Direitos Humanos, Brazil; Carlos Felipe D´Oliveira, Italy; Suvasini Sharma, Lady Hardinge Medical College and\nNational Association for Suicide Prevention, Brazil; Kieren Egan, associated Kalawati Saran Children’s Hospital, India; Pratibha\nWHO Collaborating Centre for Mental Health, HUG, Switzerland; Singhi, Post Graduate Institute of Medical Education and\nEric Emerson, Centre for Disability Research and Policy, University Research, India; Lorenzo Tarsitani, Policlinico Umberto Sapienza\nof Sydney, Australia; Saeed Farooq, Department of Psychiatry, University of Rome, Italy; Wietse Tol, Peter Alderman Foundation,\nLady Reading Hospital, Pakistan; Melissa Gladstone, University of Uganda; Sarah Skeen, Stellenbosch University, South Africa;\nLiverpool, UK; Charlotte Hanlon, Addis Ababa University, Manjari Tripathi, All India Institute of Medical Sciences, India;\nEthiopia; Angelina Kakooza, Makerere University, Uganda; Ambros Uchtenhagen, University of Zurich, Switzerland; Chris\nRajesh Kalaria, University of Newcastle, UK; Eirini Karyotaki, Vrije Underhill, Basic Needs, UK; Anna Williams, Institute of Psychiatry,\nPsychology and Neuroscience King’s College, UK."
  },
  {
    "id": 32,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "tzerland; Chris\nRajesh Kalaria, University of Newcastle, UK; Eirini Karyotaki, Vrije Underhill, Basic Needs, UK; Anna Williams, Institute of Psychiatry,\nPsychology and Neuroscience King’s College, UK. INTRODUCTION\n1\n\n2\nINTRODUCTION\nMental Health Gap Action level; as a capacity building tool for a wide range of health questionnaire and locally facilitated focus group discussions were\nprofessionals and para-professionals; and as a reference guide coordinated by WHO. Reviewer responses collected throughout\nProgramme (mhGAP) – Background\nfor developing and updating undergraduate and post-graduate this process have been incorporated into the mhGAP-IG 2.0. curricula for health professionals."
  },
  {
    "id": 33,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ted throughout\nProgramme (mhGAP) – Background\nfor developing and updating undergraduate and post-graduate this process have been incorporated into the mhGAP-IG 2.0. curricula for health professionals. According to WHO Mental Health Atlas 2014, more than 45% of\nFurthermore, several users of mhGAP-IG have highlighted the\nthe world population lives in a country where there is less than 1\nlimitations of only having a paper-based format, suggesting that\npsychiatrist for every 100,000 people and there are even fewer Development of mhGAP-Intervention\ninteractive electronic or internet-based (e-) or mobile (m-) versions\nneurologists."
  },
  {
    "id": 34,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "at, suggesting that\npsychiatrist for every 100,000 people and there are even fewer Development of mhGAP-Intervention\ninteractive electronic or internet-based (e-) or mobile (m-) versions\nneurologists. It is clear that relying solely on specialists to provide\nGuide – Version 2.0 of mhGAP-IG might have benefits in terms of increased ease of\nservices for people affected by mental, neurological and substance\nuse (MNS) disorders would prevent millions of people from acces- use, added functionality and cost savings. mhGAP-IG 2.0 has there-\nsing the services they need. Even when available, the interventions The updated mhGAP guidelines and the feedback and evaluation fore, been designed and packaged with the intention to work across\noften are not evidence-based or of high quality."
  },
  {
    "id": 35,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "able, the interventions The updated mhGAP guidelines and the feedback and evaluation fore, been designed and packaged with the intention to work across\noften are not evidence-based or of high quality. The Mental from mhGAP-IG 1.0 users have shaped the revision and develop- these multiple domains: paper, electronic, and mobile, with the\nHealth Gap Action Programme (mhGAP) was thus developed ment of this updated version of mhGAP-IG. A complete update e-mhGAP-IG currently under development and to be released soon. with the objective of scaling up care for MNS disorders."
  },
  {
    "id": 36,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "was thus developed ment of this updated version of mhGAP-IG. A complete update e-mhGAP-IG currently under development and to be released soon. with the objective of scaling up care for MNS disorders. of the mhGAP guidelines following the WHO’s process of\nguideline development methodology, including the process of Incorporating this extensive feedback, the updated 2015 mhGAP\nThe mhGAP approach consists of interventions for prevention\nevidence review, synthesis and development of recommendations guidelines and the new opportunities afforded by an e-version,\nand management of priority MNS conditions, identified on\nthrough the participation of an international panel of individual the key updates of mhGAP-IG 2.0 include:\nthe basis of evidence about the effectiveness and feasibility of\nexperts and institutions with appropriate background experi-\nscaling up these interventions in low- and middle-income Content update in various sections based on new evidence,\ncountries."
  },
  {
    "id": 37,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "easibility of\nexperts and institutions with appropriate background experi-\nscaling up these interventions in low- and middle-income Content update in various sections based on new evidence,\ncountries. Priority conditions were identified based on the ence: clinicians, researchers, programme managers, policy\nfeedback and recommendations from mhGAP users. criteria that they represented a high burden (in terms of makers and service users, was performed and published in 2015. mortality, morbidity and disability), resulted in large economic The detailed methods and updated recommendations can be Use of a vertical algorithm model, allowing for a streamlined\ncosts or were associated with violations of human rights. found in the mhGAP Evidence Resource Centre. http://www."
  },
  {
    "id": 38,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "recommendations can be Use of a vertical algorithm model, allowing for a streamlined\ncosts or were associated with violations of human rights. found in the mhGAP Evidence Resource Centre. http://www. and simplified clinical assessment. These priority conditions include depression, psychoses, who.int/mental_health/mhgap/evidence/en/. self-harm/suicide, epilepsy, dementia, disorders due to sub- Inclusion of new algorithm for follow-up in all modules. stance use and mental and behavioural disorders in children and\nFeedback has been received from experts in all WHO regions who Inclusion of two new modules: Essential care and practice\nadolescents."
  },
  {
    "id": 39,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "s. stance use and mental and behavioural disorders in children and\nFeedback has been received from experts in all WHO regions who Inclusion of two new modules: Essential care and practice\nadolescents. The mhGAP-Intervention Guide (mhGAP-IG) is a\nused the mhGAP-IG package in the past three years to train non- (which is an update for the chapter on General Principles of\nresource to facilitate delivery of the mhGAP evidence-based\nspecialized health care professionals and to provide MNS services Care in version 1.0) and Implementation module. guidelines in non-specialized health care settings. at several implementation sites."
  },
  {
    "id": 40,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "d\nspecialized health care professionals and to provide MNS services Care in version 1.0) and Implementation module. guidelines in non-specialized health care settings. at several implementation sites. A preliminary draft of mhGAP-IG\nA revised module for Psychoses (integrating both psychosis\n2.0, based on expert and field inputs, was then circulated among a\nUptake of mhGAP-IG Version 1.0 by WHO Member States and\nand bipolar disorder), Child and Adolescent Mental and\nwide group of reviewers across the world, allowing for a diversity\nother stakeholders has been remarkable and clearly shows the\nBehavioural Disorders (covering Developmental, Behavioral\nneed for such a tool. mhGAP-IG Version 1.0 has been used at of opinion in this intensive review process."
  },
  {
    "id": 41,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "been remarkable and clearly shows the\nBehavioural Disorders (covering Developmental, Behavioral\nneed for such a tool. mhGAP-IG Version 1.0 has been used at of opinion in this intensive review process. This process incorpo-\nand Emotional Disorders), and Disorders due to Substance\nthe country level through the following varied methods: most rated feedback from a range of end-users, including non-specialist\nUse (including both disorders due to alcohol and disorders\ncommonly, as a key tool in the phased approach to scale-up health care providers and people with MNS disorders across all\ndue to drug use). mental health services on a regional, national, and sub-national WHO regions."
  },
  {
    "id": 42,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "y tool in the phased approach to scale-up health care providers and people with MNS disorders across all\ndue to drug use). mental health services on a regional, national, and sub-national WHO regions. End-user feedback was collected through a\n\nUse of mhGAP-IG Version 2.0 How to use the mhGAP-IG Version 2.0\nThe mhGAP-IG is a model guide and it is essential that it is adapted The mhGAP-IG is a model guide and it is essential that it is The Assessment section is presented in a framework of\nto the unique national or local situation. Users may select a subset adapted to the unique national or local situation. Users may flowcharts with multiple clinical assessment points."
  },
  {
    "id": 43,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "in a framework of\nto the unique national or local situation. Users may select a subset adapted to the unique national or local situation. Users may flowcharts with multiple clinical assessment points. Each\nof the priority conditions or interventions to adapt and implement, select a subset of the priority conditions or interventions to module starts with common presentations of the suspected\ndepending on the contextual differences in prevalence and adapt and implement, depending on the context. condition, from which there are a series of clinical assess-\navailability of resources."
  },
  {
    "id": 44,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "spected\ndepending on the contextual differences in prevalence and adapt and implement, depending on the context. condition, from which there are a series of clinical assess-\navailability of resources. Adaptation is necessary to ensure that the\nment questions one should move down answering yes or no,\nconditions that contribute most to disease burden in a specific\nThe mhGAP-IG 2.0 begins with “Essential Care and Practice”, which directs the user to move on for further instructions to\ncountry are covered, and that mhGAP-IG 2.0 is appropriate for\na set of good clinical practices and general guidelines for reach a final clinical assessment."
  },
  {
    "id": 45,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "user to move on for further instructions to\ncountry are covered, and that mhGAP-IG 2.0 is appropriate for\na set of good clinical practices and general guidelines for reach a final clinical assessment. It is important that users of\nthe local conditions that affect treatment of people with MNS\ninteractions of health care providers with people seeking the mhGAP-IG start at the top of the assessment and move\ndisorders in the health care facility. The adaptation process should\nmental health care."
  },
  {
    "id": 46,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "eractions of health care providers with people seeking the mhGAP-IG start at the top of the assessment and move\ndisorders in the health care facility. The adaptation process should\nmental health care. All users of the mhGAP-IG should through all the decision points to develop a comprehensive\nbe used as an opportunity to develop a consensus on technical\nissues across disease conditions—this requires involvement of key familiarize themselves with these principles and should clinical assessment and management plan. national stakeholders. Adaptation will include language translation follow them as far as possible."
  },
  {
    "id": 47,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "key familiarize themselves with these principles and should clinical assessment and management plan. national stakeholders. Adaptation will include language translation follow them as far as possible. and ensuring that the interventions are acceptable in their The Management section consists of intervention details\nThe mhGAP-IG includes a “Master Chart”, which provides\nsociocultural context and suitable for the local health system. which provide information on how to manage the specific\ninformation on common presentations of the priority\nconditions that have been assessed. This includes more\nconditions. This guides the clinician to the relevant modules."
  },
  {
    "id": 48,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "on how to manage the specific\ninformation on common presentations of the priority\nconditions that have been assessed. This includes more\nconditions. This guides the clinician to the relevant modules. The target user group of mhGAP-IG is non-specialized health- technical psychosocial and pharmacological interventions\ncare providers working at first- and second-level health-care The most serious conditions should be managed first. when appropriate. facilities. These providers include primary care doctors, nurses mhGAP-IG 2.0 has a new addition to the Master Chart –\nand other members of the health-care workforce. Although Emergency Presentations of Priority MNS Conditions."
  },
  {
    "id": 49,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "include primary care doctors, nurses mhGAP-IG 2.0 has a new addition to the Master Chart –\nand other members of the health-care workforce. Although Emergency Presentations of Priority MNS Conditions. The Follow-up section provides detailed information on\nmhGAP-IG 2.0 is to be implemented primarily by non-specialists, This section has been added to help identify emergency\nhow to continue the clinical relationship and detailed\nmental health care specialists may also find it useful in their situations and direction to management guidelines. instructions for follow-up management. work."
  },
  {
    "id": 50,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e the clinical relationship and detailed\nmental health care specialists may also find it useful in their situations and direction to management guidelines. instructions for follow-up management. work. In addition, specialists have an essential and substantial\nrole in training, support and supervision, and mhGAP-IG 2.0 The modules, organized by individual priority conditions, are\nindicates where access to specialists is required for consultation a tool for clinical decision-making and management. Each The mhGAP-IG 2.0 uses a series of symbols to highlight\nor referral to improve utilization of scarce resources. Specialists module is in a different colour to allow easy differentiation. certain aspects within the modules."
  },
  {
    "id": 51,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "a series of symbols to highlight\nor referral to improve utilization of scarce resources. Specialists module is in a different colour to allow easy differentiation. certain aspects within the modules. A list of the symbols\nwould also benefit from training on public health aspects of There is an introduction at the beginning of each module and their explanation is given on the following page. the programme and service organization. Implementation of that explains which condition(s) the module covers and a Throughout the modules, important points are also\nmhGAP-IG ideally requires coordinated action by public health quick overview describing key assessment and management highlighted as key clinical tips. experts and managers, and dedicated specialists with a back-\nsteps."
  },
  {
    "id": 52,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "quires coordinated action by public health quick overview describing key assessment and management highlighted as key clinical tips. experts and managers, and dedicated specialists with a back-\nsteps. ground in public health. Therefore, training in the use of\nAlso included is a module on Implementation of mhGAP-IG,\nmhGAP-IG is best done as part of a systems approach involving Each of the modules consists of three sections: which provides summary steps on how to implement\nhealth planners, managers and policy makers so that the mhGAP-IG. Assessment\ninterventions proposed are supported by necessary infrastructure/\nAt the end of the guide, a glossary of terms used in\nresources e.g. availability of essential medicines. mhGAP-IG\nManagement\nmhGAP-IG 2.0 is provided."
  },
  {
    "id": 53,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "oposed are supported by necessary infrastructure/\nAt the end of the guide, a glossary of terms used in\nresources e.g. availability of essential medicines. mhGAP-IG\nManagement\nmhGAP-IG 2.0 is provided. training also needs to be incorporated in an ongoing manner\nwith mechanisms in place to ensure adequate support, supervi- Follow-up\nsion and refresher training for the healthcare providers."
  },
  {
    "id": 54,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "provided. training also needs to be incorporated in an ongoing manner\nwith mechanisms in place to ensure adequate support, supervi- Follow-up\nsion and refresher training for the healthcare providers. 3\n\n4\nINTRODUCTION\nVisual Elements & Symbols\nSequence of assessment steps Children / adolescents\nAssessment\n1\nWomen who are of child-bearing\nage, pregnant or breastfeeding\nManagement\nAdult\nOlder adult\nFollow-up\nCAUTION\nStop and exit module\nRefer to hospital Do not\nGo to PROTOCOL 1\nMedication Further information\nReturn to algorithm\nafter following instructions Move to another section\nPsychosocial intervention\nwithin module\nConsult specialist\nCLINICAL TIP\n\nESSENTIAL CARE & PRACTICE\nThis module outlines the principles of essential care for all people A."
  },
  {
    "id": 55,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "tions Move to another section\nPsychosocial intervention\nwithin module\nConsult specialist\nCLINICAL TIP\n\nESSENTIAL CARE & PRACTICE\nThis module outlines the principles of essential care for all people A. GENERAL PRINCIPLES\nseeking health care, including those with MNS conditions, and\n– Use effective communication skills\ntheir carers. The first section of this module covers the general prin-\n– Promote respect and dignity\nciples of clinical care and aims to promote respect for the privacy\nof people seeking care for MNS conditions, foster good relation-\nB. E SSENTIALS OF MENTAL HEALTH\nships between health care providers, service users and their carers,\nCLINICAL PRACTICE\nand ensure care is provided in a non-judgmental, non-stigmatizing,\nand supportive manner."
  },
  {
    "id": 56,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "NTIALS OF MENTAL HEALTH\nships between health care providers, service users and their carers,\nCLINICAL PRACTICE\nand ensure care is provided in a non-judgmental, non-stigmatizing,\nand supportive manner. The second section covers essentials of – Assess physical health\nmental health clinical practice and aims to present healthcare – Conduct a MNS assessment\nproviders with an overview of the assessment and management\n– Manage MNS conditions\nof MNS conditions in non-specialized settings. ESSENTIAL CARE AND PRACTICE 5\n\n6\nEECCPP\nESSENTIAL CARE & PRACTICE\nA. GENERAL PRINCIPLES\nI."
  },
  {
    "id": 57,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rview of the assessment and management\n– Manage MNS conditions\nof MNS conditions in non-specialized settings. ESSENTIAL CARE AND PRACTICE 5\n\n6\nEECCPP\nESSENTIAL CARE & PRACTICE\nA. GENERAL PRINCIPLES\nI. Use Effective Communication Skills\nUsing effective communication skills allows healthcare COMMUNICATION TIP #2 COMMUNICATION TIP #5\nproviders to deliver good quality care to adults, adolescents, Involve the person Use good verbal communication skills\nand children with mental, neurological and substance use (MNS)\nconditions. Consider the following core communication skills\nInclude the person (and with their consent, their carers Use simple language. Be clear and concise."
  },
  {
    "id": 58,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "l, neurological and substance use (MNS)\nconditions. Consider the following core communication skills\nInclude the person (and with their consent, their carers Use simple language. Be clear and concise. and tips:\nand family) in all aspects of assessment and management\nUse open-ended questions, summarizing and clarifying\nas much as possible. This includes children, adolescents\nstatements. COMMUNICATION TIP #1 and older adults. Summarize and repeat key points. Create an environment that\nAllow the person to ask questions about the information\nfacilitates open communication COMMUNICATION TIP #3\nprovided. Start by listening\nMeet the person in a private space, if possible. Be welcoming and conduct introductions in a culturally Actively listen. Be empathic and sensitive."
  },
  {
    "id": 59,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "on COMMUNICATION TIP #3\nprovided. Start by listening\nMeet the person in a private space, if possible. Be welcoming and conduct introductions in a culturally Actively listen. Be empathic and sensitive. COMMUNICATION TIP #6\nappropriate manner. Allow the person to speak without interruption. Respond with sensitivity when people\nMaintain eye contact and use body language and facial If the history is unclear, be patient and ask for clarification. disclose difficult experiences (e.g. expressions that facilitate trust. For children, use language that they can understand. For sexual assault, violence or self-harm)\nExplain that information discussed during the visit will example, ask about their interests (toys, friends, school, etc.)."
  },
  {
    "id": 60,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "language that they can understand. For sexual assault, violence or self-harm)\nExplain that information discussed during the visit will example, ask about their interests (toys, friends, school, etc.). be kept confidential and will not be shared without prior\nFor adolescents, convey that you understand their feelings Show extra sensitivity with difficult topics. permission. and situation. If carers are present, suggest to speak with the person Remind the person that what they tell you will remain\nalone (except for young children) and obtain consent to confidential. COMMUNICATION TIP #4\nshare clinical information. Acknowledge that it may have been difficult for the\nBe friendly, respectful and non-\nWhen interviewing a young woman, consider having person to disclose the information."
  },
  {
    "id": 61,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "#4\nshare clinical information. Acknowledge that it may have been difficult for the\nBe friendly, respectful and non-\nWhen interviewing a young woman, consider having person to disclose the information. another female staff member or carer present. judgemental at all times\nAlways be respectful. Don’t judge people by their behaviours and appearance. Stay calm and patient. II. Promote Respect and Dignity\nPersons with MNS conditions should be treated with respect\nand dignity in a culturally appropriate manner."
  },
  {
    "id": 62,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "le by their behaviours and appearance. Stay calm and patient. II. Promote Respect and Dignity\nPersons with MNS conditions should be treated with respect\nand dignity in a culturally appropriate manner. As a health care DOs DON'Ts\nprovider, make every effort to respect and promote the will\nand preference of people with MNS conditions and support\nTreat people with MNS conditions with respect and Do not discriminate against people with MNS\nand engage them and their carers in the most inclusive way. dignity. conditions. Persons with MNS conditions are often more vulnerable to\nhuman rights violations."
  },
  {
    "id": 63,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "discriminate against people with MNS\nand engage them and their carers in the most inclusive way. dignity. conditions. Persons with MNS conditions are often more vulnerable to\nhuman rights violations. Therefore, it is essential that in the Protect the confidentiality of people with MNS Do not ignore the priorities or wishes of people with\nhealth care setting, providers promote the rights of people with conditions. MNS conditions. MNS conditions in line with international human rights\nEnsure privacy in the clinical setting. Do not make decisions for, on behalf of, or instead of\nstandards, including the UN Convention on the Rights of Persons\nthe person with MNS conditions. with Disability (CRPD)*."
  },
  {
    "id": 64,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "in the clinical setting. Do not make decisions for, on behalf of, or instead of\nstandards, including the UN Convention on the Rights of Persons\nthe person with MNS conditions. with Disability (CRPD)*. Always provide access to information and explain the\nproposed treatment risks and benefits in writing, if Do not use overly technical language in explaining\n*For more information on CRPD: https://www.un.org/\npossible. proposed treatment. development/desa/disabilities/convention-on-the-rights-of-\npersons-with-disabilities.html Make sure the person provides consent to treatment. Promote autonomy and independent living in the\ncommunity. Provide persons with MNS conditions with access to\nsupported decision making options."
  },
  {
    "id": 65,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "html Make sure the person provides consent to treatment. Promote autonomy and independent living in the\ncommunity. Provide persons with MNS conditions with access to\nsupported decision making options. ESSENTIAL CARE AND PRACTICE 7\n\n8\nECP\nEESSSSEENNTTIIAALL CCAARREE A& NPDR APCRTAICCETICE\nB. ESSENTIALS OF MENTAL HEALTH CLINICAL PRACTICE\nI. Assess Physical Health\nAssessment of Physical Health Management of Physical Health\nPersons with MNS disorders are at higher risk of premature\nmortality from preventable disease and therefore must always\nreceive a physical health assessment as part of a comprehensive Take a detailed history and ask about risk factors. Treat existing comorbidities concurrently with the MNS\nevaluation."
  },
  {
    "id": 66,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "efore must always\nreceive a physical health assessment as part of a comprehensive Take a detailed history and ask about risk factors. Treat existing comorbidities concurrently with the MNS\nevaluation. Be sure to take a proper history, including both Physical inactivity, inappropriate diet, tobacco, disorder. Refer to/consult with specialists, if needed. physical health and MNS history, followed by a physical health harmful alcohol and/or substance use, risky behaviour\nProvide education on modifiable risk factors to prevent\nassessment to identify concurrent conditions and educate the and chronic disease. disease and encourage a healthy lifestyle. person about preventive measures. These actions must always\nPerform a physical examination."
  },
  {
    "id": 67,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "entify concurrent conditions and educate the and chronic disease. disease and encourage a healthy lifestyle. person about preventive measures. These actions must always\nPerform a physical examination. To support physical health of persons with MNS conditions,\nbe undertaken with the person’s informed consent. Consider a differential diagnosis. health care providers should:\nRule out physical conditions and underlying causes of MNS\n– Provide advice about the importance of physical activity\npresentations by history, physical examination and basic\nand a healthy diet. laboratory tests as needed and available. – Educate people about harmful alcohol use. Identify comorbidities. – Encourage cessation of tobacco and substance use."
  },
  {
    "id": 68,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "mination and basic\nand a healthy diet. laboratory tests as needed and available. – Educate people about harmful alcohol use. Identify comorbidities. – Encourage cessation of tobacco and substance use. Often, a person may have more than one MNS condition at\nthe same time. It is important to assess and manage this – Provide education about other risky behaviour (e.g. when it occurs. unprotected sex). – Conduct regular physical health checks and vaccinations. – Prepare people for developmental life changes, such as\npuberty and menopause, and provide the necessary\nCLINICAL TIP:\nsupport. Persons with severe mental disorders are 2 to 3 times\n– Discuss plans for pregnancy and contraception methods\nmore likely to die of preventable disease like infections\nwith women of childbearing age."
  },
  {
    "id": 69,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Persons with severe mental disorders are 2 to 3 times\n– Discuss plans for pregnancy and contraception methods\nmore likely to die of preventable disease like infections\nwith women of childbearing age. and cardiovascular disorders. Focus on reducing risk\nthrough education and monitoring. II. Conduct a MNS Assessment\nConducting an assessment for MNS conditions involves the following steps. First, the presenting complaint is explored, then a history is obtained including\nasking about past MNS issues, general health problems, family MNS history, and psychosocial history. Observe the person (Mental Status Exam), establish\na differential diagnosis, and identify the MNS condition. As part of the assessment, conduct a physical examination and obtain basic laboratory tests as\nneeded."
  },
  {
    "id": 70,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "person (Mental Status Exam), establish\na differential diagnosis, and identify the MNS condition. As part of the assessment, conduct a physical examination and obtain basic laboratory tests as\nneeded. The assessment is conducted with informed consent of the person. HISTORY TAKING\n1 Presenting Complaint 4 Family History of MNS Conditions\nMain symptom or reason that the person is seeking care. E xplore possible family history of MNS conditions and ask if anyone\nAsk when, why, and how it started. had similar symptoms or has received treatment for a MNS condition. It is important at this stage to gather as much information as\npossible about the person’s symptoms and their situation. 5 Psychosocial History\nA sk about current stressors, coping methods and social support."
  },
  {
    "id": 71,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "portant at this stage to gather as much information as\npossible about the person’s symptoms and their situation. 5 Psychosocial History\nA sk about current stressors, coping methods and social support. 2 Past MNS History A sk about current socio-occupational functioning (how the person is\nfunctioning at home, work and in relationships). Ask about similar problems in the past, any psychiatric hospitalizations or\nmedications prescribed for MNS conditions, and any past suicide attempts. O btain basic information including where the person lives, level of\neducation, work/employment history, marital status and number/ages\nExplore tobacco, alcohol and substance use. of children, income, and household structure/living conditions."
  },
  {
    "id": 72,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "he person lives, level of\neducation, work/employment history, marital status and number/ages\nExplore tobacco, alcohol and substance use. of children, income, and household structure/living conditions. 3 General Health History\nFor children and adolescents, ask about whether they have a carer,\nAsk about physical health problems and medications. and the nature and quality of the relationship between them. Obtain a list of current medications. Ask about allergies to medications."
  },
  {
    "id": 73,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "have a carer,\nAsk about physical health problems and medications. and the nature and quality of the relationship between them. Obtain a list of current medications. Ask about allergies to medications. ESSENTIAL CARE AND PRACTICE 9\n\n10\nECP\nEESSSSEENNTTIIAALL CCAARREE A& NPDR APCRTAICCETICE\nSuspect a priority MNS condition\nand go to the relevant module(s) for\nassessment\nASSESSMENT FOR MNS CONDITIONS\n1 Physical Examination 4 Basic Laboratory Tests\nC onduct a targeted physical examination guided by the information R equest laboratory tests when indicated and possible, especially\nfound during the MNS assessment. to rule out physical causes."
  },
  {
    "id": 74,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Tests\nC onduct a targeted physical examination guided by the information R equest laboratory tests when indicated and possible, especially\nfound during the MNS assessment. to rule out physical causes. 5 Identify the MNS Condition\n2 Mental Status Examination (MSE)*\nA sk about and observe the person’s Appearance and Behaviour,\nI dentify the MNS condition using the appropriate module(s). Mood and Affect, Content of Thought, any Perceptual disturbances and\nA ssess for other MNS symptoms and priority conditions\n(see Master Chart). Cognition. See symptom based Master Chart (MC) for details. F ollow the appropriate management algorithm and treatment\nprotocols. 3 Differential Diagnosis\nC onsider the differential diagnosis and rule out conditions that have\nsimilar presenting symptoms."
  },
  {
    "id": 75,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ails. F ollow the appropriate management algorithm and treatment\nprotocols. 3 Differential Diagnosis\nC onsider the differential diagnosis and rule out conditions that have\nsimilar presenting symptoms. CLINICAL TIP:\nOnce a MNS disorder is suspected,\nalways assess for self harm/suicide ( SUI )\n* Mental Status Examination adapted for non-specialists may include: Behavior and Appearance = symptoms and signs involving the way a person looks or acts; Mood and Affect = symptoms and signs involving\nthe regulation and expression of emotions or feeling states; Content of Thought = symptoms and signs involving subject matter of thoughts including delusions, paranoia, suspiciousness and suicidal ideation;\nPerceptual Disturbance = sensory perceptions occurring in the absence of the appropriate (external) stimulus (e.g."
  },
  {
    "id": 76,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "tter of thoughts including delusions, paranoia, suspiciousness and suicidal ideation;\nPerceptual Disturbance = sensory perceptions occurring in the absence of the appropriate (external) stimulus (e.g. auditory or visual hallucinations). The person may or may not have insight into the unreal nature of the\nperception; Cognition = symptoms, signs and clinical findings indicative of a disturbance in mental abilities and processes related to attention, memory, judgment, reasoning, problem solving, decision making,\ncomprehension and the integration of these functions. III. Manage MNS Conditions\nOnce the assessment is conducted, follow the management algorithm in mhGAP-IG to manage the MNS disorder. Key steps in management are found in the box below."
  },
  {
    "id": 77,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "hese functions. III. Manage MNS Conditions\nOnce the assessment is conducted, follow the management algorithm in mhGAP-IG to manage the MNS disorder. Key steps in management are found in the box below. MANAGEMENT STEPS FOR MNS CONDITIONS\nMany MNS conditions are chronic and require long-term monitoring and follow-up. Managing a MNS disorder over time involves the following steps. 1 Develop a treatment plan in collaboration with 4 Refer to specialists or hospital when indicated\nthe person and their carer. and available. 5 Ensure that appropriate plan for follow-up is in place. CLINICAL TIP:\nWritten treatment plan should cover:\n6 Work together with carer and families\n– Pharmacological interventions (if any)\n– Psychosocial interventions in supporting the person with the MNS disorder."
  },
  {
    "id": 78,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "TIP:\nWritten treatment plan should cover:\n6 Work together with carer and families\n– Pharmacological interventions (if any)\n– Psychosocial interventions in supporting the person with the MNS disorder. – Referrals\n– Follow-up plan\n7 Foster strong links with employment, education,\n– Management of any concurrent physical and/or other MNS conditions\nsocial services (including housing) and other relevant sectors. 2 Always offer psychosocial interventions for the person 8 Modify treatment plans for special populations. and their carers. 3 Treat the MNS disorder using pharmacological\ninterventions when indicated. ESSENTIAL CARE AND PRACTICE 11\n\n12\nECP\nEESSSSEENNTTIIAALL CCAARREE A& NPDR APCRTAICCETICE\n1. Treatment Planning B. Reduce stress and strengthen social D."
  },
  {
    "id": 79,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "pharmacological\ninterventions when indicated. ESSENTIAL CARE AND PRACTICE 11\n\n12\nECP\nEESSSSEENNTTIIAALL CCAARREE A& NPDR APCRTAICCETICE\n1. Treatment Planning B. Reduce stress and strengthen social D. Psychological Treatment\n1\nsupports\nDiscuss and determine treatment goals that respect the Psychological treatments are interventions that typically\nwillingness and preferences for care. Address current psychosocial stressors: require substantial dedicated time and tend to be provided\nIdentify and discuss relevant psychosocial issues that place by specialists trained in providing them. Nonetheless, they\nInvolve the carer after obtaining the person’s agreement."
  },
  {
    "id": 80,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "d tend to be provided\nIdentify and discuss relevant psychosocial issues that place by specialists trained in providing them. Nonetheless, they\nInvolve the carer after obtaining the person’s agreement. stress on the person and/or impact their life including, but can be effectively delivered by trained and supervised\nEncourage self-monitoring of symptoms and explain when not limited to, family and relationship problems, employ- non-specialized workers and through guided self-help (e.g. to seek care urgently. ment/occupation/livelihood issues, housing, finances, access with use of e-mental health programmes or self-help books). to basic security and services, stigma, discrimination, etc."
  },
  {
    "id": 81,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "eek care urgently. ment/occupation/livelihood issues, housing, finances, access with use of e-mental health programmes or self-help books). to basic security and services, stigma, discrimination, etc. The interventions listed below are described briefly in\nAssist the person to manage stress by discussing methods such\nthe glossary. 22. Psychosocial Interventions as problem solving techniques. Assess and manage any situation of maltreatment, abuse (e.g. A. Psychoeducation domestic violence) and neglect (e.g. of children or the elderly). Example of Intervention Recommended for:\nDiscuss with the person possible referrals to a trusted protec-\nProvide information about the MNS condition to the tion agency or informal protection network."
  },
  {
    "id": 82,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Example of Intervention Recommended for:\nDiscuss with the person possible referrals to a trusted protec-\nProvide information about the MNS condition to the tion agency or informal protection network. Contact legal and Behavioral Activation DEP\nperson, including: community resources, as appropriate. Relaxation Training DEP\nWhat the condition is and its expected course and Identify supportive family members and involve them as Problem Solving Treatment DEP\noutcome. much as possible and appropriate. Cognitive Behavioural Therapy (CBT) DEP, CMH, SUB, PSY\nContingency Management Therapy SUB\nAvailable treatments for the condition and their Strengthen social supports and try to reactivate the\nFamily Counseling or Therapy PSY, SUB\nexpected benefits. person’s social networks."
  },
  {
    "id": 83,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ent Therapy SUB\nAvailable treatments for the condition and their Strengthen social supports and try to reactivate the\nFamily Counseling or Therapy PSY, SUB\nexpected benefits. person’s social networks. Interpersonal Therapy (IPT) DEP\nDuration of treatment. Identify prior social activities that, if reinitiated, would\nMotivational Enhancement Therapy SUB\nImportance of adhering to treatment, including what have the potential for providing direct or indirect psycho- Parent Skills Training CMH\nthe person can do (e.g. taking medication or practising social support (e.g. family gatherings, visiting neighbours,\nrelevant psychological interventions such as relaxation community activities, religious activities, etc.)."
  },
  {
    "id": 84,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "taking medication or practising social support (e.g. family gatherings, visiting neighbours,\nrelevant psychological interventions such as relaxation community activities, religious activities, etc.). exercises) and what carers can do to help the person Teach stress management such as relaxation techniques. adhere to treatment. Potential side-effects (short and long term) of any C. P romote functioning in\nprescribed medication that the person (and their carers)\ndaily activities\nneed to monitor. Potential involvement of social workers, case managers,\nProvide the person support to continue regular social,\ncommunity health workers or other trusted members in the\neducational and occupational activities as much as possible. community. Facilitate inclusion in economic activities."
  },
  {
    "id": 85,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "o continue regular social,\ncommunity health workers or other trusted members in the\neducational and occupational activities as much as possible. community. Facilitate inclusion in economic activities. Refer to management section of relevant module(s) for specific\nOffer life skills training, and/or social skills training if needed. information on the MNS disorder. 33. Pharmacological Interventions 55. Follow-up\nFollow the guidelines on psychopharmacology in each A rrange a follow-up visit after the initial assessment. – Have a plan of action for when the person does not\nmodule. show up for appointments. After every visit, schedule a follow-up appointment and\nUse pharmacological interventions when available and\nencourage attendance."
  },
  {
    "id": 86,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "action for when the person does not\nmodule. show up for appointments. After every visit, schedule a follow-up appointment and\nUse pharmacological interventions when available and\nencourage attendance. Schedule the appointment at a\n– Use family and community resources to contact people\nwhen indicated in the management algorithm and table who have not returned for regular follow-up. mutually convenient time. provided. – Consult a specialist if the person does not improve or\nSchedule initial follow-up visits more frequently\nworsens. In selecting the appropriate essential medication,\nuntil the symptoms begin to respond to treatment."
  },
  {
    "id": 87,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ialist if the person does not improve or\nSchedule initial follow-up visits more frequently\nworsens. In selecting the appropriate essential medication,\nuntil the symptoms begin to respond to treatment. consider the side effect profile of the medication (short – Document key aspects of interactions with the person\nOnce symptoms start improving, schedule less frequent\nand long term), efficacy of past treatment, drug-drug and the family in the case notes. but regular appointments. interactions or drug-disease interactions. Refer to the management section of relevant\nConsult the National Formulary or the WHO Formulary as\nAt each follow-up meeting, assess for:\nmodule(s) for disorder-specific follow-up information. needed."
  },
  {
    "id": 88,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Refer to the management section of relevant\nConsult the National Formulary or the WHO Formulary as\nAt each follow-up meeting, assess for:\nmodule(s) for disorder-specific follow-up information. needed. – Response to treatment, medication side-effects, and ad-\nEducate the person about risks and benefits of treatment, herence to medications and psychosocial interventions. potential side effects, duration of treatment, and impor- – General health status (be sure to monitor physical health\ntance of adherence. status regularly). Exercise caution when providing medication to special – Self-care (e.g. diet, hygiene, clothing) and functioning in\ngroups such as older people, those with chronic disease, the person’s own environment."
  },
  {
    "id": 89,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ercise caution when providing medication to special – Self-care (e.g. diet, hygiene, clothing) and functioning in\ngroups such as older people, those with chronic disease, the person’s own environment. women who are pregnant or breastfeeding, and children/\n– Psychosocial issues and/or change in living conditions\nadolescents. Consult a specialist as needed. that can affect management. – The person’s and the carer’s understanding and expec-\ntations of the treatment. Correct any misconceptions. 44. Referral to specialist/hospital\nDuring the entire follow-up period:\nif needed\n– Acknowledge all progress towards the treatment goals\nand reinforce adherence."
  },
  {
    "id": 90,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "treatment. Correct any misconceptions. 44. Referral to specialist/hospital\nDuring the entire follow-up period:\nif needed\n– Acknowledge all progress towards the treatment goals\nand reinforce adherence. Stay alert for situations that may require referral to a\n– Maintain regular contact with the person (and their carer,\nspecialist/hospital, for example, non-response to treatment,\nwhen appropriate). If available, assign a community worker\nserious side effects with pharmacological interventions,\nor another trusted person in the community to support\ncomorbid physical and/or MNS conditions, risk of self-harm/\nthe person (such as a family member). suicide. – Explain that the person can return to the clinic at any\ntime in between follow-up visits if needed (e.g."
  },
  {
    "id": 91,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ical and/or MNS conditions, risk of self-harm/\nthe person (such as a family member). suicide. – Explain that the person can return to the clinic at any\ntime in between follow-up visits if needed (e.g. for side-\neffects of medications, etc). ESSENTIAL CARE AND PRACTICE 13\n\n14\nECP\nEESSSSEENNTTIIAALL CCAARREE A& NPDR APCRTAICCETICE\n66. Involving Carers 8 8 . Special Populations\nWhen appropriate, and with the consent of the person CHILDREN / ADOLESCENTS O LDER ADULTS\nconcerned, involve the carer or family member in the\nExplore exposure to adverse factors such as Address psychosocial stressors that are particularly\nperson’s care."
  },
  {
    "id": 92,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "HILDREN / ADOLESCENTS O LDER ADULTS\nconcerned, involve the carer or family member in the\nExplore exposure to adverse factors such as Address psychosocial stressors that are particularly\nperson’s care. violence and neglect which may affect mental health relevant to the person, respecting their need for\nAcknowledge that it can be challenging to care for people and wellbeing. autonomy. with MNS conditions. Assess the needs of carers. Identify and treat concurrent physical health problems\nExplain to the carer the importance of respecting the and manage sensory deficits (such as low vision or poor\nTreat adolescents who may come alone for help even if\ndignity and rights of the person with a MNS condition. hearing) with appropriate devices (e.g."
  },
  {
    "id": 93,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "manage sensory deficits (such as low vision or poor\nTreat adolescents who may come alone for help even if\ndignity and rights of the person with a MNS condition. hearing) with appropriate devices (e.g. magnifying glass,\nnot accompanied by parent or guardian. Obtain informed\nhearing aids). Identify psychosocial impact on carers. consent from the adolescent. Use lower doses of medications. Assess the carer’s needs to ensure necessary support Allow opportunities for the child/adolescent to express\nand resources for family life, employment, social activities, concerns in private. Anticipate increased risk of drug interactions. and health. Adapt language to the child/adolescent’s level of Address needs of carers. Encourage involvement in self-help and family support understanding."
  },
  {
    "id": 94,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "icipate increased risk of drug interactions. and health. Adapt language to the child/adolescent’s level of Address needs of carers. Encourage involvement in self-help and family support understanding. groups, where available. Explore available resources within the family, school\nWith the consent of the person, keep carers informed and community. about the person’s health status, including issues related\nto assessment, treatment, follow-up, and any potential\nW OMEN WHO ARE PREGNANT OR\nside-effects. BREAST-FEEDING\nIf the woman is of child-bearing age, ask about:\n7."
  },
  {
    "id": 95,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "alth status, including issues related\nto assessment, treatment, follow-up, and any potential\nW OMEN WHO ARE PREGNANT OR\nside-effects. BREAST-FEEDING\nIf the woman is of child-bearing age, ask about:\n7. Links with other sectors\n7\n– Breastfeeding\n– Possible pregnancy\n– Last menstrual period, if pregnant\nTo ensure comprehensive care and based on the initial\nassessment, link the person to employment, education, social\nLiaise with maternal health specialist to organize care. services (including housing) and other relevant sectors. Consider consultation with mental health specialist if\navailable. Exercise caution with pharmacological interventions –\ncheck toxicity to fetus and passage into breast milk. Consult a specialist as needed."
  },
  {
    "id": 96,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "der consultation with mental health specialist if\navailable. Exercise caution with pharmacological interventions –\ncheck toxicity to fetus and passage into breast milk. Consult a specialist as needed. MASTER CHART\nMASTER CHART 15\n\n16\nOverview of\nPriority MNS Conditions\n1. These common presentations indicate the need for assessment. 2. If people present with features of more than one condition, then all relevant conditions\nneed to be assessed. 3. All conditions apply to all ages, unless otherwise specified. 4. For emergency presentations, please see the table on page 18."
  },
  {
    "id": 97,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "than one condition, then all relevant conditions\nneed to be assessed. 3. All conditions apply to all ages, unless otherwise specified. 4. For emergency presentations, please see the table on page 18. COMMON PRESENTATION PRIORITY CONDITION\nMultiple persistent physical symptoms with no clear cause\nLow energy, fatigue, sleep problems DEPRESSION (DEP)\nPersistent sadness or depressed mood, anxiety\nLoss of interest or pleasure in activities that are normally pleasurable\nMarked behavioural changes; neglecting usual responsibilities related to work,\nschool, domestic or social activities\nAgitated, aggressive behavior, decreased or increased activity PSYCHOSES (PSY)\nFixed false beliefs not shared by others in the person’s culture\nHearing voices or seeing things that are not there\nLack of realization that one is having mental health problems\nConvulsive movement or fits/seizures\nDuring the convulsion: loss of consciousness or impaired consciousness, stiffness,\nEPILEPSY (EPI)\nrigidity, tongue bite, injury, incontinence of urine or faeces\nAfter the convulsion: fatigue, drowsiness, sleepiness, confusion, abnormal behaviour,\nheadache, muscle aches, or weakness on one side of the body\n\nChild/adolescent being seen for physical complaints or Behaviour (e.g."
  },
  {
    "id": 98,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ion: fatigue, drowsiness, sleepiness, confusion, abnormal behaviour,\nheadache, muscle aches, or weakness on one side of the body\n\nChild/adolescent being seen for physical complaints or Behaviour (e.g. too active, aggressive, having frequent\na general health assessment who has: and/or severe tantrums, wanting to be alone too much,\nrefusing to do regular activities or go to school)\nProblem with development, emotions or behaviour CHILD & ADOLESCENT\n(e.g. inattention, over-activity, or repeated defiant, Teacher with concerns about a child/adolescent\ndisobedient and aggressive behaviour) MENTAL & BEHAVIOURAL\ne.g."
  },
  {
    "id": 99,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ns or behaviour CHILD & ADOLESCENT\n(e.g. inattention, over-activity, or repeated defiant, Teacher with concerns about a child/adolescent\ndisobedient and aggressive behaviour) MENTAL & BEHAVIOURAL\ne.g. easily distracted, disruptive in class, often getting\nRisk factors such as malnutrition, abuse and/or neglect, frequent into trouble, difficulty completing school work\nDISORDERS (CMH)\nillness, chronic diseases (e.g. HIV/AIDS or history of difficult birth)\nCommunity health or social services worker with\nCarer with concerns about the child/adolescent’s: concerns about a child/adolescent\nCommon presentations of emotional, behavioral\nDifficulty keeping up with peers or carrying out daily e.g."
  },
  {
    "id": 100,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "orker with\nCarer with concerns about the child/adolescent’s: concerns about a child/adolescent\nCommon presentations of emotional, behavioral\nDifficulty keeping up with peers or carrying out daily e.g. rule- or law-breaking behaviour, physical aggression and developmental disorders vary by age in\nactivities considered normal for age at home or in the community children and adolescents."
  },
  {
    "id": 101,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ut daily e.g. rule- or law-breaking behaviour, physical aggression and developmental disorders vary by age in\nactivities considered normal for age at home or in the community children and adolescents. Decline or problems with memory (severe forgetfulness) and orientation (awareness of time, place and person)\nDEMENTIA (DEM)\nMood or behavioural problems such as apathy (appearing uninterested) or irritability\nLoss of emotional control (easily upset, irritable or tearful)\nDifficulties in carrying out usual work, domestic or social activities\nAppearing affected by alcohol or other substance Incidental findings: macrocytic anaemia, low\n(e.g."
  },
  {
    "id": 102,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "upset, irritable or tearful)\nDifficulties in carrying out usual work, domestic or social activities\nAppearing affected by alcohol or other substance Incidental findings: macrocytic anaemia, low\n(e.g. smell of alcohol, slurred speech, sedated, erratic platelet count, elevated mean corpuscular\nbehaviour) volume (MCV) DISORDERS DUE\nSigns and symptoms of acute behavioural effects, Emergency presentation due to substance\nTO SUBSTANCE\nwithdrawal features or effects of prolonged use withdrawal, overdose, or intoxication. Person may appear sedated, overstimulated,\nDeterioration of social functioning (i.e."
  },
  {
    "id": 103,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ue to substance\nTO SUBSTANCE\nwithdrawal features or effects of prolonged use withdrawal, overdose, or intoxication. Person may appear sedated, overstimulated,\nDeterioration of social functioning (i.e. difficulties at USE (SUB)\nagitated, anxious or confused\nwork or home, unkempt appearance)\nPersons with disorders due to substance use\nSigns of chronic liver disease (abnormal liver enzymes), All persons presenting to\nmay not report any problems with substance\njaundiced (yellow) skin and eyes, palpable and tender health care facilities should\nuse."
  },
  {
    "id": 104,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ic liver disease (abnormal liver enzymes), All persons presenting to\nmay not report any problems with substance\njaundiced (yellow) skin and eyes, palpable and tender health care facilities should\nuse. Look for:\nliver edge (in early liver disease), ascites (distended be asked about\nabdomen is filled with fluid), spider naevi (spider-like – Recurrent requests for psychoactive their tobacco and\nblood vessels visible on the surface of the skin), and medications including analgesics alcohol use."
  },
  {
    "id": 105,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "lled with fluid), spider naevi (spider-like – Recurrent requests for psychoactive their tobacco and\nblood vessels visible on the surface of the skin), and medications including analgesics alcohol use. altered mental status (hepatic encephalopathy) – Injuries\n– Infections associated with intravenous drug\nProblems with balance, walking, coordinated\nuse (HIV/AIDS, Hepatitis C)\nmovements, and nystagmus\nExtreme hopelessness and despair\nCurrent thoughts, plan or act of self-harm/ SELF-HARM/SUICIDE (SUI)\nsuicide, or history thereof\nAny of the other priority conditions, chronic\npain, or extreme emotional distress\n17\n\n18\nEMERGENCY Presentations of Priority MNS Conditions\nEMERGENCY PRESENTATION CONDITION TO CONSIDER GO TO\nAct of self-harm with signs of poisoning or intoxication,\nbleeding from self-inflicted wound, loss of consciousness MEDICALLY SERIOUS ACT OF SELF-HARM\nand/or extreme lethargy\nSUI\nCurrent thoughts, plan, or act of self-harm or suicide, or\nIMMINENT RISK OF SELF-HARM/SUICIDE\nhistory of thoughts, plan, or act of self-harm or suicide in a\nperson who is now extremely agitated, violent, distressed\nor lacks communication\nAcute convulsion with loss of consciousness or impaired\nEPILEPSY\nconsciousness\nEPI, SUB\nSTATUS EPILEPTICUS\nContinuous convulsions\nALCOHOL OR OTHER SEDATIVE WITHDRAWAL\nAgitated and/or aggressive behaviour DEM, PSY, SUB\nSmell of alcohol on the breath, slurred speech, uninhibited\nbehaviour; disturbance in the level of consciousness, cognition, ACUTE ALCOHOL INTOXICATION\nperception, affect or behaviour\nTremor in hands, sweating, vomiting, increased pulse and ALCOHOL WITHDRAWAL\nSUB\nblood pressure, agitation, headache, nausea, anxiety; seizure ALCOHOL WITHDRAWAL DELIRIUM\nand confusion in severe cases\nUnresponsive or minimally responsive, slow respiratory rate,\nSEDATIVE OVERDOSE OR INTOXICATION\npinpoint pupils\nDilated pupils, excited, racing thoughts, disordered thinking,\nACUTE STIMULANT INTOXICATION OR OVERDOSE\nstrange behaviour, recent use of cocaine or other stimulants,\nincreased pulse and blood pressure, aggressive, erratic or\nviolent behaviour\n\nDEPRESSION\nPeople with depression experience a range of symptoms Depression commonly occurs alongside other MNS conditions as\nincluding persistent depressed mood or loss of interest and well as physical conditions."
  },
  {
    "id": 106,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ple with depression experience a range of symptoms Depression commonly occurs alongside other MNS conditions as\nincluding persistent depressed mood or loss of interest and well as physical conditions. pleasure for at least 2 weeks. The management of symptoms not fully meeting the criteria\nPeople with depression as described in this module have for depression is covered within the module on Other Significant\nconsiderable difficulty with daily functioning in personal, family, Mental Health Complaints. Go to » OTH. social, educational, occupational or other areas. Many people with depression also suffer from anxiety symptoms\nand medically unexplained somatic symptoms. 19\n\n20\nDEP\nDEPRESSION\nDEP Quick Overview\nASSESSMENT MANAGEMENT\nD oes the person have depression? Management Protocols\n1."
  },
  {
    "id": 107,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "n also suffer from anxiety symptoms\nand medically unexplained somatic symptoms. 19\n\n20\nDEP\nDEPRESSION\nDEP Quick Overview\nASSESSMENT MANAGEMENT\nD oes the person have depression? Management Protocols\n1. Depression\nAre there other explanations for the symptoms? 2. Depressive episode in bipolar disorder\n3."
  },
  {
    "id": 108,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "EP Quick Overview\nASSESSMENT MANAGEMENT\nD oes the person have depression? Management Protocols\n1. Depression\nAre there other explanations for the symptoms? 2. Depressive episode in bipolar disorder\n3. Special populations\n– Rule out physical conditions\n– Rule out a history of mania\n– Rule out normal reactions to recent major loss\nPsychosocial Interventions\nAssess for other priority MNS conditions\nPharmacological Interventions\nFOLLOW-UP\n\nDEPRESSION Assessment\nDEP 1 Assessment\nCOMMON PRESENTATIONS OF DEPRESSION\nM ultiple persistent physical symptoms with no clear cause\nL ow energy, fatigue, sleep problems\nP ersistent sadness or depressed mood, anxiety\nL oss of interest or pleasure in activities that are normally pleasurable\n11\nDoes the person have depression?"
  },
  {
    "id": 109,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "cause\nL ow energy, fatigue, sleep problems\nP ersistent sadness or depressed mood, anxiety\nL oss of interest or pleasure in activities that are normally pleasurable\n11\nDoes the person have depression? Has the person had at least one of the following\ncore symptoms of depression for at least 2 weeks?"
  },
  {
    "id": 110,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "interest or pleasure in activities that are normally pleasurable\n11\nDoes the person have depression? Has the person had at least one of the following\ncore symptoms of depression for at least 2 weeks? – Persistent depressed mood\n– Markedly diminished interest in or pleasure from activities\nDepression is unlikely\nGo to OTH\nDEPRESSION 21\n\n22\nDEP 1\nDEPRESSION Assessment\nHas the person had several of the following additional symptoms\nfor at least 2 weeks:\n– Disturbed sleep or sleeping too much – Indecisiveness\n– Significant change in appetite or weight – Observable agitation or physical\n(decrease or increase) restlessness\n– Beliefs of worthlessness or excessive guilt – Talking or moving more slowly than usual\n– Fatigue or loss of energy – Hopelessness\n– Reduced concentration – Suicidal thoughts or acts\nDepression is unlikely\nGo to OTH\nDoes the person have considerable difficulty with\ndaily functioning in personal, family, social, educational,\noccupational or other areas?"
  },
  {
    "id": 111,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "– Suicidal thoughts or acts\nDepression is unlikely\nGo to OTH\nDoes the person have considerable difficulty with\ndaily functioning in personal, family, social, educational,\noccupational or other areas? Depression is unlikely\nGo to OTH CLINICAL TIP:\nA person with depression may have psychotic\nsymptoms such as delusions or hallucinations. If\npresent, treatment for depression needs to be\nConsider DEPRESSION\nadapted. CONSULT A SPECIALIST. 2\nAre there other possible explanations\nfor the symptoms? IS THIS A PHYSICAL CONDITION THAT CAN RESEMBLE OR EXACERBATE DEPRESSION? Are there signs and symptoms suggesting anaemia, malnutrition,\nhypothyroidism, mood changes from substance use and medication side-effects\n(e.g. mood changes from steroids)?"
  },
  {
    "id": 112,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "OR EXACERBATE DEPRESSION? Are there signs and symptoms suggesting anaemia, malnutrition,\nhypothyroidism, mood changes from substance use and medication side-effects\n(e.g. mood changes from steroids)? MANAGE THE\nPHYSICAL CONDITION\nDo depressive symptoms remain\nafter treatment? No treatment\nneeded. DEPRESSION 23\n\n24\nDEP 1\nDEPRESSION Assessment\nIS THERE A HISTORY OF MANIA? Have several of the following symptoms occurred simultaneously, lasting for at least 1 week, and severely\nenough to interfere significantly with work and social activities or requiring hospitalization or confinement?"
  },
  {
    "id": 113,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "the following symptoms occurred simultaneously, lasting for at least 1 week, and severely\nenough to interfere significantly with work and social activities or requiring hospitalization or confinement? – Elevation of mood and/or irritability – Loss of normal social inhibitions resulting in inappropriate\n– Decreased need for sleep behaviours\n– Increased activity, feeling of increased energy, increased – Being easily distracted\ntalkativeness or rapid speech – Unrealistically inflated self-esteem\n– Impulsive or reckless behaviours such as excessive spending, making\nimportant decisions without planning and sexual indiscretion\nCLINICAL TIP:\nDEPRESSIVE EPISODE\nPeople with depressive episode in\nIN BIPOLAR bipolar disorder are at risk for mania."
  },
  {
    "id": 114,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "sive spending, making\nimportant decisions without planning and sexual indiscretion\nCLINICAL TIP:\nDEPRESSIVE EPISODE\nPeople with depressive episode in\nIN BIPOLAR bipolar disorder are at risk for mania. Treatment is different from depres-\nDISORDER is likely\nsion. Protocol 2 must be applied. Go to STEP 1 30 then to PROTOCOL 2\nHAS THERE BEEN A MAJOR LOSS (E.G. BEREAVEMENT)\nWITHIN THE LAST 6 MONTHS? DEPRESSION is likely\nG o to STEP 1 30 then to PROTOCOL 1\n\nAre any of the following symptoms present? – Suicidal ideation – Talking or moving more\n– Beliefs of worthlessness slowly than normal\n– Psychotic symptoms\nDoes the person have a previous\nhistory of depression? DEPRESSION is likely\nDo not manage for depression. Go to OTH\n3\nIF THERE IS IMMINENT RISK\nAre there concurrent priority MNS conditions?"
  },
  {
    "id": 115,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "c symptoms\nDoes the person have a previous\nhistory of depression? DEPRESSION is likely\nDo not manage for depression. Go to OTH\n3\nIF THERE IS IMMINENT RISK\nAre there concurrent priority MNS conditions? OF SUICIDE, ASSESS AND MANAGE\n»\nbefore continuing. Go to SUI. A ssess for concurrent MNS conditions according to the\nmhGAP-IG master chart. Go to\n»\nMC. People with depression are at higher risk for most other priority MNS conditions. Assess for disorders due to substance use. Go to PROTOCOL 1\nDEPRESSION 25\n\n26\nDEP 2\nDEPRESSION Management\nDEP 2 Management\nSpecial populations\nNote that interventions may differ\nfor these populations\nPROTOCOL PROTOCOL\n1 2\nDepression Depression in Bipolar Disorder CHILD / ADOLESCENT\nFor management of depression in\n» » children/adolescents, go to CMH."
  },
  {
    "id": 116,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "t interventions may differ\nfor these populations\nPROTOCOL PROTOCOL\n1 2\nDepression Depression in Bipolar Disorder CHILD / ADOLESCENT\nFor management of depression in\n» » children/adolescents, go to CMH. Provide psychoeducation to the person and their Consult a specialist. carers. (2.1) »\nIf a specialist is not immediately available,\n»\nReduce stress and strengthen social supports. (2.2) follow treatment for depression (PROTOCOL 1). » However, NEVER prescribe antidepressants\nPromote functioning in daily activities and\nalone without a mood stabilizer such as lithium,\ncommunity life. (2.3) WOMEN WHO ARE PREGNANT OR\ncarbamazepine or valproate because anti-\nBREASTFEEDING\n»\nConsider antidepressants. (2.5) depressants can lead to mania in people with\n» bipolar disorder (Go to PSY)."
  },
  {
    "id": 117,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e. (2.3) WOMEN WHO ARE PREGNANT OR\ncarbamazepine or valproate because anti-\nBREASTFEEDING\n»\nConsider antidepressants. (2.5) depressants can lead to mania in people with\n» bipolar disorder (Go to PSY). If available, consider referral for one of the\n»\n» F ollow treatment for depression\nfollowing brief psychological treatments: If symptoms of mania develop, tell the person\n(PROTOCOL 1) but AVOID anti-\ninterpersonal therapy (IPT), cognitive behavioural and the carers to stop the antidepressant\ndepressants if possible, especially during\ntherapy (CBT), behaviour activation and problem- immediately and return for help. the first trimester. solving counselling."
  },
  {
    "id": 118,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "carers to stop the antidepressant\ndepressants if possible, especially during\ntherapy (CBT), behaviour activation and problem- immediately and return for help. the first trimester. solving counselling. (2.4)\n»\n» I f no response to psychological treat-\nDO NOT manage the symptoms with ineffective\nment, consider using with caution the\ntreatments, e.g. vitamin injections. lowest effective dose of antidepressants. »\nOffer regular follow-up. »\nI f breastfeeding, avoid long acting\nmedication such as fluoxetine. »\nC ONSULT A SPECIALIST, if available."
  },
  {
    "id": 119,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "g. vitamin injections. lowest effective dose of antidepressants. »\nOffer regular follow-up. »\nI f breastfeeding, avoid long acting\nmedication such as fluoxetine. »\nC ONSULT A SPECIALIST, if available. PSYCHOSOCIAL INTERVENTIONS\n2.1 P sychoeducation: key messages 2.2 R educe stress and strengthen 2.4 B rief psychological treatments\nto the person and the carers social support for depression\nDepression is a very common condition that can happen Assess for and try to reduce stressors. (Go to » ECP) This guide does not provide specific protocols to implement\nto anybody. brief psychological interventions. WHO, among other\nReactivate the person’s previous social network."
  },
  {
    "id": 120,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ce stressors. (Go to » ECP) This guide does not provide specific protocols to implement\nto anybody. brief psychological interventions. WHO, among other\nReactivate the person’s previous social network. Identify prior\nagencies, has developed manuals that describe their use\nThe occurrence of depression does not mean that the person social activities that, if started again, may potentially provide for depression. An example is, Problem Management Plus,\ndirect or indirect psychosocial support, e.g. family gatherings,\nis weak or lazy. (http://www.who.int/mental_health/emergencies/ problem_\nvisiting neighbours, and community activities. management_plus/en/), which describes the use of\nNegative attitudes of others (e.g."
  },
  {
    "id": 121,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "weak or lazy. (http://www.who.int/mental_health/emergencies/ problem_\nvisiting neighbours, and community activities. management_plus/en/), which describes the use of\nNegative attitudes of others (e.g. “You should be stronger”,\nbehavioural activation, relaxation training, problem solving\n“Pull yourself together”) may be because depression is\ntreatment and strengthening social supports. Moreover, the\nnot a visible condition, unlike a fracture or a wound. There\n2.3 P romote functioning in daily\nmanual Group Interpersonal Therapy (IPT) for Depression\nis also the misconception that people with depression can activities and community life\ndescribes group treatment of depression (http://www.who. easily control their symptoms by sheer willpower. int/mental_health/mhgap/interpersonal_therapy/en)."
  },
  {
    "id": 122,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "pression can activities and community life\ndescribes group treatment of depression (http://www.who. easily control their symptoms by sheer willpower. int/mental_health/mhgap/interpersonal_therapy/en). Even if it is difficult, encourage the person to try to do as Thinking Healthy, (http://www.who.int/mental_health/\nPeople with depression tend to have unrealistically negative\nmany of the following as possible: maternal-child/ thinking_healthy/en), describes the use of\nopinions about themselves, their life and their future. Their\ncognitive-behavioural therapy for perinatal depression. current situation may be very difficult, but depression can – Try to start again (or continue) activities that were\ncause unjustified thoughts of hopelessness and previously pleasurable. worthlessness."
  },
  {
    "id": 123,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "urrent situation may be very difficult, but depression can – Try to start again (or continue) activities that were\ncause unjustified thoughts of hopelessness and previously pleasurable. worthlessness. These views are likely to improve once the\n– Try to maintain regular sleeping and waking times. depression improves. – Try to be as physically active as possible. Thoughts of self-harm or suicide are common. If they\n– Try to eat regularly despite changes in appetite. notice these thoughts, they should not act on them, but\nshould tell a trusted person and come back for help – Try to spend time with trusted friends and family. immediately. – Try to participate in community and other social activities\nas much as possible."
  },
  {
    "id": 124,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "should tell a trusted person and come back for help – Try to spend time with trusted friends and family. immediately. – Try to participate in community and other social activities\nas much as possible. Explain to the person and carer that these activities can\nall help improve mood. DEPRESSION 27\n\n28\nDEP 2\nDEPRESSION Management\nPHARMACOLOGICAL INTERVENTIONS\n2.5 C onsider antidepressants\nDiscuss with the person and decide together whether to CAUTION OLDER ADULTS\nprescribe antidepressants. Explain that:\nIf the person develops a manic episode, stop the anti-\nAvoid amitriptyline if possible. – Antidepressants are not addictive. depressant immediately; it may trigger a manic episode\n– It is very important to take the medication every day as\nin untreated bipolar disorder."
  },
  {
    "id": 125,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "yline if possible. – Antidepressants are not addictive. depressant immediately; it may trigger a manic episode\n– It is very important to take the medication every day as\nin untreated bipolar disorder. PEOPLE WITH CARDIOVASCULAR DISEASE\nprescribed. Do not combine with other antidepressants, as this may Do NOT prescribe amitriptyline. – Some side effects may be experienced within the first few cause serotonin syndrome. days but they usually resolve. Antidepressants may increase suicidal ideation, especially in ADULTS WITH THOUGHTS OR PLANS OF SUICIDE\n– It usually takes several weeks before improvements in adolescents and young adults. SSRIs are the first choice. Overdose of TCAs such as\nmood, interest or energy is noticed."
  },
  {
    "id": 126,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "GHTS OR PLANS OF SUICIDE\n– It usually takes several weeks before improvements in adolescents and young adults. SSRIs are the first choice. Overdose of TCAs such as\nmood, interest or energy is noticed. amitriptyline may be fatal and therefore should be avoided in\nConsider the person’s age, concurrent medical conditions, Antidepressants in special populations this group. and drug side-effect profile. If there is an imminent risk of self-harm or suicide\nStart with only one medication at the lowest starting dose. ADOLESCENTS 12 YEARS OF AGE OR OLDER\n(Go to\n»\nSUI), give a limited supply of antidepressants\n(e.g. one week supply at a time)."
  },
  {
    "id": 127,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rm or suicide\nStart with only one medication at the lowest starting dose. ADOLESCENTS 12 YEARS OF AGE OR OLDER\n(Go to\n»\nSUI), give a limited supply of antidepressants\n(e.g. one week supply at a time). If symptoms persist or worsen despite psychosocial inter-\nAntidepressant medications usually need to be continued\nventions, consider fluoxetine (but no other selective serotonin Ask the person’s carers to keep and monitor medications\nfor at least 9-12 months after the resolution of symptoms.. reuptake inhibitor (SSRI) or tricyclic antidepressant (TCA)). and to follow-up frequently to prevent medication overdose. Medications should never be stopped just because the\nIf fluoxetine is prescribed, ask the adolescent to return weekly,\nperson experiences some improvement."
  },
  {
    "id": 128,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "p frequently to prevent medication overdose. Medications should never be stopped just because the\nIf fluoxetine is prescribed, ask the adolescent to return weekly,\nperson experiences some improvement. Educate the person\nfor the first 4 weeks, to monitor thoughts or plans of suicide. on the recommended timeframe to take medications. WOMEN WHO ARE PREGNANT OR BREASTFEEDING\nAvoid antidepressants, if possible. Consider antidepressants at the lowest effective dose if there\nis no response to psychosocial interventions. If the woman is breastfeeding, avoid long acting\nantidepressant medication such as fluoxetine. Consult a specialist if available. TABLE 1: Antidepressants\nMEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nAMITRIPTYLINE Start 25 mg at bedtime."
  },
  {
    "id": 129,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "idepressant medication such as fluoxetine. Consult a specialist if available. TABLE 1: Antidepressants\nMEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nAMITRIPTYLINE Start 25 mg at bedtime. Common: Sedation, orthostatic hypotension (risk of fall), Avoid in persons with cardiac disease, history of seizure,\n(a tricyclic antidepressant Increase by 25-50 mg per week to 100-150 mg blurred vision, difficulty urinating, nausea, weight gain, hyperthyroidism, urinary retention, or narrow angle-closure glaucoma,\n(TCA)) daily (maximum 300 mg). sexual dysfunction. and bipolar disorder (can trigger mania in people with untreated bipolar\nNote: Minimum effective dose in adults is 75 mg. disorder). Sedation may be seen at lower doses. Serious: ECG changes (e.g."
  },
  {
    "id": 130,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "on. and bipolar disorder (can trigger mania in people with untreated bipolar\nNote: Minimum effective dose in adults is 75 mg. disorder). Sedation may be seen at lower doses. Serious: ECG changes (e.g. QTc prolongation), cardiac\narrhythmia, increased risk of seizure. Overdose can lead to seizures, cardiac arrhythmias, hypotension,\nElderly/Medically Ill: Start 25 mg at bedtime to coma, or death. 50-75 mg daily (maximum 100 mg). Levels of amitriptyline may be increased by anti-malarials including\nChildren/Adolescents: Do not use. quinine. FLUOXETINE Start 10 mg daily for one week then 20 mg daily. Common: Sedation, insomnia, headache, dizziness, Caution in persons with history of seizure."
  },
  {
    "id": 131,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ding\nChildren/Adolescents: Do not use. quinine. FLUOXETINE Start 10 mg daily for one week then 20 mg daily. Common: Sedation, insomnia, headache, dizziness, Caution in persons with history of seizure. (a selective serotonin If no response in 6 weeks, increase to 40 mg gastrointestinal disturbances, changes in appetite, and\nreuptake inhibitor (SSRI)) (maximum 80 mg). sexual dysfunction. Drug-Drug interactions: Avoid combination with warfarin\n(may increase bleeding risk). May increase levels of TCAs, antipsychotics,\nElderly/medically ill: preferred choice. Serious: bleeding abnormalities in those who use and beta-blockers. Start 10 mg daily, then increase to 20 mg aspirin or other non-steroidal anti-inflammatory drugs, low\n(maximum 40 mg). sodium levels."
  },
  {
    "id": 132,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "erious: bleeding abnormalities in those who use and beta-blockers. Start 10 mg daily, then increase to 20 mg aspirin or other non-steroidal anti-inflammatory drugs, low\n(maximum 40 mg). sodium levels. Caution in combination with tamoxifen, codeine, and tramadol (reduces\nthe effect of these drugs). Adolescents\nStart 10 mg daily. Increase to 20 mg daily if no\nresponse in 6 weeks (maximum 40 mg). DEPRESSION 29\n\n30\nDEP 3\nDEPRESSION Follow-up\nDEP 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n1 »\nSchedule the second appointment\nwithin 1 week. ASSESS FOR IMPROVEMENT »\nInitially maintain regular contact\nvia telephone, home visits, letters,\nor contact cards more frequently,\nIs the person improving? e.g. monthly, for the first 3 months."
  },
  {
    "id": 133,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "week. ASSESS FOR IMPROVEMENT »\nInitially maintain regular contact\nvia telephone, home visits, letters,\nor contact cards more frequently,\nIs the person improving? e.g. monthly, for the first 3 months. » If not yet receiving psychological treatment, » Encourage the person to continue with their\nconsider psychological treatment. current management plan until they are symptom\n» free for 9-12 months. If receiving a psychological treatment, evaluate engagement in\nand experience of current psychological treatment. » A rrange a further follow up appointment\n» in 1-2 weeks. If not yet on antidepressants, consider antidepressants. »\n» D ecrease contact as the person’s symptoms improve,\nIf on antidepressants, assess:\ne.g. once every 3 months after the initial 3 months."
  },
  {
    "id": 134,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ks. If not yet on antidepressants, consider antidepressants. »\n» D ecrease contact as the person’s symptoms improve,\nIf on antidepressants, assess:\ne.g. once every 3 months after the initial 3 months. – Does the person take the medication as prescribed? Note: follow up should continue until the person no longer\nIf not, explore reasons why and encourage adherence. has any symptoms of depression. – Are there side effects? If yes, evaluate and weigh benefits of treatment. If no to side effects to antidepressants, increase dose (TABLE 1). Follow-up in 1-2 weeks. CAUTION WITH DOSE INCREASE. CLOSE FOLLOW-UP NEEDED\nDUE TO POSSIBLE INCREASE IN SIDE EFFECTS. Are there symptoms of mania? »\nDiscontinue antidepressant medication. 2\n»\nT reat mania and consult a specialist. Go to PSY."
  },
  {
    "id": 135,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "E INCREASE. CLOSE FOLLOW-UP NEEDED\nDUE TO POSSIBLE INCREASE IN SIDE EFFECTS. Are there symptoms of mania? »\nDiscontinue antidepressant medication. 2\n»\nT reat mania and consult a specialist. Go to PSY. MONITOR TREATMENT\nAt every contact:\n»\nProvide psychoeducation, reduce stress and strengthen social supports, promote functioning in daily activities\nand community life, and review, if applicable, antidepressant medication use and psychological treatment. »\nDoes the person have any new symptoms of concern? Review for MNS and concurrent physical conditions. »\nIs the person a woman of childbearing age and considering pregnancy? If so, CONSULT A SPECIALIST. Assess for any IMMINENT RISK OF SUICIDE (Go to SUI). 3\nREVISE TREATMENT AS APPROPRIATE\nHas the person been symptom free for 9-12 months?"
  },
  {
    "id": 136,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ing age and considering pregnancy? If so, CONSULT A SPECIALIST. Assess for any IMMINENT RISK OF SUICIDE (Go to SUI). 3\nREVISE TREATMENT AS APPROPRIATE\nHas the person been symptom free for 9-12 months? »\nDiscuss with the person the risks and\nbenefits of stopping the medication\n»\n» Taper the dose of medication gradually,\nContinue medication until person is\nover a minimum of 4 weeks. Monitor\nsymptom free for 9-12 months. the person for symptom recurrence. DEPRESSION 31\n\n32\nDEPRESSION\n\nPSYCHOSES\nThe psychoses module covers management of two severe mental Bipolar disorder is characterized by episodes in which the person’s\nhealth conditions, psychosis and bipolar disorder. People with mood and activity levels are significantly disturbed."
  },
  {
    "id": 137,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "o severe mental Bipolar disorder is characterized by episodes in which the person’s\nhealth conditions, psychosis and bipolar disorder. People with mood and activity levels are significantly disturbed. This disturbance\npsychosis or bipolar disorder are at high risk of exposure to stigma, consists on some occasions of an elevation of mood and increased\ndiscrimination and violation of their right to live with dignity. energy and activity (mania), and on others of a lowering of mood\nand decreased energy and activity (depression). Characteristically,\nPsychosis is characterised by distorted thoughts and perceptions, recovery is complete between episodes. People who experience only\nas well as disturbed emotions and behaviours."
  },
  {
    "id": 138,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "). Characteristically,\nPsychosis is characterised by distorted thoughts and perceptions, recovery is complete between episodes. People who experience only\nas well as disturbed emotions and behaviours. Incoherent or irrele- manic episodes are also classified as having bipolar disorder. vant speech may also be present. Symptoms such as hallucinations –\nhearing voices, or seeing things that are not there; delusions –\nfixed, false beliefs; severe abnormalities of behaviour – disorganised\nbehaviour, agitation, excitement, inactivity, or hyperactivity;\ndisturbances of emotion – marked apathy, or disconnect between\nreported emotion and observed affect, such as facial expression\nand body language, may also be detected."
  },
  {
    "id": 139,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "t, inactivity, or hyperactivity;\ndisturbances of emotion – marked apathy, or disconnect between\nreported emotion and observed affect, such as facial expression\nand body language, may also be detected. 33\n\n34\nPSY 1\nPSYCHOSES\nPSY Quick Overview\nASSESSMENT MANAGEMENT\nE xplore other explanations for the symptoms Management Protocols\n1. Bipolar disorder – manic episode\n– EVALUATE FOR MEDICAL CONDITIONS\n2. Psychosis\ne.g. rule out delirium, medications and metabolic abnormalities\n3. Special populations: women who are pregnant or\n– EVALUATE FOR OTHER RELEVANT MNS CONDITIONS breast-feeding, adolescents, and older adults\nAssess for acute manic episode Psychosocial Interventions\nEvaluate if the person has psychosis\nPharmacological Interventions\n1. Psychosis: initiation of antipsychotics\n2."
  },
  {
    "id": 140,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "adolescents, and older adults\nAssess for acute manic episode Psychosocial Interventions\nEvaluate if the person has psychosis\nPharmacological Interventions\n1. Psychosis: initiation of antipsychotics\n2. Manic episode: initiation of mood stabilizer or\nantipsychotic; avoid antidepressants\nFOLLOW-UP\n\nPSY 1 Assessment\nCOMMON PRESENTATIONS OF PSYCHOSES\nM arked behavioural changes, neglecting F ixed false beliefs not shared by others in\nusual responsibilities related to work, the person’s culture. school, domestic or social activities. H earing voices or seeing things that are\nA gitated, aggressive behaviour, decreased not there. or increased activity. L ack of realization that one is having\nmental health problems. 1\nAre there any other explanations for the symptoms?"
  },
  {
    "id": 141,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "at are\nA gitated, aggressive behaviour, decreased not there. or increased activity. L ack of realization that one is having\nmental health problems. 1\nAre there any other explanations for the symptoms? EVALUATE FOR MEDICAL CONDITIONS\nBy history, clinical examination, or laboratory findings, are there signs and symptoms\nsuggesting delirium due to an acute physical condition, e.g. infection, cerebral malaria,\ndehydration, metabolic abnormalities (such as hypoglycaemia or hyponatraemia);\nor medication side effects, e.g. due to some antimalarial medication or steroids? Assess and manage the\nacute physical condition, and\nrefer to emergency services/\nspecialist as needed."
  },
  {
    "id": 142,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "hyponatraemia);\nor medication side effects, e.g. due to some antimalarial medication or steroids? Assess and manage the\nacute physical condition, and\nrefer to emergency services/\nspecialist as needed. If symptoms persist after management\nof the acute cause, go to STEP 2\nPSYCHOSES 35\n\n36\nPSY 1\nPSYCHOSES Assessment\n»\nEVALUATE FOR DEMENTIA, DEPRESSION, DRUG/\nALCOHOL INTOXICATION OR WITHDRAWAL. MANAGEMENT OF ACUTE\nAGITATION AND/OR AGRESSION\nConsider consultation with a mental If the person presents with either acute\nhealth specialist for management of agitation and/or acute agression\nconcurrent conditions. Go to “Management of persons with\nagitated and/or aggressive behaviour”\nManage concurrent conditions. (Table 5) in this module before\nGo to relevant modules. continuing."
  },
  {
    "id": 143,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ression\nconcurrent conditions. Go to “Management of persons with\nagitated and/or aggressive behaviour”\nManage concurrent conditions. (Table 5) in this module before\nGo to relevant modules. continuing. 2\nIs the person having an acute manic episode?"
  },
  {
    "id": 144,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "t of persons with\nagitated and/or aggressive behaviour”\nManage concurrent conditions. (Table 5) in this module before\nGo to relevant modules. continuing. 2\nIs the person having an acute manic episode? Have several of the following symptoms occurred simultaneously, lasting for at least 1 week, and severely enough\nto interfere significantly with work and social activities or requiring confinement or hospitalization:\n– Elevated or irritable mood – Loss of normal social inhibitions such – Being easily distracted\n– Decreased need for sleep as sexual indiscretion – Unrealistically inflated self-esteem\n– Increased activity, feeling of increased – Impulsive or reckless behaviours such as\nenergy, increased talkativeness or excessive spending, making important\nrapid speech decisions without planning\nSuspect\nCLINICAL TIP Persons with bipolar disorder can\nBIPOLAR DISORDER Manic Episode\nexperience manic episodes only or a combination of manic\nand depressive episodes in their lifetime."
  },
  {
    "id": 145,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "thout planning\nSuspect\nCLINICAL TIP Persons with bipolar disorder can\nBIPOLAR DISORDER Manic Episode\nexperience manic episodes only or a combination of manic\nand depressive episodes in their lifetime. To learn how to assess and manage depressive episode\nIF THERE IS IMMINENT RISK\n»\nof bipolar disorder, go to DEP. Go to PROTOCOL 1\nOF SUICIDE, ASSESS AND MANAGE\n»\nbefore continuing. Go to SUI. 3\nDoes the person have psychosis? Does the person have at least two of the following:\n– Delusions, fixed false beliefs not shared by others in the person’s culture\n– Hallucinations, hearing voices or seeing things that are not there\n– Disorganized speech and/or behaviour, e.g."
  },
  {
    "id": 146,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "llowing:\n– Delusions, fixed false beliefs not shared by others in the person’s culture\n– Hallucinations, hearing voices or seeing things that are not there\n– Disorganized speech and/or behaviour, e.g. incoherent/irrelevant speech such as mumbling\nor laughing to self, strange appearance, signs of self-neglect or appearing unkempt\nSuspect\nConsider consultation with specialist\nto review other possible causes of PSYCHOSIS\npsychosis. Go to PROTOCOL 2\nIF THERE IS IMMINENT RISK\nOF SUICIDE, ASSESS AND MANAGE\n»\nbefore continuing. Go to SUI. PSYCHOSES 37\n\n38\nPSY 2\nPSYCHOSES Management\nPSY 2 Management\nPROTOCOL PROTOCOL\n1 2\nManic Episode in Bipolar Disorder Psychosis\n» »\nProvide psychoeducation to the person and carers. (2.1) Provide psychoeducation to the person and carers."
  },
  {
    "id": 147,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "agement\nPSY 2 Management\nPROTOCOL PROTOCOL\n1 2\nManic Episode in Bipolar Disorder Psychosis\n» »\nProvide psychoeducation to the person and carers. (2.1) Provide psychoeducation to the person and carers. (2.2)\n» »\nPharmacological Intervention. (2.6) Begin antipsychotic medication. (2.5)\nStart with a low dose within the therapeutic range and\nI f patient is on antidepressants – DISCONTINUE\nincrease slowly to the lowest effective dose, in order to reduce\nto prevent further risk of mania. the risk of side-effects. – B egin treatment with lithium, valproate, carbamazepine, »\nP romote functioning in daily activities. (2.3)\nor with antipsychotics. Consider a short term (2-4 weeks\n»\nmaximum) benzodiazepine for behavioural disturbance or E nsure safety of the person and safety of others. agitation."
  },
  {
    "id": 148,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "daily activities. (2.3)\nor with antipsychotics. Consider a short term (2-4 weeks\n»\nmaximum) benzodiazepine for behavioural disturbance or E nsure safety of the person and safety of others. agitation. »\nP rovide regular follow-up. »\nPromote functioning in daily activities. (2.3) »\nS upport rehabilitation in the community. »\nEnsure safety of the person and safety of others. »\nR educe stress and strengthen social supports. (2.2)\n»\nProvide regular follow-up. »\nSupport rehabilitation in the community. »\nReduce stress and strengthen social supports. (2.2)\n\nSpecial populations\nNote that interventions may differ for PSYCHOSES in these populations\nWOMEN WHO ARE PREGNANT OR BREASTFEEDING ADOLESCENTS\n» Liaise with maternal health specialists to organize care."
  },
  {
    "id": 149,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "pecial populations\nNote that interventions may differ for PSYCHOSES in these populations\nWOMEN WHO ARE PREGNANT OR BREASTFEEDING ADOLESCENTS\n» Liaise with maternal health specialists to organize care. » Consider consultation with mental health\n» Consider consultation with mental health specialist if available. specialist. » »\nExplain the risk of adverse consequences for the mother and her baby, including obstetric In adolescents with psychotic or bipolar\ncomplications and psychotic relapses, particularly if medication stopped. disorder, risperidone can be offered as a\n» treatment option only under supervision of\nConsider pharmacological intervention when appropriate and available. See below. a specialist."
  },
  {
    "id": 150,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "edication stopped. disorder, risperidone can be offered as a\n» treatment option only under supervision of\nConsider pharmacological intervention when appropriate and available. See below. a specialist. »\nPharmacological Interventions If treatment with risperidone is not feasible,\nhaloperidol or chlorpromazine may be\nPSYCHOSIS MANIC EPISODE IN BIPOLAR DISORDER used only under supervision of a specialist. » »\nIn women with psychosis who are planning AVOID VALPROATE, LITHIUM and\na pregnancy or pregnant or breastfeeding, CARBAMAZEPINE during pregnancy and\nlow-dose oral haloperidol, or chlorpromazine breastfeeding due to the risk of birth defects. may be considered."
  },
  {
    "id": 151,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "LITHIUM and\na pregnancy or pregnant or breastfeeding, CARBAMAZEPINE during pregnancy and\nlow-dose oral haloperidol, or chlorpromazine breastfeeding due to the risk of birth defects. may be considered. »\nConsider low-dose haloperidol with caution\n» OLDER ADULTS\nAnticholinergics should NOT prescribed and in consultation with a specialist, if available. to women who are pregnant due to extrapyra- »\nWeigh the risks and benefits of medications in\nmidal side-effects of antipsychotic medications,\nwomen of childbearing age. »\nUse lower doses of medication. except in cases of acute, short-term use."
  },
  {
    "id": 152,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "»\nWeigh the risks and benefits of medications in\nmidal side-effects of antipsychotic medications,\nwomen of childbearing age. »\nUse lower doses of medication. except in cases of acute, short-term use. »\n» Depot antipsychotics should not be routinely If a pregnant woman develops acute mania » Anticipate an increased risk of drug-drug\nwhile taking mood stabilizers, consider switching\nprescribed to women with psychotic disorders interactions. to low dose haloperidol. who are planning a pregnancy, pregnant, or\nCAUTION\nbreastfeeding because there is relatively little\nAntipsychotics carry an increased risk of\ninformation on their safety in this population. cerebrovascular events and death in older\nadults with dementia-related psychosis."
  },
  {
    "id": 153,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e there is relatively little\nAntipsychotics carry an increased risk of\ninformation on their safety in this population. cerebrovascular events and death in older\nadults with dementia-related psychosis. PSYCHOSES 39\n\n40\nPSY 2\nPSYCHOSES Management\nPSYCHOSOCIAL INTERVENTIONS\n2.1 Psychoeducation 2.3 Promote functioning in daily\nRecommend avoiding alcohol, cannabis or other non-\nprescription drugs, as they can worsen the psychotic or living activities\nKey messages for the person and their carers: bipolar symptoms. Continue regular social, educational and occupational\nExplain that the symptoms are due to a mental health Advise them about maintaining a healthy lifestyle, e.g. a\nactivities as much as possible."
  },
  {
    "id": 154,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ms. Continue regular social, educational and occupational\nExplain that the symptoms are due to a mental health Advise them about maintaining a healthy lifestyle, e.g. a\nactivities as much as possible. It is best for the person to have\ncondition, that psychosis and bipolar disorders can be balanced diet, physical activity, regular sleep, good personal\na job or to be otherwise meaningfully occupied. treated, and that the person can recover. Clarify common hygiene, and no stressors. Stress can worsen psychotic\nmisconceptions about psychosis and bipolar disorder. symptoms. Note: Lifestyle changes should be continued as long Facilitate inclusion in economic activities, including culturally\nas needed, potentially indefinitely. These changes should be\nappropriate supported employment."
  },
  {
    "id": 155,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "yle changes should be continued as long Facilitate inclusion in economic activities, including culturally\nas needed, potentially indefinitely. These changes should be\nappropriate supported employment. Do not blame the person or their family or accuse them\nplanned and developed for sustainability. of being the cause of the symptoms. Offer life skills training and/or social skills training to enhance\nindependent living skills for people with psychosis and bipolar\nEducate the person and the family that the person needs\n2.2 Reduce stress and strengthen\ndisorders and for their families and/or carers. to take the prescribed medications and return for follow-up\nsocial supports\nregularly."
  },
  {
    "id": 156,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "the family that the person needs\n2.2 Reduce stress and strengthen\ndisorders and for their families and/or carers. to take the prescribed medications and return for follow-up\nsocial supports\nregularly. Facilitate, if available and needed, independent living and\nsupported housing that is culturally and contextually appropriate\nExplain that return and/or worsening of symptoms are\nCoordinate with available health and social resources to meet in the community. common and that it is important to recognize these early\nthe family’s physical, social, and mental health needs. and visit to the health facility as soon as possible."
  },
  {
    "id": 157,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "sources to meet in the community. common and that it is important to recognize these early\nthe family’s physical, social, and mental health needs. and visit to the health facility as soon as possible. Identify the person’s prior social activities that, if reinitiated, 2.4 General advice for carers\nPlan a regular work or school schedule that avoids sleep\nwould have the potential to provide direct or indirect psycho-\ndeprivation and stress for both the person and the carers. logical and social support, e.g. family gatherings, outings with Do not try to convince the person that his or her beliefs or\nEncourage the person to solicit advice about major decisions\nfriends, visiting neighbors, social activities at work sites, sports, experiences are false or not real."
  },
  {
    "id": 158,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "person that his or her beliefs or\nEncourage the person to solicit advice about major decisions\nfriends, visiting neighbors, social activities at work sites, sports, experiences are false or not real. Try to be neutral and\nespecially ones involving money or major commitments. and community activities. Encourage the person to resume supportive, even when the person shows unusual behaviour. these social activities and advise family members about this. Avoid expressing constant or severe criticism or hostility\nEncourage the person and carers to improve social towards the person with psychosis. CLINICAL TIP\nsupport systems. Build rapport with the person. Give the person freedom of movement."
  },
  {
    "id": 159,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "cism or hostility\nEncourage the person and carers to improve social towards the person with psychosis. CLINICAL TIP\nsupport systems. Build rapport with the person. Give the person freedom of movement. Avoid restraining the\nMutual trust between the person and the person, while also ensuring that their basic security and that\nhealth-care provider is critical to ensure CLINICAL TIP of others is met. treatment adherence and long-term outcomes. Ensure persons with psychosis are\nIn general it is better for the person to live with family or\ntreated with respect and dignity. For\ncommunity members in a supportive environment outside of\n»\nfurther details go to ECP. the hospital setting. Long-term hospitalization should be avoided."
  },
  {
    "id": 160,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "family or\ntreated with respect and dignity. For\ncommunity members in a supportive environment outside of\n»\nfurther details go to ECP. the hospital setting. Long-term hospitalization should be avoided. PHARMACOLOGICAL INTERVENTIONS FOR SPECIAL POPULATIONS, (women who are pregnant or breastfeeding,\nchildren/adolescents, and older adults), see detailed recommendations. 2.5 Psychosis 2.6 Manic Episode in Bipolar Disorder\nAntipsychotics should routinely be offered to a person If patient is on antidepressants: CAUTION\nwith psychosis. For women who are pregnant or breastfeeding, avoid\nDISCONTINUE ANTIDEPRESSANTS\nStart antipsychotic medication immediately. See Table 1. valproate, lithium and carbamazepine. Use of low-dose\nto prevent further risk of mania. Prescribe one antipsychotic at a time."
  },
  {
    "id": 161,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ANTIDEPRESSANTS\nStart antipsychotic medication immediately. See Table 1. valproate, lithium and carbamazepine. Use of low-dose\nto prevent further risk of mania. Prescribe one antipsychotic at a time. haloperidol is recommended with caution and under the\nBegin treatment with lithium, valproate, carba- care of a specialist, if available. Start at lowest dose and titrate up slowly to reduce risk of\nmazepine, or with antipsychotics (see Table 3). side effects. Consider a short term (2-4 weeks maximum)\nTry the medication at a typically effective dose for at Lithium: consider using lithium as first line treatment of benzodiazepine for behavioural disturbances or\nleast 4-6 weeks before considering it ineffective."
  },
  {
    "id": 162,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "cation at a typically effective dose for at Lithium: consider using lithium as first line treatment of benzodiazepine for behavioural disturbances or\nleast 4-6 weeks before considering it ineffective. bipolar disorder only if clinical and laboratory monitoring are agitation:\navailable, a nd prescribe only under specialist supervision. If\nContinue to monitor at that dose as frequently as possible and – Persons with mania who are experiencing agitation may\nlaboratory examinations are not available or feasible, lithium\nas required for the first 4-6 weeks of therapy. If there is no benefit from short-term ( 2-4 weeks maximum) use of a\nshould be avoided and valproate or carbamazepine should\nimprovement, see Follow-up and Table 4. be considered."
  },
  {
    "id": 163,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "-6 weeks of therapy. If there is no benefit from short-term ( 2-4 weeks maximum) use of a\nshould be avoided and valproate or carbamazepine should\nimprovement, see Follow-up and Table 4. be considered. Erratic compliance or stopping lithium benzodiazepine such as diazepam. Monitor weight, blood pressure, fasting sugar, cholesterol and treatment suddenly may increase the risk of relapse. Do not – Benzodiazepines should be discontinued gradually as soon\nECG for persons on antipsychotics if possible (see below). prescribe lithium where the lithium supply may be frequently as symptoms improve, as tolerance can develop. interrupted. Obtain kidney and thyroid function, complete\nblood count, ECG, and pregnancy tests before beginning Continue maintenance treatment for at least 2 years\nCAUTION!"
  },
  {
    "id": 164,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "as tolerance can develop. interrupted. Obtain kidney and thyroid function, complete\nblood count, ECG, and pregnancy tests before beginning Continue maintenance treatment for at least 2 years\nCAUTION! treatment if possible. after the last bipolar episode. Side effects to look for:\nValproate and Carbamazepine: Consider these – Lithium or valproate can be offered for the maintenance\nMANI CO– L EAxRt rDaIpSOyrRaDmEidal side effects (EPS): akathisia, acute medications if clinical or laboratory monitoring for lithium is treatment of bipolar disorder. If treatment with one of\ndystonic reactions, tremor, cog- wheeling, muscular rigidity, not available or if specialist is not available to supervise these agents is not feasible, haloperidol, chloropromazine\nand tardive dyskinesia."
  },
  {
    "id": 165,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nic reactions, tremor, cog- wheeling, muscular rigidity, not available or if specialist is not available to supervise these agents is not feasible, haloperidol, chloropromazine\nand tardive dyskinesia. Treat with anticholinergic medications\nlithium prescription. or carbamazepine may be used. Offer maintenance\nwhen indicated and available (see Table 2). treatment in primary care settings under specialist\nHaloperidol and risperidone: consider haloperidol and\n– Metabolic changes: weight gain, high blood pressure, supervision. increased blood sugar and cholesterol. risperidone only if no clinical or laboratory monitoring is\navailable to start lithium or valproate."
  },
  {
    "id": 166,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "olic changes: weight gain, high blood pressure, supervision. increased blood sugar and cholesterol. risperidone only if no clinical or laboratory monitoring is\navailable to start lithium or valproate. Risperidone can be\n– ECG changes (prolonged QT interval): monitor ECG\nused as an alternative to haloperidol in individuals with\nif possible. bipolar mania if availability can be assured, and cost is not a\n– Neuroleptic malignant syndrome (NMS): a rare,\nconstraint. potentially life-threatening disorder characterized by muscular\nrigidity, elevated temperature, and high blood pressure. PSYCHOSES 41\n\n42\nPSY 2\nPSYCHOSES Management\nTABLE 1: Antipsychotic medications\nMEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nHALOPERIDOL Start 1.5-3 mg daily."
  },
  {
    "id": 167,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e, and high blood pressure. PSYCHOSES 41\n\n42\nPSY 2\nPSYCHOSES Management\nTABLE 1: Antipsychotic medications\nMEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nHALOPERIDOL Start 1.5-3 mg daily. Common: sedation, dizziness, blurred vision, Caution in patients with: kidney disease, liver disease,\nIncrease as needed (maximum 20 mg daily). dry mouth, urinary retention, constipation. cardiac disease, long QT syndrome or taking QT-prolonging medications. Route: oral (p.o.) or intramuscular (i.m.). Monitor ECG if possible. Serious: orthostatic hypotension, extrapyramidal side\neffects (EPS), ECG changes (prolonged QT interval),\nweight gain, galactorrhea, amenorrhea, Neuroleptic\nmalignant syndrome (NMS). RISPERIDONE Start 1 mg daily. Common: sedation, dizziness, tachycardia."
  },
  {
    "id": 168,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "effects (EPS), ECG changes (prolonged QT interval),\nweight gain, galactorrhea, amenorrhea, Neuroleptic\nmalignant syndrome (NMS). RISPERIDONE Start 1 mg daily. Common: sedation, dizziness, tachycardia. Caution in patients with: cardiac disease. Increase to 2-6 mg daily (maximum 10 mg). Route: p.o. Serious: orthostatic hypotension, metabolic effects (elevated Drug-drug interactions: carbamazepine can reduce levels of\nlipids, insulin resistance, weight gain), EPS, elevated prolactin, risperidone, whereas fluoxetine can increase levels. sexual dysfunction, NMS. CHLORPROMAZINE Start 25-50 mg daily."
  },
  {
    "id": 169,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "n reduce levels of\nlipids, insulin resistance, weight gain), EPS, elevated prolactin, risperidone, whereas fluoxetine can increase levels. sexual dysfunction, NMS. CHLORPROMAZINE Start 25-50 mg daily. Common: sedation, dizziness, blurred vision, dry mouth, Contraindications: impaired consciousness, bone marrow depression,\nIncrease to 75-300 mg daily (up to 1000 mg urinary retention, constipation, tachycardia. pheochromocytoma. may be necessary for severe cases). Route: p.o."
  },
  {
    "id": 170,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "paired consciousness, bone marrow depression,\nIncrease to 75-300 mg daily (up to 1000 mg urinary retention, constipation, tachycardia. pheochromocytoma. may be necessary for severe cases). Route: p.o. Serious: orthostatic hypotension, syncope, EPS, Caution in patients with: respiratory disease, kidney disease, liver\nphotosensitivity, weight gain, galactorrhea, amenorrhea, disease, glaucoma, urinary retention, cardiac disease, long QT syndrome\nsexual dysfunction, priapism, NMS, agranulocytosis, or taking QT-prolonging medications. Monitor ECG if possible. jaundice. Drug-drug interactions:\n– Increases effects of blood pressure lowering medications. – Lowers blood pressure if combined with epinephrine. – Levels may be increased by antimalarials including quinine. FLUPHENAZINE Start 12.5 mg."
  },
  {
    "id": 171,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ncreases effects of blood pressure lowering medications. – Lowers blood pressure if combined with epinephrine. – Levels may be increased by antimalarials including quinine. FLUPHENAZINE Start 12.5 mg. Common: sedation, dizziness, blurred vision, dry mouth, Contraindications: impaired consciousness, parkinsonism. depot/long-acting Use 12.5-50 mg every 2-4 weeks. urinary retention, constipation, tachycardia. Route: i.m. in gluteal region. Caution in patients with: cardiac disease, kidney disease, liver disease. Serious: orthostatic hypotension, syncope, EPS, Use with caution in older adults. Avoid in women who are pregnant/ photosensitivity, weight gain,galactorrhea, amenorrhea,\nbreastfeeding. sexual dysfunction, priapism, NMS, agranulocytosis, Drug-drug interactions:\njaundice."
  },
  {
    "id": 172,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "er adults. Avoid in women who are pregnant/ photosensitivity, weight gain,galactorrhea, amenorrhea,\nbreastfeeding. sexual dysfunction, priapism, NMS, agranulocytosis, Drug-drug interactions:\njaundice. – Increases effects of blood pressure lowering medications. Do not use in children/adolescents. – Can lower blood pressure if used with epinephrine. TABLE 2: Anticholinergic medications\n(for treatment of extrapyramidal side effects (EPS) Avoid in women who are pregnant or breastfeeding if possible. MEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nBIPERIDEN Start 1 mg twice daily. Common: sedation, confusion and memory Caution in patients with: cardiac, liver, or kidney disease. Increase to 3-12 mg daily."
  },
  {
    "id": 173,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "DE EFFECTS CONTRAINDICATIONS / CAUTIONS\nBIPERIDEN Start 1 mg twice daily. Common: sedation, confusion and memory Caution in patients with: cardiac, liver, or kidney disease. Increase to 3-12 mg daily. disturbance (especially in older adults), tachycardia, dry\nDrug-drug interactions: Caution when combining with other\nRoute: p.o or intravenous (i.v.). mouth, urinary retention and constipation. anticholinergic medications. TRIHEXYPHENIDYL Start 1 mg daily. Rarely, angle-closure glaucoma, myasthenia gravis and\n(Benzhexol) Increase to 4-12 mg per day in 3-4 divided doses gastrointestinal obstruction. (maximum 20 mg daily). Route: p.o\nTABLE 3: Mood stabilizers\nAvoid in women who are pregnant or breastfeeding if possible."
  },
  {
    "id": 174,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Increase to 4-12 mg per day in 3-4 divided doses gastrointestinal obstruction. (maximum 20 mg daily). Route: p.o\nTABLE 3: Mood stabilizers\nAvoid in women who are pregnant or breastfeeding if possible. MEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nLITHIUM Start 300 mg daily. Increase gradually every Common: sedation, cognitive problems, tremor, : Contraindicated in patients with: severe cardiac or kidney disease. 7 days until target blood level reached (maximum impaired coordination, hypotension, leukocytosis,\nDehydration can increase lithium levels. 600-1200 mg daily). Monitor every 2-3 months. polyuria, polydipsia, nausea, diarrhea, weight gain, hair\nUse only if clinical\nRoute: p.o loss, rash."
  },
  {
    "id": 175,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ukocytosis,\nDehydration can increase lithium levels. 600-1200 mg daily). Monitor every 2-3 months. polyuria, polydipsia, nausea, diarrhea, weight gain, hair\nUse only if clinical\nRoute: p.o loss, rash. Drug-drug interactions: nonsteroidal anti-inflammatory drugs (NSAIDs),\nand laboratory monitoring angiotensin-converting-enzyme inhibitor (ACE inhibitor), thiazide diuretics,\nTarget blood levels: 0.6-1.0 mEq/liter Serious: diabetes insipidus, hypothyroidism,\nare available. metronidazole, and tetracycline can increase lithium levels. – In acute manic episode: 0.8-1.0 mEq/liter ECG changes (arrhythmia, sick sinus syndrome,\n– For maintenance treatment: 0.6-0.8 mEq/liter. T-wave changes). Lithium toxicity can cause seizures, delirium, coma, and death."
  },
  {
    "id": 176,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "pisode: 0.8-1.0 mEq/liter ECG changes (arrhythmia, sick sinus syndrome,\n– For maintenance treatment: 0.6-0.8 mEq/liter. T-wave changes). Lithium toxicity can cause seizures, delirium, coma, and death. 6 months on medication is needed to determine full\neffectiveness of maintenance treatment. SODIUM VALPROATE Start 500 mg daily. Common: sedation, headache, tremor, ataxia, nausea, Caution in patients with: underlying or suspected hepatic disease. Increase slowly to 1000-2000 mg daily vomiting, diarrhea, weight gain, transient hair loss. Monitor liver function tests and platelets if possible. (maximum 60 mg/kg/day). Serious: impaired hepatic function, Drug-drug interactions:\nRoute: p.o\nthrombocytopenia, leucopenia, drowsiness/ Valproate levels decreased by carbamazepine, increased by aspirin."
  },
  {
    "id": 177,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ximum 60 mg/kg/day). Serious: impaired hepatic function, Drug-drug interactions:\nRoute: p.o\nthrombocytopenia, leucopenia, drowsiness/ Valproate levels decreased by carbamazepine, increased by aspirin. Preferred choice in persons living with confusion, liver failure, hemorrhagic pancreatitis. HIV\nHIV/AIDS due to drug-drug interactions. CARBAMAZEPINE Start 200 mg daily. Common: sedation, confusion, dizziness, ataxia, Contraindicated in patients with: history of blood disorders,\nIncrease by 200 mg weekly to 400-600 mg daily in double vision, nausea, diarrhea, benign leucopenia. kidney, liver, or cardiac disease. two divided doses (maximum 1200 mg daily). Serious: hepatotoxicity, cardiac conduction delay, Drug-drug interactions. Route: p.o\nlow sodium levels, severe rash."
  },
  {
    "id": 178,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nia. kidney, liver, or cardiac disease. two divided doses (maximum 1200 mg daily). Serious: hepatotoxicity, cardiac conduction delay, Drug-drug interactions. Route: p.o\nlow sodium levels, severe rash. – May reduce the effects of hormonal birth control, immunosuppressants,\nNote: Dose may need to be adjusted after antiepileptics, antipsychotics, methadone and some antiretrovirals. 2 weeks due to induction of its own metabolism. – Levels can be increased by certain antifungals and antibiotics. PSYCHOSES 43\n\n44\nPSY 2\nPSYCHOSES Management\nTABLE 4: Review adherence, side effects and dosing based on clinical situation/ presentation\nCLINICAL SITUATION ACTION\nThe person is not tolerating antipsychotic Reduce the dose of antipsychotic medication. medication, i.e."
  },
  {
    "id": 179,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ce, side effects and dosing based on clinical situation/ presentation\nCLINICAL SITUATION ACTION\nThe person is not tolerating antipsychotic Reduce the dose of antipsychotic medication. medication, i.e. the person has If side-effects persist, consider switching to another antipsychotic medication. extrapyramidal symptoms (EPS) or other Consider adding anticholinergic medication for short-term use to treat EPS if these strategies fail or if symptoms are severe (see Table 2). serious side effects\nAdherence to treatment is Discuss reasons for non-adherence with the person and carers. unsatisfactory And provide information regarding importance of medication."
  },
  {
    "id": 180,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e (see Table 2). serious side effects\nAdherence to treatment is Discuss reasons for non-adherence with the person and carers. unsatisfactory And provide information regarding importance of medication. Consider depot/long-acting injectable antipsychotic medication as an option after discussing possible side effects of oral versus\ndepot preparations. Treatment response is inadequate Verify that the person is receiving an effective dose of medication. If the dose is low, increase gradually to lowest effective dose to reduce\n(i.e. symptoms persist or worsen) despite the risk of side effects. adherence to medication Enquire about alcohol or substance use and take measures to reduce this. Go to » SUB."
  },
  {
    "id": 181,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "fective dose to reduce\n(i.e. symptoms persist or worsen) despite the risk of side effects. adherence to medication Enquire about alcohol or substance use and take measures to reduce this. Go to » SUB. Enquire about recent stressful event that may have led to worsening of clinical condition and take measures to reduce stress. »\nReview symptoms to rule out physical and/or other priority MNS conditions. Go to PSY 1, see STEP 1\nConsider risperidone as an alternative to haloperidol or chlorpromazine, if cost and availability are not constraints."
  },
  {
    "id": 182,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "o rule out physical and/or other priority MNS conditions. Go to PSY 1, see STEP 1\nConsider risperidone as an alternative to haloperidol or chlorpromazine, if cost and availability are not constraints. If the person does not respond to adequate dose and duration of more than one antipsychotic medication, using one medicine at a time,\nthen antipsychotic combination treatment may be considered; preferably under the supervision of a specialist, with close clinical monitoring. Consider consultation with a specialist for the use of clozapine in those who have not responded to other antipsychotic medications\nat adequate doses and durations."
  },
  {
    "id": 183,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "st, with close clinical monitoring. Consider consultation with a specialist for the use of clozapine in those who have not responded to other antipsychotic medications\nat adequate doses and durations. Only use clozapine under the supervision of a specialist and only if routine laboratory monitoring is available,\ndue to the risk of life-threatening agranulocytosis. TABLE 5: Management of Persons with Agitated and/or Aggressive Behaviour\nASSESSMENT COMMUNICATION SEDATION AND USE OF MEDICATION\nAttempt to communicate with the person. Safety is first! Sedate as appropriate to prevent injury. Evaluate for underlying cause: Remain calm and encourage the patient to talk For agitation due to psychosis or mania, consider use of haloperidol\n– Check Blood Glucose. If low, give glucose."
  },
  {
    "id": 184,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "t injury. Evaluate for underlying cause: Remain calm and encourage the patient to talk For agitation due to psychosis or mania, consider use of haloperidol\n– Check Blood Glucose. If low, give glucose. about his or her concerns. 2mg p.o./i.m. hourly up to 5 doses (maximum 10 mg). Caution: high doses of haloperidol can cause dystonic reactions. Use a calm voice and try to address the concerns\n– Check vital signs, including temperature and oxygen\nUse biperiden to treat acute reactions. if possible. saturation. Give oxygen if needed. For agitation due to ingestion of substances, such as\nListen attentively. Devote time to the person. – Rule out delirium and medical causes\nalcohol/sedative withdrawal or stimulant intoxication,\nincluding poisoning. Never laugh at the person."
  },
  {
    "id": 185,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "es, such as\nListen attentively. Devote time to the person. – Rule out delirium and medical causes\nalcohol/sedative withdrawal or stimulant intoxication,\nincluding poisoning. Never laugh at the person. use diazepam 10-20 mg p.o. and repeat as needed. Go to SUB. – Rule out drug and alcohol use. Do not be aggressive back. In cases of extreme violence\nSpecifically consider stimulant intoxication and/or\nTry to find the source of the problem and solutions – Seek help from police or staff\nalcohol/sedative withdrawal. Go to SUB. for the person. – Use haloperidol 5mg i.m., repeat in 15-30mins if needed\n– Rule out agitation due to psychosis or manic\nInvolve carers and other staff members. (maximum 15 mg)\nepisode in bipolar disorder. Go to Assessment,\n»\nPSY 1."
  },
  {
    "id": 186,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "l 5mg i.m., repeat in 15-30mins if needed\n– Rule out agitation due to psychosis or manic\nInvolve carers and other staff members. (maximum 15 mg)\nepisode in bipolar disorder. Go to Assessment,\n»\nPSY 1. Remove from the situation anyone who may be a – Consult a specialist. trigger for the aggression. if the person remains agitated, recheck oxygen saturation,\nIf all possibilities have been exhausted and the person\nvital signs and glucose. Consider pain. Refer to hospital. is still aggressive, it may be necessary to use medication\nOnce agitation subsides, refer to the master chart (MC) and\n(if available) to prevent injury. select relevant modules for assessment. Special Populations:\nConsult a specialist for treatment."
  },
  {
    "id": 187,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "edication\nOnce agitation subsides, refer to the master chart (MC) and\n(if available) to prevent injury. select relevant modules for assessment. Special Populations:\nConsult a specialist for treatment. PSYCHOSES 45\n\n46\nPSY 3\nPSYCHOSES Follow -up\nPSY 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\nPSYCHOSIS\n1\n»\nInitial follow-up should be as\nfrequent as possible, even daily,\nASSESS FOR IMPROVEMENT until acute symptoms respond to\ntreatment. »\nRegular follow-up is needed. Once\nIs the person improving? symptoms respond, monthly to\nquarterly follow-up is recommended\n(based on clinical need and feasibility\nfactors such as staff availability,\ndistance from clinic, etc.)\n»\nContinue with treatment plan. »\nDecrease frequency of follow-up once\nsymptoms have subsided. »\nFollow-up as needed."
  },
  {
    "id": 188,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ed and feasibility\nfactors such as staff availability,\ndistance from clinic, etc.)\n»\nContinue with treatment plan. »\nDecrease frequency of follow-up once\nsymptoms have subsided. »\nFollow-up as needed. Is the person taking medication? SKIP to STEP 120\n»\nSTART ANTIPSYCHOTIC MEDICATIONS\n(Go to Table 1). »\nMaintain a high frequency of contact until symptoms\nstart to respond to treatment. »\nEnsure that person has been on a typical\n»\neffective dose for minimum of 4-6 weeks. Involve the person and carers in treatment plan\nchanges and decisions. »\nMaintain a high frequency of contact until\nsymptoms start to respond to treatment. »\nInvolve the person and carers in treatment plan\nchanges and decisions. 2\nROUTINELY MONITOR TREATMENT\n»\nReview psychosocial interventions."
  },
  {
    "id": 189,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ncy of contact until\nsymptoms start to respond to treatment. »\nInvolve the person and carers in treatment plan\nchanges and decisions. 2\nROUTINELY MONITOR TREATMENT\n»\nReview psychosocial interventions. »\nIf on medication, review adherence, side effects and dosing (Table 4). Check weight, blood pressure, and blood glucose. »\nIf the person starts to use any other medications with potential drug-drug\ninteractions, consider reviewing the medication dose. »\nAsk regarding the onset of symptoms, prior episodes, and details of any\nprevious or current treatment."
  },
  {
    "id": 190,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ther medications with potential drug-drug\ninteractions, consider reviewing the medication dose. »\nAsk regarding the onset of symptoms, prior episodes, and details of any\nprevious or current treatment. 3\nDISCONTINUE MEDICATIONS\nPerson with first episode, relapse, Person with psychotic symptoms\nor worsening of psychosis symptoms: persisting more than 3 months:\n» »\nConsider discontinuation of medications Consider discontinuation of medications if person is in\n12 MONTHS after symptoms have resolved. FULL REMISSION of symptoms for several years. »\nDiscuss risks of relapse against long-term medication side-effects with person and family. »\nIf possible, consult a specialist. »\nGradually and slowly reduce the medication dose."
  },
  {
    "id": 191,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "for several years. »\nDiscuss risks of relapse against long-term medication side-effects with person and family. »\nIf possible, consult a specialist. »\nGradually and slowly reduce the medication dose. When medications are withdrawn,\nindividuals and family members need to be educated to detect early symptoms of relapse. Close clinical monitoring is recommended. PSYCHOSES 47\n\n48\nPSY 3\nPSYCHOSES Follow -up\nPSY 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\nMANIC EPISODE IN BIPOLAR DISORDER »\nFor acute mania: Initial follow-up\nshould be as frequent as possible,\neven daily, until acute symptoms\n1\nrespond to treatment. Once\nsymptoms respond, monthly to\nASSESS FOR IMPROVEMENT\nquarterly follow-up is recommended."
  },
  {
    "id": 192,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "itial follow-up\nshould be as frequent as possible,\neven daily, until acute symptoms\n1\nrespond to treatment. Once\nsymptoms respond, monthly to\nASSESS FOR IMPROVEMENT\nquarterly follow-up is recommended. »\nFor persons not currently in manic\nor depressed states, follow-up at\nIs the person improving? least every three months. Consider\n» more frequent follow up when\nFollow-up as needed until symptoms\nneeded. Monitor closely for relapse. have subsided. »\nContinue maintenance medications\nfor at least 2 years. SKIP to STEP 1 20\nIs the person taking medication? »\nIf appropriate, initiate medication. »\nCheck dosing and side effects. Go to Table 1 or Table 3."
  },
  {
    "id": 193,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "tinue maintenance medications\nfor at least 2 years. SKIP to STEP 1 20\nIs the person taking medication? »\nIf appropriate, initiate medication. »\nCheck dosing and side effects. Go to Table 1 or Table 3. CLINICAL TIP\n»\nIf switching to another Ensure that person has been on a typical effective dose of\nmedication, begin that medi- medication for a minimum of four to six weeks. cation first and treat with » »\nIf on typical effective dose of medications for four to six weeks Review psychosocial interventions. both medications for 2 weeks\nwith no improvement, consider switching medication. See Table 3. »\nbefore tapering off the first Evaluate for medical problems. »\nmedication. If response is still poor, consult a specialist."
  },
  {
    "id": 194,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "r 2 weeks\nwith no improvement, consider switching medication. See Table 3. »\nbefore tapering off the first Evaluate for medical problems. »\nmedication. If response is still poor, consult a specialist. 2\nROUTINELY MONITOR TREATMENT\n»\nReview and provide psychosocial interventions. »\nIf on medication, review adherence, side effects and dosing. See Table 4. »\nIf the person starts any other medications with the potential for drug-drug\ninteractions, consider reviewing the medication dose. 3\nDISCONTINUE MEDICATIONS\nHas the person been in full remission of symptoms with\nno episodes of bipolar disorder for at least two years? » »\nConsider discontinuation of medications Routinely follow up and monitor treatment. – Discuss with person/carer the risk of discontinuation."
  },
  {
    "id": 195,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "no episodes of bipolar disorder for at least two years? » »\nConsider discontinuation of medications Routinely follow up and monitor treatment. – Discuss with person/carer the risk of discontinuation. – Consult a specialist regarding the decision to discontinue\nmaintenance treatment after 2 years. – Reduce gradually over period of weeks or months. PSYCHOSES 49\n\n50\nPSYCHOSES\nPPSSYYCCHHOOSSEESS\n\nEPILEPSY\nEpilepsy is a chronic noncommunicable disorder of the brain, Seizures are caused by abnormal electrical activity in the brain and\ncharacterized by recurrent unprovoked seizures. Epilepsy is one are of two types: convulsive and non-convulsive."
  },
  {
    "id": 196,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rder of the brain, Seizures are caused by abnormal electrical activity in the brain and\ncharacterized by recurrent unprovoked seizures. Epilepsy is one are of two types: convulsive and non-convulsive. Non-convulsive\nof the most common neurological disorders and with proper epilepsy has features such as change in mental status while con-\ntreatment, can be well controlled in the majority of people. vulsive epilepsy has features such as sudden abnormal movements,\nincluding stiffening and shaking of the body. The latter is associated\nEpilepsy has many causes. It may be genetic. Epilepsy may occur with greater stigma and higher morbidity and mortality. This module\nin people who have a past history of birth trauma, brain injury covers only convulsive epilepsy."
  },
  {
    "id": 197,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "may be genetic. Epilepsy may occur with greater stigma and higher morbidity and mortality. This module\nin people who have a past history of birth trauma, brain injury covers only convulsive epilepsy. (including head trauma and strokes), or brain infections. In some\npeople, no cause may be identified. 51\n\n52\nEPI\nEPILEPSY\nEPI Quick Overview\nAcute presentation of seizures/convulsions warrants\nemergency treatment & management\nASSESSMENT MANAGEMENT\nEMERGENCY: M anagement Protocol and\nAssessment & management of acute Special Populations\nconvulsions\n1. Epilepsy\n2. Special Populations (women of childbearing age,\nAssess if person has convulsive seizures children/adolescents, and people living with HIV)\nAssess for an acute cause\nPsychosocial Interventions\n(e.g."
  },
  {
    "id": 198,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "2. Special Populations (women of childbearing age,\nAssess if person has convulsive seizures children/adolescents, and people living with HIV)\nAssess for an acute cause\nPsychosocial Interventions\n(e.g. neuroinfection, trauma, etc.)\nPharmacological Interventions\nAssess if the person has epilepsy and\nfor any underlying causes (by history or\nexamination)\nAssess for concurrent priority MNS\nconditions FOLLOW-UP\n\nEPI EMERGENCY\nPERSON PRESENTS WITH\nCONVULSION OR IS\nUNRESPONSIVE AND STIFF\n1\nCLINICAL TIP:\nAssessment and management Any sign of head or neck injury? should occur simultaneously."
  },
  {
    "id": 199,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "conditions FOLLOW-UP\n\nEPI EMERGENCY\nPERSON PRESENTS WITH\nCONVULSION OR IS\nUNRESPONSIVE AND STIFF\n1\nCLINICAL TIP:\nAssessment and management Any sign of head or neck injury? should occur simultaneously. KEEP HEAD AND NECK STABLE\n2\nCheck AIRWAY, BREATHING, CIRCULATION (ABCs) Place an intravenous (i.v.) line for medication/\nEnsure the person has nothing in their airway, is breathing fluid administration if possible\nwell and has a stable pulse\nDO NOT LEAVE THE PERSON ALONE\nCheck BLOOD PRESSURE, TEMPERATURE and RESPIRATORY RATE\nDO NOT PUT ANYTHING IN THE MOUTH\nStart timing the duration of the convulsions, if possible\nFOR A PERSON WITH POSSIBLE HEAD INJURY,\nMake sure the person is in a safe place and if possible, put NEUROINFECTION (FEVER) OR FOCAL DEFICITS,\nthem down on their side to help breathing; loosen any neckties or REFER URGENTLY TO HOSPITAL\nclothing around the neck, take off eye glasses, and place something\nsoft under the head (if available)\nEPILEPSY 53\n\n54\nEPI\nEPILEPSY Emergency\nSPECIAL POPULATION: Pregnancy/Post-partum\n3\nIs the woman in the second half of pregnancy OR\nup to 1 week post partum AND has no past history of epilepsy?"
  },
  {
    "id": 200,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ilable)\nEPILEPSY 53\n\n54\nEPI\nEPILEPSY Emergency\nSPECIAL POPULATION: Pregnancy/Post-partum\n3\nIs the woman in the second half of pregnancy OR\nup to 1 week post partum AND has no past history of epilepsy? SUSPECT ECLAMPSIA\nGive magnesium sulphate 10 g\n4\nintramuscular (i.m.)\nI f diastolic blood pressure >110 mmHg, GIVE MEDICATION TO STOP CONVULSIONS\ngive hydralazine 5 mg i.v. slowly (3-4min). Repeat every 30 min until ≤ 90 mmHg;\nDo not give more than 20 mg total\nR EFER URGENTLY TO HOSPITAL IF NO I.V. ESTABLISHED IF I.V. ESTABLISHED\nGive: S tart normal saline administration slowly\n(30 drops/minute)\ndiazepam rectally\n(adult 10 mg, child 1 mg/year of age) G ive glucose i.v."
  },
  {
    "id": 201,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "TLY TO HOSPITAL IF NO I.V. ESTABLISHED IF I.V. ESTABLISHED\nGive: S tart normal saline administration slowly\n(30 drops/minute)\ndiazepam rectally\n(adult 10 mg, child 1 mg/year of age) G ive glucose i.v. (adult 5 ml of 50%; child 2-5 ml/kg of 10%)\nOR\nmidazolam buccally/intranasally\nG ive emergency medication:\n(5-10 mg adult, child 0.2 mg/kg) – diazepam 10 mg i.v. (child 1mg/year of age i.v.)\nOR\n– lorazepam 4 mg i.v (child 0.1 mg/kg i.v.)\n\n5\nHave the convulsions stopped within\n10 minutes of 1st dose of emergency medication? Proceed to EPI 1 (Assessment)\nGIVE 2nd DOSE OF EMERGENCY MEDICATION\n6\nHave the convulsions stopped?"
  },
  {
    "id": 202,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "1 mg/kg i.v.)\n\n5\nHave the convulsions stopped within\n10 minutes of 1st dose of emergency medication? Proceed to EPI 1 (Assessment)\nGIVE 2nd DOSE OF EMERGENCY MEDICATION\n6\nHave the convulsions stopped? Proceed to EPI 1 (Assessment)\nR EFER URGENTLY TO HEALTH FACILITY\nDO NOT GIVE MORE THAN 2 DOSES\nOF EMERGENCY MEDICATION\nEPILEPSY 55\n\n56\nEPI\nEPILEPSY Emergency\n7\nIS THE PERSON IN STATUS EPILEPTICUS? Convulsions continue after 2 doses of emergency medication, OR\nNo recovery in between convulsions\nSKSSKKIPIIPP t ottoo S SSTTTEEEPPP 1111100000\n(e.g."
  },
  {
    "id": 203,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Y Emergency\n7\nIS THE PERSON IN STATUS EPILEPTICUS? Convulsions continue after 2 doses of emergency medication, OR\nNo recovery in between convulsions\nSKSSKKIPIIPP t ottoo S SSTTTEEEPPP 1111100000\n(e.g. convulsions stopped after\nsecond dose of emergency medication\nSTATUS EPILEPTICUS IS LIKELY\non arrival to health facility)\n8 Management should occur in health facility\nC ontinue to check AIRWAY, BREATHING, and CIRCULATION (ABCs)\nG ive oxygen\nM onitor need for intubation/ventilation continuously\n9\nGIVE ONE OF THE FOLLOWING MEDICATIONS INTRAVENEOUSLY\nV ALPROIC ACID: P HENYOTIN:\n20 mg/kg i.v. once up to maximum dose of 1 g, over 30 min 15-20 mg/kg i.v. up to max dose of 1 g, over 60 min\n– use second i.v."
  },
  {
    "id": 204,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "OF THE FOLLOWING MEDICATIONS INTRAVENEOUSLY\nV ALPROIC ACID: P HENYOTIN:\n20 mg/kg i.v. once up to maximum dose of 1 g, over 30 min 15-20 mg/kg i.v. up to max dose of 1 g, over 60 min\n– use second i.v. line (DIFFERENT FROM DIAZEPAM)\nP HENOBARBITAL:\nPHENYTOIN CAUSES SIGNIFICANT DAMAGE IF\n15-20 mg/kg i.v.* up to maximum dose of 1 g, over 100 mg/min\nEXTRAVASATES, MUST HAVE GOOD I.V. LINE! *If no i.v. access, can use i.m. phenobarbital (same dose as i.v.)\n\nHave the convulsions stopped? Use one of the other medications (if available) OR\nadditional 10 mg/kg phenytoin (given over 30 min)\nMonitor for respiratory depression,\nhypotension, arrhythmia."
  },
  {
    "id": 205,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "s i.v.)\n\nHave the convulsions stopped? Use one of the other medications (if available) OR\nadditional 10 mg/kg phenytoin (given over 30 min)\nMonitor for respiratory depression,\nhypotension, arrhythmia. 10\nE VALUATE (AND TREAT AS APPROPRIATE) FOR\nUNDERLYING CAUSE OF CONVULSIONS:\n– Neuroinfection (fever, stiff neck, headache, confusion)\n– Substance use (alcohol withdrawal or drug ingestion)\n– Trauma\n– Metabolic abnormality (hypernatraemia or hypoglycaemia)\n– Stroke (focal deficit)\n– Tumor (focal deficit)\n– Known epilepsy (prior history of seizures)\nHave the convulsions stopped?"
  },
  {
    "id": 206,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ngestion)\n– Trauma\n– Metabolic abnormality (hypernatraemia or hypoglycaemia)\n– Stroke (focal deficit)\n– Tumor (focal deficit)\n– Known epilepsy (prior history of seizures)\nHave the convulsions stopped? R EFER TO SPECIALIST\nFOR FURTHER DIAGNOSTIC Proceed to EPI 1 (Assessment)\nEVALUATION\nEPILEPSY 57\n\n58\nEPI 1\nEPILEPSY Assessment\nCLINICAL TIP\nEPI 1 Assessment\nSyncope and pseudoseizures\nshould be considered during\ninitial evaluation and in cases of\ntreatment failure. COMMON PRESENTATIONS OF EPILEPSY\n» Syncopal (fainting) spells often\nare associated with flushing,\nConvulsive movement or fits/seizures\nsweating, pallor, and occasio-\nDuring the convulsion:\nnally a feeling of vision darken-\n– Loss of consciousness or impaired consciousness ing prior to an episode."
  },
  {
    "id": 207,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Convulsive movement or fits/seizures\nsweating, pallor, and occasio-\nDuring the convulsion:\nnally a feeling of vision darken-\n– Loss of consciousness or impaired consciousness ing prior to an episode. Mild\n– Stiffness, rigidity shaking may occur at the end. – Tongue bite, injury, incontinence of urine or faeces\n» Pseudoseizures are typically\nAfter the convulsion: fatigue, drowsiness, sleepiness, confusion, associated with a stress trigger. Episodes are often prolonged\nabnormal behaviour, headache, muscle aches, or weakness on\nand can involve nonrhythmic\none side of the body\njerking of the body, eyes may be\nclosed, and pelvic thrusting is\noften seen. There is typically a\nrapid return to baseline after\n1\nthe episode. If pseudoseizures\nare suspected, go to OTH."
  },
  {
    "id": 208,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "of the body\njerking of the body, eyes may be\nclosed, and pelvic thrusting is\noften seen. There is typically a\nrapid return to baseline after\n1\nthe episode. If pseudoseizures\nare suspected, go to OTH. Does the person have convulsive seizures? Has the person had convulsive movements\nlasting longer than 1-2 minutes? Convulsive seizures unlikely\nConsult a specialist for recurrent episodes\nFollow-up in 3 months\n\nHas the person had at least 2 of the following symptoms during the episode(s)?"
  },
  {
    "id": 209,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "longer than 1-2 minutes? Convulsive seizures unlikely\nConsult a specialist for recurrent episodes\nFollow-up in 3 months\n\nHas the person had at least 2 of the following symptoms during the episode(s)? – Loss of consciousness or impaired consciousness – After the convulsion: fatigue, drowsiness,\n– Stiffness, rigidity sleepiness, confusion, abnormal behaviour,\n– Bitten or bruised tongue, bodily injury headache, muscle aches, or weakness on one\n– Incontinence of faeces/urine side of the body\nConvulsive seizures unlikely\nConsult a specialist for recurrent episodes\nFollow-up in 3 months\nSuspect\nCONVULSIVE SEIZURES\n2\nIs there an acute cause? Is there neuroinfection or other possible causes of convulsions?"
  },
  {
    "id": 210,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "zures unlikely\nConsult a specialist for recurrent episodes\nFollow-up in 3 months\nSuspect\nCONVULSIVE SEIZURES\n2\nIs there an acute cause? Is there neuroinfection or other possible causes of convulsions? »\nCheck for signs and symptoms:\n– Fever – Meningeal irritation – Metabolic abnormality – Alcohol or drug\n– Headache (e.g. stiff neck) (e.g. hypogylcemia/ intoxication or\n– Confusion – Head injury hyponatremia) withdrawal\nSuspect EPILEPSY\nEPILEPSY 59\n\n60\nEPI 1\nEPILEPSY Assessment\nIS IT A CHILD 6 MONTHS TO SKIP to STEP 3\n»\n6 YEARS OLD WITH A FEVER?"
  },
  {
    "id": 211,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "emia/ intoxication or\n– Confusion – Head injury hyponatremia) withdrawal\nSuspect EPILEPSY\nEPILEPSY 59\n\n60\nEPI 1\nEPILEPSY Assessment\nIS IT A CHILD 6 MONTHS TO SKIP to STEP 3\n»\n6 YEARS OLD WITH A FEVER? EVALUATE & TREAT MEDICAL\nCONDITION\n»\nREFER TO HOSPITAL\nIF POSSIBLE FOR HEAD INJURY,\nMENINGITIS, AND METABOLIC\nAre the convulsions: ABNORMALITIES\n– Focal: Starts in one part of the body\nANTIEPILEPTIC MEDICATION\n– Prolonged: Lasts more than 15 min\nNOT REQUIRED\n– Repetitive: More than 1 episode during the\n»\ncurrent illness Follow-up in 3 months to\nassess for possible epilepsy\nCOMPLEX FEBRILE SEIZURE\nR EFER TO HOSPITAL\nFOR ADMISSION\nSIMPLE FEBRILE SEIZURE\nLook for cause (local Integrated Management\nof Childhood Illness (IMCI) guidelines)\nObserve over 24 hours\nNo antiepileptic treatment needed\n\n3\nDoes the person have epilepsy?"
  },
  {
    "id": 212,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ION\nSIMPLE FEBRILE SEIZURE\nLook for cause (local Integrated Management\nof Childhood Illness (IMCI) guidelines)\nObserve over 24 hours\nNo antiepileptic treatment needed\n\n3\nDoes the person have epilepsy? CLINICAL TIP\nAsk about:\n– How frequent are the episodes? Has the person had at least two seizures on two\n– How many in the past year? different days in the past year? – When was the last episode? Does not meet criteria for epilepsy\nMaintenance antiepileptic medication not necessary\nFollow-up in 3 months and assess for possible\nepilepsy EPILEPSY\nis likely\nAsses for underlying cause. Do a physical examination. CLINICAL TIP\nPhysical examination should include\nA re any of the following present? neurologic examination and evaluate for\nany focal deficits; e.g."
  },
  {
    "id": 213,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "es for underlying cause. Do a physical examination. CLINICAL TIP\nPhysical examination should include\nA re any of the following present? neurologic examination and evaluate for\nany focal deficits; e.g. any asymmetry in – Birth asphyxia or trauma history – Infection of the brain\nstrength or reflexes. – Head injury – Family history of seizures\nR EFER TO SPECIALIST FOR FURTHER\nEVALUATION OF CAUSE\nEPILEPSY 61\n\n62\nEPI 1\nEPILEPSY Assessment\n4\nAre there concurrent MNS conditions? A ssess for other concurrent MNS conditions according to the\nmhGAP-IG Master Chart (MC)\nPlease note persons with EPILEPSY are at higher risk for DEPRESSION, DISORDERS\nDUE TO SUBSTANCE USE. CHILDREN AND ADOLSCENTS MAY HAVE ASSOCIATED MENTAL\nAND BEHAVIOURAL DISORDERS."
  },
  {
    "id": 214,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "-IG Master Chart (MC)\nPlease note persons with EPILEPSY are at higher risk for DEPRESSION, DISORDERS\nDUE TO SUBSTANCE USE. CHILDREN AND ADOLSCENTS MAY HAVE ASSOCIATED MENTAL\nAND BEHAVIOURAL DISORDERS. SUBSTANCE USE DISORDERS\nGo to PROTOCOL 1\nIF THERE IS IMMINENT RISK\nOF SUICIDE, ASSESS AND\nMANAGE before continuing\nto Protocol. Go to SUI."
  },
  {
    "id": 215,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "LSCENTS MAY HAVE ASSOCIATED MENTAL\nAND BEHAVIOURAL DISORDERS. SUBSTANCE USE DISORDERS\nGo to PROTOCOL 1\nIF THERE IS IMMINENT RISK\nOF SUICIDE, ASSESS AND\nMANAGE before continuing\nto Protocol. Go to SUI. EPI 2 Management\nPROTOCOL\n1\nProvide psychoeducation to the person and carers (2.1)\nInitiate antiepileptic medications (2.3)\nPromote functioning in daily activities (2.2)\nSpecial populations\nNote that interventions are different for EPILEPSY in these populations\nHIV\nWOMAN OF CHILDBEARING AGE CHILD / ADOLESCENT PERSON LIVING WITH HIV\nConcern: Risk of antiepileptic medication to fetus/child Concern: Effect of antiepileptic medication Concern: Drug interactions between antiepileptic\non development and/or behavior medications and antiretrovirals\nAdvise folate (5 mg/day) to prevent neural tube For those with a developmental disorder, When available, refer to specific drug interactions\ndefects, in ALL women of childbearing age."
  },
  {
    "id": 216,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "antiretrovirals\nAdvise folate (5 mg/day) to prevent neural tube For those with a developmental disorder, When available, refer to specific drug interactions\ndefects, in ALL women of childbearing age. manage the condition. Go to CMH. for person’s antiretroviral regimen and antiepileptic\nmedication. AVOID VALPROATE. For children with behavioural disorder, avoid\nphenobarbital if possible. Manage the condition. Valproate is preferred due to fewer drug-drug\nCAUTION If Pregnant:\nGo to CMH. interactions. – Avoid polytherapy. Multiple medications in combination\nincrease the risk of teratogenic effects during pregnancy. AVOID PHENYTOIN AND CARBAMAZEPINE\n– If medications are stopped during pregnancy, WHEN POSSIBLE. they should always be tapered. – Advise delivery in hospital."
  },
  {
    "id": 217,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "k of teratogenic effects during pregnancy. AVOID PHENYTOIN AND CARBAMAZEPINE\n– If medications are stopped during pregnancy, WHEN POSSIBLE. they should always be tapered. – Advise delivery in hospital. – At delivery, give 1 mg vitamin K i.m. to the newborn\nto prevent haemorrhagic disease. If breastfeeding, carbamazepine preferred to other\nmedication. EPILEPSY 63\n\n64\nEPI 2\nEPILEPSY Management\nPSYCHOSOCIAL INTERVENTIONS\n2.1 Psychoeducation 2.2 P romote functioning in daily\nactivities and community life\nProvide information on: \"What is a convulsion/epilepsy\" Provide information on: How carers can manage\nand the importance of medication. convulsion at home. »\nRefer to Essential Care and Practice (ECP) for interventions\nthat promote functioning in daily living and community life."
  },
  {
    "id": 218,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "How carers can manage\nand the importance of medication. convulsion at home. »\nRefer to Essential Care and Practice (ECP) for interventions\nthat promote functioning in daily living and community life. “A convulsion is caused by excess electrical activity in the Lay person down, on their side, head turned to help breathing. brain – it is not caused by witchcraft or spirits.” »\nDO NOT PUT ANYTHING IN THEIR MOUTH OR RESTRAIN In addition, inform carers and people\n“Epilepsy is the recurrent tendency for convulsions.” THE PERSON. with epilepsy that:\n“It is a chronic condition, but if you take your medicine as\nEnsure the person is breathing properly. – People with epilepsy can lead normal lives."
  },
  {
    "id": 219,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "cy for convulsions.” THE PERSON. with epilepsy that:\n“It is a chronic condition, but if you take your medicine as\nEnsure the person is breathing properly. – People with epilepsy can lead normal lives. prescribed, in the majority of people it can be fully Stay with person until the convulsion stops and they wake up. They can marry and have children. controlled.”\nSometimes people with epilepsy know that a convulsion is\n– Parents should not remove children with epilepsy from\nThe person may have several people helping them take care imminent. They should lie down somewhere safe if they have school. of their convulsions. Discuss this with the person. that feeling. – People with epilepsy can work in most jobs."
  },
  {
    "id": 220,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "elping them take care imminent. They should lie down somewhere safe if they have school. of their convulsions. Discuss this with the person. that feeling. – People with epilepsy can work in most jobs. However they\nAsk the person to let you know if they are seeing a Epilepsy is not contagious. You cannot catch the disorder by should avoid jobs with high risk of injury to self or others\ntraditional or a faith healer, showing respect for this, but assisting the person experiencing convulsions. (e.g. working with heavy machinery). emphasizing the need for being seen at a healthcare facility. – People with epilepsy should avoid cooking on open fires\nThe person should also be informed that medicines and\nProvide information on: When to get medical help. and swimming alone."
  },
  {
    "id": 221,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "althcare facility. – People with epilepsy should avoid cooking on open fires\nThe person should also be informed that medicines and\nProvide information on: When to get medical help. and swimming alone. herbal products can sometimes have adverse interactions,\nso the health care providers must know about everything – People with epilepsy should avoid excessive alcohol and\nWhen a person with epilepsy appears to have trouble\nthey take. recreational substances, sleeping too little, or going to\nbreathing during a convulsion, they need immediate\nplaces with flashing lights. medical help. CLINICAL TIP: When a person with epilepsy has a convulsion lasting longer – Local driving laws related to epilepsy should be observed."
  },
  {
    "id": 222,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "n, they need immediate\nplaces with flashing lights. medical help. CLINICAL TIP: When a person with epilepsy has a convulsion lasting longer – Local driving laws related to epilepsy should be observed. Seizures lasting greater than 5 minutes are than 5 minutes outside of a health facility, they need to be – People with epilepsy may qualify for disability benefits. a medical emergency – one should seek help taken to one. immediately. – Community programs for people with epilepsy can provide\nWhen a person with epilepsy is not waking up after a\nassistance in jobs and support for both the person and\nMost people with epilepsy can have normal convulsion, they need to be taken to a health facility. family. lives with good adherence to treatment."
  },
  {
    "id": 223,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "assistance in jobs and support for both the person and\nMost people with epilepsy can have normal convulsion, they need to be taken to a health facility. family. lives with good adherence to treatment. PHARMACOLOGICAL INTERVENTIONS\n2.3 Initiate antiepileptic medications\nChoose a medication that will be consistently available. CAUTION! If special population (children, women of childbearing Check for drug-drug interactions. When used together, When possible, avoid use of sodium valproate in\nage, person living with HIV), see relevant section of this antiepileptics may increase or reduce the effect of other pregnant women due to risk of neural tube defects. module. antiepilepileptics."
  },
  {
    "id": 224,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e in\nage, person living with HIV), see relevant section of this antiepileptics may increase or reduce the effect of other pregnant women due to risk of neural tube defects. module. antiepilepileptics. Antiepileptics may also reduce effect of\nAll anticonvulsant medications should be discontinued slowly as\nStart with only one medication at lowest starting dose. hormonal birth control, immunosuppressants, antipsy- stopping them abruptly can cause seizure breakthrough. chotics, methadone, and some antiretrovirals. Increase dose slowly until convulsions are controlled. Rarely, can cause severe bone marrow depression,\nConsider monitoring blood count, blood chemistry and\nhypersensitivity reactions including Stevens-Johnson\nliver function tests, if available."
  },
  {
    "id": 225,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ntrolled. Rarely, can cause severe bone marrow depression,\nConsider monitoring blood count, blood chemistry and\nhypersensitivity reactions including Stevens-Johnson\nliver function tests, if available. Syndrome, altered Vitamin D metabolism and Vitamin\nK-deficient hemorrhagic disease of newborns. TABLE 1: Antiepileptic medications\nMEDICATION ORAL DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nCARBAMAZEPINE Adults: Common: Sedation, confusion, dizziness, ataxia, Caution in patients with history of blood disorders, kidney,\nStart 100-200 mg daily in 2-3 divided doses. double vision, nausea, diarrhea, benign leukopenia. liver or cardiac disease. Increase by 200 mg each week (max 1400mg daily)."
  },
  {
    "id": 226,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "of blood disorders, kidney,\nStart 100-200 mg daily in 2-3 divided doses. double vision, nausea, diarrhea, benign leukopenia. liver or cardiac disease. Increase by 200 mg each week (max 1400mg daily). Serious: Hepatotoxicity, cardiac conduction delay, Dose may need to be adjusted after 2 weeks due to induction of\nChildren: low sodium levels. its own metabolism. Start 5 mg/kg daily in 2-3 divided doses. Increase\nby 5 mg/kg daily each week (max 40mg/kg daily\nOR 1400mg daily). Women who are pregnant or breastfeeding:\nUse with caution."
  },
  {
    "id": 227,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "evels. its own metabolism. Start 5 mg/kg daily in 2-3 divided doses. Increase\nby 5 mg/kg daily each week (max 40mg/kg daily\nOR 1400mg daily). Women who are pregnant or breastfeeding:\nUse with caution. EPILEPSY 65\n\n66\nEPI 2\nEPILEPSY Management\nTABLE 1: Antiepileptic medications (cont.)\nMEDICATION ORAL DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nPHENOBARBITAL Adults: Common: Sedation, hyperactivity in children, ataxia, Contraindicated in patients with acute intermittent porphyria. Start 60 mg daily in 1-2 divided doses. nystagmus, sexual dysfunction, depression. Increase weekly by 2.5-5 mg (maximum 180 mg daily). Lower doses for patients with kidney or liver disease. Serious: Liver failure (hypersensitivity reaction), decreased\nChildren: bone mineral density."
  },
  {
    "id": 228,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Increase weekly by 2.5-5 mg (maximum 180 mg daily). Lower doses for patients with kidney or liver disease. Serious: Liver failure (hypersensitivity reaction), decreased\nChildren: bone mineral density. Start 2-3 mg/kg daily in 2 divided doses. Increase weekly by 1-2 mg/kg daily depending\non tolerance (maximum 6mg daily). PHENYTOIN Adults: Common: Sedation, confusion, dizziness, tremor, motor Lower doses for patients with kidney or liver disease. Start 150-200 mg daily in two divided doses. twitching, ataxia, double vision, nystagmus, slurred\nIncrease by 50 mg daily every 3-4 weeks speech, nausea, vomiting, constipation. (max 400 mg daily). Serious: Hematologic abnormalities, hepatitis,\nChildren: polyneuropathy, gum hypertrophy, acne, lymphadeno-\nStart 3-4 mg/kg daily in 2 divided doses."
  },
  {
    "id": 229,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ausea, vomiting, constipation. (max 400 mg daily). Serious: Hematologic abnormalities, hepatitis,\nChildren: polyneuropathy, gum hypertrophy, acne, lymphadeno-\nStart 3-4 mg/kg daily in 2 divided doses. pathy, increase in suicidal ideation. Increase by 5 mg/kg daily every 3-4 weeks\n(maximum 300 mg per day). Women who are pregnant or\nbreastfeeding: Avoid\nOlder adults: Use lower doses\nSODIUM VALPROATE Adults: Common: Sedation, headache, tremor, ataxia, nausea, Use with caution if underlying or suspected hepatic disease. Start 400 mg daily in 2 divided doses. vomiting, diarrhea, weight gain, transient hair loss. Increase by 500 mg daily each week Drug-drug interactions: Valproate levels decreased by carbamazepine,\nSerious: Impaired hepatic function, thrombocytopenia,\n(maximum 3000 mg daily)."
  },
  {
    "id": 230,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nsient hair loss. Increase by 500 mg daily each week Drug-drug interactions: Valproate levels decreased by carbamazepine,\nSerious: Impaired hepatic function, thrombocytopenia,\n(maximum 3000 mg daily). increased by aspirin. leukopenia, drowsiness/confusion (valproate-induced\nChildren: hyperammonemic encephalopathy, a sign of toxicity),\nStart 15-20 mg/kg daily in 2-3 divided doses. liver failure, hemorrhagic pancreatitis. Increase each week by 15 mg/kg daily\n(max 15-40 mg/kg daily). Women who are pregnant: Avoid\nOlder adults: Use lower doses\n\nEPI 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n1 » Follow up should occur\nevery 3-6 months\nREVIEW THE CURRENT CONDITION\nDoes the person have more than 50% seizure reduction in convulsion frequency?"
  },
  {
    "id": 231,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n1 » Follow up should occur\nevery 3-6 months\nREVIEW THE CURRENT CONDITION\nDoes the person have more than 50% seizure reduction in convulsion frequency? IF THE PERSON IS NOT IMPROVING ON CURRENT DOSE:\n»\nReview adherence to medications. »\nConsider increase in medication dose as needed to\nmaximal dose if no adverse effects. »\nIf response is still poor,\n– Consider switching medication. The new medication\nshould be at an optimum dose before slowly discon-\ntinuing the first. »\nIf response is still poor,\n– Review diagnosis. – REFER TO SPECIALIST. »\nFollow-up more frequently. CLINICAL TIP:\n»\nADVERSE EFFECTS (e.g. drowsiness, nystagmus, diplopia, ataxia)\nare from too high doses of medication for the person."
  },
  {
    "id": 232,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "view diagnosis. – REFER TO SPECIALIST. »\nFollow-up more frequently. CLINICAL TIP:\n»\nADVERSE EFFECTS (e.g. drowsiness, nystagmus, diplopia, ataxia)\nare from too high doses of medication for the person. »\nIf there is an IDIOSYNCRATIC REACTION (allergic reaction, bone\nmarrow depression, hepatic failure), switch antiepileptic medication. EPILEPSY 67\n\n68\nEPI 3\nEPILEPSY Follow-up\n2\nMONITOR TREATMENT\nAt every contact:\n» »\nEvaluate side-effects of medication including adverse effects Does the patient have any new symptoms of concern? and idiosyncratic reactions (clinically and with appropriate laboratory tests Review for any new symptoms of depression and anxiety given\nwhen available). high risk of co-morbidity with epilepsy. » »\nProvide psychoeducation and review psychosocial interventions."
  },
  {
    "id": 233,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "aboratory tests Review for any new symptoms of depression and anxiety given\nwhen available). high risk of co-morbidity with epilepsy. » »\nProvide psychoeducation and review psychosocial interventions. Is the patient on any new medications that may have interactions? » (Many anticonvulsants have interactions with other medications). If so,\nIs the person a woman of childbearing age and considering\nconsult a specialist. pregnancy? If so, consult specialist. 3\nCONSIDER MEDICATION DISCONTINUATION WHEN APPROPRIATE\nHas the person been convulsion free for several years? »\nD iscuss risk of seizure occurrence with person/carer\nIF THERE ARE NO PROBLEMS WITH MEDICATIONS (if epilepsy is due to head injury, stroke or neuroinfection,\n» Continue at current dose."
  },
  {
    "id": 234,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "veral years? »\nD iscuss risk of seizure occurrence with person/carer\nIF THERE ARE NO PROBLEMS WITH MEDICATIONS (if epilepsy is due to head injury, stroke or neuroinfection,\n» Continue at current dose. Correct dosing is lowest there is a higher risk of seizure recurrence off medication),\ntherapeutic dose for seizure control, while minimizing and risks and benefits of discontinuing medications. adverse side-effects. » If in agreement, gradually take the person off\n» Continue close follow-up and review for possible dis- medication by reducing the doses over 2 months and\ncontinuation of medications once seizure free for at monitoring closely for seizure recurrence. least two years."
  },
  {
    "id": 235,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "llow-up and review for possible dis- medication by reducing the doses over 2 months and\ncontinuation of medications once seizure free for at monitoring closely for seizure recurrence. least two years. CHILD & ADOLESCENT\nMENTAL & BEHAVIOURAL DISORDERS\nThis module covers assessment and management of developmental EMOTIONAL DISORDERS are among the leading mental health-\ndisorders, behavioural disorders, and emotional disorders in children related causes of the global burden of disease in young people. and adolescents. Emotional disorders are characterized by increased levels of anxiety,\ndepression, fear, and somatic symptoms."
  },
  {
    "id": 236,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "children related causes of the global burden of disease in young people. and adolescents. Emotional disorders are characterized by increased levels of anxiety,\ndepression, fear, and somatic symptoms. DEVELOPMENTAL DISORDER is an umbrella term covering\ndisorders such as intellectual disability as well as autism spectrum Children and adolescents often present with symptoms of more\ndisorders. These disorders usually have a childhood onset, impair- than one condition and sometimes the symptoms overlap. The\nment or delay in functions related to central nervous system matu- quality of home and social educational environments influence\nration, and a steady course rather than the remissions and relapses children’s and adolescents’ wellbeing and functioning."
  },
  {
    "id": 237,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "us system matu- quality of home and social educational environments influence\nration, and a steady course rather than the remissions and relapses children’s and adolescents’ wellbeing and functioning. Exploring\nthat tend to characterize many other mental disorders. and addressing psychosocial stressors along with opportunities\nto activate supports are critical elements of the assessment and\nBEHAVIOURAL DISORDERS is an umbrella term that includes management plan. specific disorders such as attention deficit hyperactivity disorder\n(ADHD) and conduct disorders. Behavioural symptoms of varying\nlevels of severity are very common in the general population."
  },
  {
    "id": 238,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nt plan. specific disorders such as attention deficit hyperactivity disorder\n(ADHD) and conduct disorders. Behavioural symptoms of varying\nlevels of severity are very common in the general population. Only\nchildren and adolescents with a moderate to severe degree of psy-\nchological, social, educational or occupational impairment in multiple\nsettings should be diagnosed as having behavioural disorders. 69\n\n70\nCMH\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS\nCMH Quick Overview\nASSESSMENT MANAGEMENT\nA ssess for problems with development Management Protocols\n1. Developmental Delay/Disorder\nAssess for problems with inattention\n2. Problems with Behaviour\nor over-activity 3. Attention Deficit Hyperactivity Disorder (ADHD)\n4. Conduct Disorder\nAssess for problems with emotions. If an 5."
  },
  {
    "id": 239,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rder\nAssess for problems with inattention\n2. Problems with Behaviour\nor over-activity 3. Attention Deficit Hyperactivity Disorder (ADHD)\n4. Conduct Disorder\nAssess for problems with emotions. If an 5. Problems with Emotions\n6. Emotional disorders and Moderate to Severe Depression\nadolescent, evaluate for moderate to severe\nin Adolescents\ndepression\nPsychosocial Interventions\nAssess for repeated defiant, disobedient,\nand aggressive behaviour\nAssess for presence of other priority\nMNS conditions\nFOLLOW-UP\nAssess the home environment\nA ssess the school environment\n\nTABLE 1: COMMON PRESENTATIONS OF CHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS BY AGE GROUP\nMay be reported by carer, self-reported or observed during the assessment process."
  },
  {
    "id": 240,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e school environment\n\nTABLE 1: COMMON PRESENTATIONS OF CHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS BY AGE GROUP\nMay be reported by carer, self-reported or observed during the assessment process. DEVELOPMENTAL DISORDERS BEHAVIORAL DISORDERS EMOTIONAL DISORDERS\nInfants and Young – Poor feeding, failure to thrive, poor motor tone, delay – Excessive crying, clinging to a carer, freezing (holding\nChildren (age <5) in meeting expected developmental milestones for the body very still and being silent) and/or tantrums\nappropriate age (eg. smiling, sitting, interacting with – Extreme shyness or changes in functioning (e.g."
  },
  {
    "id": 241,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ng expected developmental milestones for the body very still and being silent) and/or tantrums\nappropriate age (eg. smiling, sitting, interacting with – Extreme shyness or changes in functioning (e.g. new\nothers, sharing attention, walking, talking and toilet wetting or soiling behaviour or thumb sucking)\ntraining – Diminished initiation of play and social interaction\n– Sleep and eating difficulties\nAges 4-18\nMiddle Childhood – Delay in reading and writing – Excess over-activity: excessive running around, – Recurrent, unexplained physical symptoms\n(age 6-12) – Delay in self-care such as dressing, bathing, extreme difficulties remaining seated, excessive (e.g."
  },
  {
    "id": 242,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ss over-activity: excessive running around, – Recurrent, unexplained physical symptoms\n(age 6-12) – Delay in self-care such as dressing, bathing, extreme difficulties remaining seated, excessive (e.g. stomach ache, headache, nausea)\nbrushing teeth talking or moving restlessly – Reluctance or refusal to go to school\n– Excessive inattention, absent-mindedness, – Extreme shyness or changes in functioning\nrepeatedly stopping tasks before completion and (e.g. new wetting or soiling behaviour or thumb\nswitching to other activities sucking)\nAdolescents – Poor school performance – Excessive impulsivity: frequently doing things – Problems with mood, anxiety or worry (e.g."
  },
  {
    "id": 243,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "or soiling behaviour or thumb\nswitching to other activities sucking)\nAdolescents – Poor school performance – Excessive impulsivity: frequently doing things – Problems with mood, anxiety or worry (e.g. irritable,\n(age 13-18) – Difficulty understanding instructions without forethought easily annoyed, frustrated or depressed mood, extreme\n– Difficulty in social interaction and adjusting to changes – Repeated and continued behaviour that disturbs or rapid and unexpected changes in mood, emotional\nothers (e.g. unusually frequent and severe outbursts), excessive distress\ntantrums, cruel behaviour, persistent and severe – Changes in functioning (e.g."
  },
  {
    "id": 244,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "apid and unexpected changes in mood, emotional\nothers (e.g. unusually frequent and severe outbursts), excessive distress\ntantrums, cruel behaviour, persistent and severe – Changes in functioning (e.g. difficulty concentrating,\ndisobedience, stealing) poor school performance, often wanting to be alone or\n– Sudden changes in behaviour or peer relations, stay home)\nincluding withdrawal and anger\nAll Ages – Difficulty carrying out daily activities considered – Excessive fear, anxiety or avoidance of specific\nnormal for the person’s age; difficulty understanding situations or objects (e.g."
  },
  {
    "id": 245,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nger\nAll Ages – Difficulty carrying out daily activities considered – Excessive fear, anxiety or avoidance of specific\nnormal for the person’s age; difficulty understanding situations or objects (e.g. separation from caregivers,\ninstructions; difficulty in social interactions and adjusting social situations, certain animals or insects, heights,\nto changes; difficulties or oddities in communication; closed spaces, sight of blood or injury)\nrestrictive/repetitive patterns of behaviours, interests – Changes in in sleeping and eating habits\nand activities – Diminished interest or participation in activities\n– Oppositional or attention-seeking behaviour\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 71\n\n72\nCMH 1\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Assessment\nCMH 1 Assessment\nCOMMON PRESENTATIONS OF CHILD & ADOLESCENT\nMENTAL & BEHAVIOURAL DISORDERS\nChild/adolescent being seen for physical complaints or a general health assessment who has:\n– Any of the typical presenting complaints of emotional, behavioural or developmental disorders (See Table 1)\n– Risk factors such as malnutrition, abuse and/or neglect, frequent illness, chronic diseases (e.g."
  },
  {
    "id": 246,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "the typical presenting complaints of emotional, behavioural or developmental disorders (See Table 1)\n– Risk factors such as malnutrition, abuse and/or neglect, frequent illness, chronic diseases (e.g. HIV/AIDS or history of difficult birth)\nCarer with concerns about the child/adolescent’s:\n– Difficulty keeping up with peers or carrying out daily activities considered normal for age\n– Behaviour (e.g. too active, aggressive, having frequent and/or severe tantrums, wanting to be alone too much,\nrefusing to do regular activities or go to school)\nTeacher with concerns about a child/adolescent\n– e.g. easily distracted, disruptive in class, often getting into trouble, difficulty completing school work\nCommunity health or social services worker with concerns about a child/adolescent\n– e.g."
  },
  {
    "id": 247,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nt\n– e.g. easily distracted, disruptive in class, often getting into trouble, difficulty completing school work\nCommunity health or social services worker with concerns about a child/adolescent\n– e.g. rule- or law-breaking behaviour, physical aggression at home or in the community\n\nCLINICAL TIP\n1\n»\nAdolescents should always be\noffered the opportunity to be\nASSESS FOR DEVELOPMENTAL DISORDERS\nseen on their own, without\ncarers present. »\nClarify the confidential nature\nof the discussion. Assess all domains – motor, cognitive, social, communication, and adaptive. »\nIndicate in what circumstances\nF or toddlers and young children: F or older children and adolescents: parents or other adults will be\ngiven information."
  },
  {
    "id": 248,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "gnitive, social, communication, and adaptive. »\nIndicate in what circumstances\nF or toddlers and young children: F or older children and adolescents: parents or other adults will be\ngiven information. Has the child had any difficulties with age- Are there difficulties with school (learning, reading,\n»\nExplore the presenting\nappropriate milestones across all developmental and writing), communicating and interacting with\ncomplaint with the child/\nareas? others, self-care, and everyday household activities? adolescent and carer."
  },
  {
    "id": 249,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "priate milestones across all developmental and writing), communicating and interacting with\ncomplaint with the child/\nareas? others, self-care, and everyday household activities? adolescent and carer. SKIP to STEP 120\nSuspect DEVELOPMENTAL\nDELAY / DISORDER\nAre there signs/symptoms suggesting any of the following:\n– Nutritional deficiency, including iodine deficiency – Acute or chronic infectious illness, including ear\n– Anaemia infection and HIV/AIDS\n– Malnutrition\nManage conditions using Integrated\nManagement of Childhood Illness (IMCI)\n(www.who.int/maternal_child_adolescent/documents/\nIMCI_chartbooklet) or other available guidelines."
  },
  {
    "id": 250,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nd HIV/AIDS\n– Malnutrition\nManage conditions using Integrated\nManagement of Childhood Illness (IMCI)\n(www.who.int/maternal_child_adolescent/documents/\nIMCI_chartbooklet) or other available guidelines. CHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 73\n\n74\nCMH 1\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Assessment\nAssess the child for visual and/or hearing impairment:\nFor vision assessment, see if the child fails to: For hearing assessment, see if the child fails to:\n– Look at your eyes – Turn head to see someone behind them when they speak\n– Follow a moving object with the head and eyes – Show reaction to loud noise\n– Grab an object – Make a lot of different sounds (tata, dada, baba), if an infant\n– Recognize familiar people\nCONSULT WITH SPECIALIST FOR EVALUATION."
  },
  {
    "id": 251,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "h the head and eyes – Show reaction to loud noise\n– Grab an object – Make a lot of different sounds (tata, dada, baba), if an infant\n– Recognize familiar people\nCONSULT WITH SPECIALIST FOR EVALUATION. Go to PROTOCOL 1\n2\nASSESS FOR PROBLEMS WITH\nINATTENTION OR HYPERACTIVITY\nIs the child/adolescent:\n– Easily distracted, has difficulty completing tasks? – Overactive? – Moving restlessly? – Unable to stay still for long? SKIP to STEP 130\n\nAre symptoms persistent, severe, and causing considerable difficulty with daily functioning? Are ALL of the following true? – Are symptoms present in multiple settings? – Is there considerable difficulty with daily\n– Have they lasted at least 6 months?"
  },
  {
    "id": 252,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rable difficulty with daily functioning? Are ALL of the following true? – Are symptoms present in multiple settings? – Is there considerable difficulty with daily\n– Have they lasted at least 6 months? functioning in personal, family, social,\n– Are they inappropriate for the child/ educational, occupational or other areas? adolescent’s developmental level? ADHD Consider\nis unlikely PROBLEMS WITH BEHAVIOUR\nConsider ADHD Go to PROTOCOL 2\nSSKKIIPP ttoo SSTTEEPP 113300\nRule out physical conditions that can resemble ADHD. Does the child/adolescent have any of the following:\n– Thyroid diseases\n– Acute or chronic infectious illness, including HIV/AIDS\n– Uncontrolled pain e.g."
  },
  {
    "id": 253,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "t physical conditions that can resemble ADHD. Does the child/adolescent have any of the following:\n– Thyroid diseases\n– Acute or chronic infectious illness, including HIV/AIDS\n– Uncontrolled pain e.g. from an ear infection, sickle cell disease\nTreat the physical condition\nGo to PROTOCOL 3\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 75\n\n76\nCMH 1\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Assessment\n3\nASSESS FOR CONDUCT DISORDER\nDoes the child/adolescent show repeated aggressive, disobedient, or defiant behaviour, for example:\n– Arguing with adults – Provocative behaviour\n– Defying or refusing to comply with their requests or rules – Excessive levels of fighting or bullying\n– Extreme irritability/anger – Cruelty to animals or people\n– Frequent and severe temper tantrums – Severe destructiveness to property, fire-setting\n– Difficulty getting along with others – Stealing, repeated lying, truancy from school, running away from home\nCONDUCT DISORDER\nSKIP to STEP 140\nis unlikely\nCLINICAL TIP: AGE-APPROPRIATE DISRUPTIVE OR\nCHALLENGING BEHAVIOUR IN CHILDREN/ADOLESCENTS\nToddlers and – Refusing to do what they are told, breaking rules, arguing, whining,\nyoung children exaggerating, saying things that aren’t true, denying they did anything wrong,\n(age 18 months – being physically aggressive and blaming others for their misbehaviour."
  },
  {
    "id": 254,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "arguing, whining,\nyoung children exaggerating, saying things that aren’t true, denying they did anything wrong,\n(age 18 months – being physically aggressive and blaming others for their misbehaviour. 5 years)\n– Brief tantrums (emotional outbursts with crying, screaming, hitting, etc.),\nusually lasting less than 5 minutes and not longer than 25 minutes, typically\noccur less than 3 times per week. Developmentally typical tantrums should\nnot result in self-injury or frequent physical aggression toward others, and\nthe child can typically calm themselves down afterward. Middle Childhood – Avoidance of or delay in following instructions, complaining or arguing with\n(age 6-12) adults or other children, occasionally losing their temper."
  },
  {
    "id": 255,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "y calm themselves down afterward. Middle Childhood – Avoidance of or delay in following instructions, complaining or arguing with\n(age 6-12) adults or other children, occasionally losing their temper. Adolescents – Testing rules and limits, saying that rules and limits are unfair or unnecessary,\n(age 13-18) occasionally being rude, dismissive, argumentative or defiant with adults. Are symptoms persistent, severe, and inappropriate for the\nchild/adolescent’s developmental level:\n– Symptoms are present in different settings (e.g. at home, at school and in\nother social settings). – Symptoms have been present for at least 6 months. – More severe than ordinary childish mischief or adolescent rebelliousness."
  },
  {
    "id": 256,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "fferent settings (e.g. at home, at school and in\nother social settings). – Symptoms have been present for at least 6 months. – More severe than ordinary childish mischief or adolescent rebelliousness. – Is there considerable difficulty with daily functioning in personal, family, social,\neducational, occupational or other areas? Consider\nPROBLEMS WITH Consider\nBEHAVIOUR CONDUCT DISORDER\nGo to PROTOCOL 2 Go to PROTOCOL 4\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 77\n\n78\nCMH 1\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Assessment\n4\nASSESS FOR EMOTIONAL DISORDERS\n(prolonged, disabling distress involving sadness, fearfulness, anxiety or irritability)\nAsk if the child/adolescent:\n– Is often feeling irritable, easily annoyed, down or sad?"
  },
  {
    "id": 257,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "FOR EMOTIONAL DISORDERS\n(prolonged, disabling distress involving sadness, fearfulness, anxiety or irritability)\nAsk if the child/adolescent:\n– Is often feeling irritable, easily annoyed, down or sad? – Often complains of headaches, stomach-aches or sickness? – Has lost interest in or enjoyment of activities? – Is often unhappy, down-hearted or tearful? – Has many worries or often seems worried? – Avoids or strongly dislikes certain situations (e.g. separation\n– Has many fears or is easily scared? from carers, meeting new people, or closed spaces)?"
  },
  {
    "id": 258,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "? – Has many worries or often seems worried? – Avoids or strongly dislikes certain situations (e.g. separation\n– Has many fears or is easily scared? from carers, meeting new people, or closed spaces)? SKIP to STEP 150\nCLINICAL TIP: AGE-APPROPRIATE FEARS AND\nANXIETIES IN CHILDREN AND ADOLESCENTS\nBabies & Toddlers – Fear of strangers, distress when separating\n(age 9 months – 2 years) from caregivers\nYoung Children – Fear of storms, fire, water, darkness,\n(age 2-5) nightmares, and animals\nMiddle Childhood – Fear of monsters, ghosts, germs, natural\n(age 6-12) disasters, physical illness, and being badly injured\n– Anxiety about school or about performing in\nfront of others\nAdolescents – Fear of rejection by peers, performing in\n(age 13-18) front of others, physical illness, medical\nprocedures, catastrophes (e.g."
  },
  {
    "id": 259,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nxiety about school or about performing in\nfront of others\nAdolescents – Fear of rejection by peers, performing in\n(age 13-18) front of others, physical illness, medical\nprocedures, catastrophes (e.g. war, terrorist\nattack, disasters)\n\nIs there considerable difficulty with daily functioning in personal,\nfamily, social, educational, occupational or other areas? Consider\nPROBLEMS WITH\nEMOTIONS\nConsider Go to PROTOCOL 5\nEMOTIONAL DISORDER\nSKIP to STEP 150\nRule out physical conditions that can resemble or exacerbate emotional disorders. Are there any signs/symptoms suggesting:\n– Thyroid diseases – Obesity – Medication side-effects\n– Infectious illness, including HIV/AIDS – Malnutrition (e.g. from corticosteroids or\n– Anaemia – Asthma inhaled asthma medications)\nManage the physical condition."
  },
  {
    "id": 260,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "– Obesity – Medication side-effects\n– Infectious illness, including HIV/AIDS – Malnutrition (e.g. from corticosteroids or\n– Anaemia – Asthma inhaled asthma medications)\nManage the physical condition. Go to PROTOCOL 6\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 79\n\n80\nCMH 1\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Assessment\nIn adolescents, assess for moderate to severe depression. Does the adolescent have problems with mood (feeling irritable, down or sad)\nOR has lost interest in or enjoyment of activities? SKIP to STEP 150\nHas the adolescent had several of the following additional symptoms most days for the last 2 weeks?"
  },
  {
    "id": 261,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "feeling irritable, down or sad)\nOR has lost interest in or enjoyment of activities? SKIP to STEP 150\nHas the adolescent had several of the following additional symptoms most days for the last 2 weeks? – Disturbed sleep or sleeping too much – Fatigue or loss of energy – Talking or moving more slowly than usual\n– Significant change in appetite or weight – Reduced concentration – Hopelessness\n(decrease or increase) – Indecisiveness – Suicidal thoughts or acts\n– Beliefs of worthlessness or excessive guilt – Observable agitation or physical restlessness\nIs there considerable difficulty with daily functioning in personal,\nfamily, social, educational, occupational or other areas?"
  },
  {
    "id": 262,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ssness or excessive guilt – Observable agitation or physical restlessness\nIs there considerable difficulty with daily functioning in personal,\nfamily, social, educational, occupational or other areas? Consider\nGo to PROTOCOL 5\nPROBLEMS WITH\nEMOTIONS\nSKIP to STEP 150\n\nCLINICAL TIP\nDelusions or hallucinations may be present. If\nConsider DEPRESSION\npresent, treatment for depression needs to be\nadapted. CONSULT A SPECIALIST\nRule out a history of manic episode(s) and normal\nGo to PROTOCOL 6\n»\nreaction to recent major loss. See DEP. 5\nIF THERE IS IMMINENT RISK\nASSESS FOR OTHER PRIORITY MNS CONDITIONS OF SUICIDE, ASSESS AND MANAGE\n»\nbefore continuing. Go to SUI. Are there any other concurrent MNS conditions? Assess according to the\n»\nmhGAP-IG Master Chart. See MC."
  },
  {
    "id": 263,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "FOR OTHER PRIORITY MNS CONDITIONS OF SUICIDE, ASSESS AND MANAGE\n»\nbefore continuing. Go to SUI. Are there any other concurrent MNS conditions? Assess according to the\n»\nmhGAP-IG Master Chart. See MC. Do not forget to assess for disorders due to substance use. See » SUB. For children with developmental delay/disorders, do not forget to assess for epilepsy. See » EPI. ASSESS AND MANAGE\nconcurrent MNS conditions\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 81\n\n82\nCMH 1\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Assessment\nCLINICAL TIP CLINICAL TIP:\n6\nRED FLAGS FOR CHILD MALTREATMENT\nA sk the child/adolescent directly\nabout these exposures when\nASSESS THE HOME ENVIRONMENT CLINICAL FEATURES\ndevelopmentally appropriate and safe\nto do so (e.g."
  },
  {
    "id": 264,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "TIP:\n6\nRED FLAGS FOR CHILD MALTREATMENT\nA sk the child/adolescent directly\nabout these exposures when\nASSESS THE HOME ENVIRONMENT CLINICAL FEATURES\ndevelopmentally appropriate and safe\nto do so (e.g. not in the presence of a Physical abuse\ncarer who may have committed the – Injuries (e.g. bruises, burns, strangulation marks or marks\nmaltreatment). Are the emotional, behavioural or developmental problems a from a belt, whip, switch or other object)\n– Any serious or unusual injury without an explanation or\nA dolescents should always be offered\nreaction to or aggravated by a distressing or frightening situation? with an unsuitable explanation\nthe opportunity to be seen on their own, Sexual abuse\nAssess for:\nwithout carers present."
  },
  {
    "id": 265,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "be offered\nreaction to or aggravated by a distressing or frightening situation? with an unsuitable explanation\nthe opportunity to be seen on their own, Sexual abuse\nAssess for:\nwithout carers present. – Genital or anal injuries or symptoms that are medically\nClinical features or any element in the clinical history that suggest\nunexplained\nmaltreatment or exposure to violence (see CLINICAL TIP). – Sexually transmitted infections or pregnancy\n– Sexualised behaviours (e.g. indication of age-inappropriate\nAny recent or ongoing severe stressors (e.g. illness or death of a\nsexual knowledge)\nfamily member, difficult living and financial circumstances, being\nNeglect\nbullied or harmed)."
  },
  {
    "id": 266,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "of age-inappropriate\nAny recent or ongoing severe stressors (e.g. illness or death of a\nsexual knowledge)\nfamily member, difficult living and financial circumstances, being\nNeglect\nbullied or harmed). – Being excessively dirty, unsuitable clothing\n– Signs of malnutrition, very poor dental health\nEmotional abuse and all other forms of maltreatment\nAny sudden or significant change in the behaviour or\nemotional state of the child/adolescent that is not better\nexplained by another cause, such as:\n– Unusual fearfulness or severe distress (e.g."
  },
  {
    "id": 267,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ment\nAny sudden or significant change in the behaviour or\nemotional state of the child/adolescent that is not better\nexplained by another cause, such as:\n– Unusual fearfulness or severe distress (e.g. inconsolable crying)\n– Self-harm or social withdrawal\nRefer to child protection services if necessary – Aggression or running away from home\n– Indiscriminate affection seeking from adults\nExplore and manage stressors\n– Development of new soiling and wetting behaviours, thumb\nEnsure child/adolescent’s safety as a first priority sucking\nReassure the child/adolescent that all children/adolescents need to\nASPECTS OF CARER INTERACTION WITH THE\nbe protected from abuse\nCHILD/ADOLESCENT\nProvide information about where to seek help for any ongoing abuse\nArrange additional support including referral to specialist Persistently unresponsive behaviour, especially toward an\ninfant (e.g."
  },
  {
    "id": 268,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "NT\nProvide information about where to seek help for any ongoing abuse\nArrange additional support including referral to specialist Persistently unresponsive behaviour, especially toward an\ninfant (e.g. not offering comfort or care when the child/\nContact legal and community resources, as appropriate and as mandated\nadolescent is scared, hurt or sick)\nConsider additional psychosocial interventions Hostile or rejecting behaviour\nUsing inappropriate threats (e.g. to abandon the child/\nEnsure appropriate follow-up\nadolescent) or harsh methods of discipline\n\nCLINICAL TIP\nDo the carers have any priority MNS condition that could impact »\nDepressive disorder in carers\ntheir ability to care for the child/adolescent?"
  },
  {
    "id": 269,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "adolescent) or harsh methods of discipline\n\nCLINICAL TIP\nDo the carers have any priority MNS condition that could impact »\nDepressive disorder in carers\ntheir ability to care for the child/adolescent? can worsen emotional, behavioural\nor developmental disorders in\nConsider especially depression and disorders due to substance use. their children/adolescents. Assess and manage for carer\nMNS conditions. Go to Management 2.6 (Carer support)\nIs the child getting adequate opportunities for play and\nsocial interaction/communication at home? Consider asking:\nWith whom does the child spend most of their time? How do you/they play with the child? How often? How do you/they communicate with the child? How often? Provide advise on age-appropriate stimulation\nand parenting."
  },
  {
    "id": 270,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "the child spend most of their time? How do you/they play with the child? How often? How do you/they communicate with the child? How often? Provide advise on age-appropriate stimulation\nand parenting. Refer to Care for Child\nDevelopment http://www.who.int/maternal_\nchild_adolescent/documents/care_child_\ndevelopment/en/\nConsider need for additional support for the\nchild including referral to child protection services\nwhere available. CHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 83\n\n84\nCMH 1\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Assessment\n7\nASSESS THE SCHOOL ENVIRONMENT\nIs the child/adolescent in school? Provide information regarding educational services\nand educate carer on importance of keeping the\nchild/adolescent in school as much as possible."
  },
  {
    "id": 271,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "SCHOOL ENVIRONMENT\nIs the child/adolescent in school? Provide information regarding educational services\nand educate carer on importance of keeping the\nchild/adolescent in school as much as possible. Is the child/adolescent:\nCLINICAL TIP\n»\nA sk the child/adolescent directly about Being bullied, picked on or made fun of? these exposures when developmentally Not able to participate and learn? appropriate and safe to do so. Not wanting/refusing to attend school? A fter getting consent, liaise with teachers and\nother school staff. Go to Management (2.7). I f there has been an absence from school,\ntry to help the child/adolescent return to school\nas soon as possible and explore reasons for\nabsence."
  },
  {
    "id": 272,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "achers and\nother school staff. Go to Management (2.7). I f there has been an absence from school,\ntry to help the child/adolescent return to school\nas soon as possible and explore reasons for\nabsence. Go to CMH 2 (Management)\n\nCMH 2 Management\nPROTOCOL PROTOCOL PROTOCOL\n1 2 3\nDevelopmental Delay/Disorder Problems with Behaviour Attention Deficit Hyperactivity\nDisorder (ADHD)\n» »\nProvide guidance on child/adolescent well-being. (2.1) Provide guidance on child/adolescent well-being. (2.1)\n» Provide psychoeducation to person and carers and » Provide guidance on improving behaviour. (2.3) » Provide guidance on child/adolescent well-being. (2.1)\nparenting advice. Provide guidance on developmental\ndisorders."
  },
  {
    "id": 273,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "cation to person and carers and » Provide guidance on improving behaviour. (2.3) » Provide guidance on child/adolescent well-being. (2.1)\nparenting advice. Provide guidance on developmental\ndisorders. (2.2 and 2.3)\n» Assess for and manage stressors, reduce stress and » Provide psychoeducation to person and carers and\nstrengthen social supports. parenting advice. Provide guidance on improving\n»\nProvide carer support. (2.6) » behaviour. (2.2 and 2.3)\nLiaise with teachers and other school staff. (2.7)\n» Liaise with teachers and other school staff. (2.7) » » Assess for and manage stressors, reduce stress and\nLink with other available resources in\n» strengthen social supports. Link with other available resources in the community the community. such as Community-Based Rehabilitation."
  },
  {
    "id": 274,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "sors, reduce stress and\nLink with other available resources in\n» strengthen social supports. Link with other available resources in the community the community. such as Community-Based Rehabilitation. » » Provide carer support. (2.6)\nOffer follow-up. » Offer Parent Skills Training, when available. (2.8) » Liaise with teachers and other school staff. (2.7)\n» Refer children with developmental disorders » Link with other available resources in the community. to specialist for further assessment, advice on\n»\nmanagement plan and family planning. Consider Parent Skills Training when available. (2.8)\n»\n» Consider behavioural interventions when available. (2.8)\nEnsure appropriate follow-up every three months\nor more, if needed."
  },
  {
    "id": 275,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "family planning. Consider Parent Skills Training when available. (2.8)\n»\n» Consider behavioural interventions when available. (2.8)\nEnsure appropriate follow-up every three months\nor more, if needed. » If above treatments have failed AND the child/\n» adolescent has a diagnosis of ADHD AND is at least\nDO NOT offer pharmacological treatment. 6 years old, refer to a specialist for methylphenidate\ntreatment. »\nEnsure appropriate follow-up every three months\nor more, if needed. CHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 85\n\n86\nCMH 2\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Management\nPROTOCOL PROTOCOL PROTOCOL\n4 5 6\nConduct Disorder Problems with Emotions Emotional Disorder or Depression\n» » »\nProvide guidance on child/adolescent well-being."
  },
  {
    "id": 276,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "NTAL & BEHAVIOURAL DISORDERS Management\nPROTOCOL PROTOCOL PROTOCOL\n4 5 6\nConduct Disorder Problems with Emotions Emotional Disorder or Depression\n» » »\nProvide guidance on child/adolescent well-being. (2.1) Provide guidance on child/adolescent well-being. (2.1) DO NOT consider pharmacological treatment\n» » as first line treatment. Provide psychoeducation to person and carers and Provide psychoeducation to the person and carers\nparenting advice. (2.2) and advice on parenting. (2.2)\n»\nDO NOT prescribe pharmacological treatment\n» » for children younger than 12 years. Provide guidance on improving behaviour. (2.3) Assess for and manage stressors, reduce stress and\n»\nstrengthen social supports. Provide guidance on child/adolescent well-being."
  },
  {
    "id": 277,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "younger than 12 years. Provide guidance on improving behaviour. (2.3) Assess for and manage stressors, reduce stress and\n»\nstrengthen social supports. Provide guidance on child/adolescent well-being. (2.1)\n»\nAssess for and manage stressors, and strengthen\n» »\nsocial supports. Liaise with teachers and other school staff. (2.7) Provide psychoeducation to the person and carers. » » (2.2 and 2.5)\nProvide carer support. (2.6) Link with other available resources in the\n»\ncommunity. Provide carer support. (2.6)\n»\nLiaise with teachers and other school staff. (2.7)\n»\nLiaise with teachers and other school staff. (2.7)\n»\nConsider Parent Skills Training when available. (2.8)\n»\nLink with other available resources in the community. »\nLink with other available resources in the community."
  },
  {
    "id": 278,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rs and other school staff. (2.7)\n»\nConsider Parent Skills Training when available. (2.8)\n»\nLink with other available resources in the community. »\nLink with other available resources in the community. »\nAssess for and manage stressors, reduce stress and\n»\nEnsure appropriate follow-up every three months\nstrengthen social supports. or more, if needed. »\nConsider Parent Skills Training when available. (2.8)\n»\nConsider behavioural interventions when available. (2.8)\n»\nConsider referral for behavioural intervention or\n»\nD O NOT offer pharmacological treatment. interpersonal therapy. »\nWhen psychological interventions prove ineffective,\nconsult a specialist for Fluoxetine (no other SSRIs or\n»\nTCAs). Go to DEP for medication details. »\nEnsure appropriate follow-up once a month\nor more, if needed."
  },
  {
    "id": 279,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "gical interventions prove ineffective,\nconsult a specialist for Fluoxetine (no other SSRIs or\n»\nTCAs). Go to DEP for medication details. »\nEnsure appropriate follow-up once a month\nor more, if needed. Guidance for improving behaviour can be provided to all carers\nPSYCHOSOCIAL INTERVENTIONS who are having difficulty with their child/adolescent’s behaviour\neven if a behavioural disorder is not suspected. 2.1 G uidance to promote child/adoles- physical activity each day through daily activities, play, or 2.3 Guidance for improving behaviour\ncent well-being and functioning\nsports."
  },
  {
    "id": 280,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rder is not suspected. 2.1 G uidance to promote child/adoles- physical activity each day through daily activities, play, or 2.3 Guidance for improving behaviour\ncent well-being and functioning\nsports. See www.who.int/dietphysicalactivity/publications/\nrecommendations5_17years ENCOURAGE THE CARER TO:\nParticipate in school, community, and other social activities Give loving attention, including playing with the child every day. Can be provided to all children, adolescents as much as possible. Provide opportunities for the adolescents to talk to you. and carers even if no disorder is suspected. Spend time with trusted friends and family. Be consistent about what your child/adolescent is allowed\nand not allowed to do. Give clear, simple, and short\nAvoid the use of drugs, alcohol, and nicotine."
  },
  {
    "id": 281,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "pend time with trusted friends and family. Be consistent about what your child/adolescent is allowed\nand not allowed to do. Give clear, simple, and short\nAvoid the use of drugs, alcohol, and nicotine. instructions on what the child should and should not do. ENCOURAGE THE CARER TO:\nSpend time with their child in enjoyable activities. Give the child/adolescent simple daily household tasks to do that\n2.2 P sychoeducation to person and\nPlay and communicate with their child/adolescent. match their ability level and praise them immediately after they do\nhttp://www.who.int/maternal_child_adolescent/documents/ carers and parenting advice the task."
  },
  {
    "id": 282,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "mmunicate with their child/adolescent. match their ability level and praise them immediately after they do\nhttp://www.who.int/maternal_child_adolescent/documents/ carers and parenting advice the task. care_child_development/en/\nPraise or reward the child/adolescent when you observe good\nListen to the child/adolescent and show understanding Explain the delay or difficulty to the carer and the child/ behaviour and give no reward when behaviour is problematic. adolescent as appropriate and help them identify strengths\nand respect. Find ways to avoid severe confrontations or foreseeable\nand resources. Protect them from any form of maltreatment, including difficult situations. Praise the carer and the child/adolescents for their efforts."
  },
  {
    "id": 283,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "s to avoid severe confrontations or foreseeable\nand resources. Protect them from any form of maltreatment, including difficult situations. Praise the carer and the child/adolescents for their efforts. bullying and exposure to violence in the home, at school,\nRespond only to the most important problem behaviours\nand in the community. and make punishment mild (e.g. witholding rewards and fun\nExplain to the carer that parenting a child/adolescent with an\nAnticipate major life changes (such as puberty, starting emotional, behavioural or developmental delay or disorder activities) and infrequent compared to the amount of praise. school, or birth of a sibling) and provide support. can be rewarding but also very challenging. Put off discussions with the child/adolescent until you are\ncalm."
  },
  {
    "id": 284,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "uent compared to the amount of praise. school, or birth of a sibling) and provide support. can be rewarding but also very challenging. Put off discussions with the child/adolescent until you are\ncalm. Avoid using criticism, yelling, and name-calling. Explain that persons with mental disorders should not be\nENCOURAGE AND HELP THE CHILD / ADOLESCENT TO: blamed for having the disorder. Encourage carers to be kind\nDO NOT use threats or physical punishment, and never\nand supportive and show love and affection. Get enough sleep. Promote regular bed routines and physically abuse the child/adolescent."
  },
  {
    "id": 285,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rs to be kind\nDO NOT use threats or physical punishment, and never\nand supportive and show love and affection. Get enough sleep. Promote regular bed routines and physically abuse the child/adolescent. Physical punishment can\nremove TV or other electronic devices with screens from the Promote and protect human rights of the person and the family harm the child-carer relationship; it does not work as well as\nsleeping area/bedroom. and be vigilant about maintaining human rights and dignity. other methods and can make behaviour problems worse. Eat regularly. All children/adolescents need three meals Help carers to have realistic expectations and encourage Encourage age-appropriate play (e.g. sports, drawing or\n(breakfast, mid-day, and evening) and some snacks each day."
  },
  {
    "id": 286,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "dolescents need three meals Help carers to have realistic expectations and encourage Encourage age-appropriate play (e.g. sports, drawing or\n(breakfast, mid-day, and evening) and some snacks each day. them to contact other carers of children/adolescents with other hobbies) for adolescents and offer age-appropriate\nsupport in practical ways (e.g. with homework or other\nsimilar conditions for mutual support. Be physically active. If they are able, children and\nlife skillls). adolescents aged 5–17 should do 60 minutes or more of\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 87\n\n88\nCMH 2\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Management\n2.4 Psychoeducation for Persons with developmental disorders may often have Make predictable routines in the morning and at bedtime."
  },
  {
    "id": 287,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "CMH 2\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Management\n2.4 Psychoeducation for Persons with developmental disorders may often have Make predictable routines in the morning and at bedtime. developmental delay/disorder associated behavioural problems that are difficult for the carer Promote regular sleep habits. Schedule the day with regular\nto manage. See guidance for improving behaviours. (2.3) times for eating, playing, learning, and sleeping. ENCOURAGE THE CARER TO: Promote and protect the human rights of the person For excessive and unrealistic fears:\nand family and be vigilant about maintaining human\nLearn what the child’s strengths and weaknesses are and – Praise the child/adolescent or give small rewards when\nrights and dignity."
  },
  {
    "id": 288,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "realistic fears:\nand family and be vigilant about maintaining human\nLearn what the child’s strengths and weaknesses are and – Praise the child/adolescent or give small rewards when\nrights and dignity. how they learn best, what is stressful to the child and what they try new things or act bravely. makes him/her happy, and what causes problem behaviours – Educate carers to avoid institutionalization. – Help the child practice facing the difficult situation one\nand what prevents them. – Promote access to health information and services. small step at a time (e.g. if the child is afraid of separating\n– Promote access to schooling and other forms of education."
  },
  {
    "id": 289,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "and what prevents them. – Promote access to health information and services. small step at a time (e.g. if the child is afraid of separating\n– Promote access to schooling and other forms of education. from the carer, help the child gradually increase the\nLearn how the child communicates and responds (using\n– Promote access to occupations. amount of time he/she plays alone while the carer is\nwords, gestures, non-verbal expression, and behaviours). – Promote participation in family and community life. nearby). Help the child develop by engaging with her/him in everyday – Acknowledge the child’s feelings and worries and\nactivities and play. encourage them to confront their fears."
  },
  {
    "id": 290,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "and community life. nearby). Help the child develop by engaging with her/him in everyday – Acknowledge the child’s feelings and worries and\nactivities and play. encourage them to confront their fears. 2.5 Psychoeducation for emotional\n– Help the child/adolescent create a plan to help them cope\nChildren learn best during activities that are fun and positive. problems/disorders including\nin case a feared situation occurs. Involve them in everyday life, starting with simple tasks, one depression in adolescents\nat a time. Break complex activities down into simple steps so Explain that emotional disorders are common and can\nthat the child can learn and be rewarded one step at a time. happen to anybody."
  },
  {
    "id": 291,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "scents\nat a time. Break complex activities down into simple steps so Explain that emotional disorders are common and can\nthat the child can learn and be rewarded one step at a time. happen to anybody. The occurrence of emotional disorders\nAddress any stressful situation in the family environment\ndoes not mean that the person is weak or lazy. Make predictable daily routines by scheduling regular times such as parental discord or a parent’s mental disorder. With\nfor eating, playing, learning, and sleeping. the help of teachers explore possible adverse circumstances Emotional disorders can cause unjustified thoughts of\nin the school environment. hopelessness and worthlessness."
  },
  {
    "id": 292,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ng, learning, and sleeping. the help of teachers explore possible adverse circumstances Emotional disorders can cause unjustified thoughts of\nin the school environment. hopelessness and worthlessness. Explain that these views\nKeep their environment stimulating: avoid leaving the child\nare likely to improve once the emotional disorders improve. alone for hours without someone to talk to and limit time Provide opportunities for quality time with the carer and\nspent watching TV and playing electronic games. the family. Make the person aware that if they notice thoughts of\nself-harm or suicide, they should tell a trusted person and\nKeep them in the school setting for as long as possible, Encourage and help the child/adolescent to continue\ncome back for help immediately."
  },
  {
    "id": 293,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "self-harm or suicide, they should tell a trusted person and\nKeep them in the school setting for as long as possible, Encourage and help the child/adolescent to continue\ncome back for help immediately. attending mainstream schools even if only part-time. (or restart) pleasurable and social activities. Use balanced discipline. When the child/adolescent does Encourage the child/adolescent to practice regular physical\nsomething good, offer a reward. Distract the child/adolescent activity, gradually increasing the duration of sessions. from things they should not do. Consider training the child/adolescent and carer in breathing\nDO NOT use threats or physical punishments when the exercises, progressive muscle relaxation and other cultural\nbehaviour is problematic. equivalents."
  },
  {
    "id": 294,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ining the child/adolescent and carer in breathing\nDO NOT use threats or physical punishments when the exercises, progressive muscle relaxation and other cultural\nbehaviour is problematic. equivalents. PSYCHOSOCIAL INTERVENTIONS (CONT.)\n2.6 Carer support Ask about any stressful situations that may have an adverse 2.8 Brief psychological treatments\nimpact on the child’s emotional well-being and learning. If\nthe child is being bullied, advise the teacher on appropriate This guide does not provide specific protocols to implement\nAssess the psychosocial impact of the child/adolescent’s\naction to stop it. brief psychological interventions, such as parent skills training,\ndisorders on the carers, and offer support for their personal,\ninterpersonal therapy and behavioural therapy."
  },
  {
    "id": 295,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nt’s\naction to stop it. brief psychological interventions, such as parent skills training,\ndisorders on the carers, and offer support for their personal,\ninterpersonal therapy and behavioural therapy. WHO has\nsocial, and mental health needs. Explore strategies to help engage the child in school\ndeveloped Parent Skills Training package for caregivers of\nactivities and facilitate learning, inclusion, and participation. Promote necessary support and resources for their family children with developmental delay/disorders and is available\nlife, employment, social activities, and health. Simple tips: on request."
  },
  {
    "id": 296,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ipation. Promote necessary support and resources for their family children with developmental delay/disorders and is available\nlife, employment, social activities, and health. Simple tips: on request. Arrange for respite care (trustworthy carers taking over – Provide opportunities for the child/adolescent to use\ncare on a short term basis) to give primary carers a break, their skills and strengths. especially if the child has a developmental disorder. – Ask the student to sit at the front of the class. Support family to handle social and familial problems and – Give the student extra time to understand and complete\nhelp to problem solve. assignments. – Divide long assignments into smaller pieces and assign\none piece at a time."
  },
  {
    "id": 297,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ial and familial problems and – Give the student extra time to understand and complete\nhelp to problem solve. assignments. – Divide long assignments into smaller pieces and assign\none piece at a time. 2.7 Liaise with teachers and other\n– Provide extra praise for effort and rewards for achievements. school staff\n– DO NOT use threats or physical punishments or\nexcessive criticism. After getting consent from the child/adolescent and carer,\n– For students with significant difficulties in the classroom,\ncontact the child/adolescent’s teacher and provide advice/\nrecruit a volunteer to come to class to provide one-on-one\nmake a plan on how to support the child with learning and\nattention or pair the student with a peer who can provide\nparticipation in school activities."
  },
  {
    "id": 298,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "volunteer to come to class to provide one-on-one\nmake a plan on how to support the child with learning and\nattention or pair the student with a peer who can provide\nparticipation in school activities. support or help with learning. Explain that the child/adolescent’s mental disorder is\n– If the child/adolescent has been out of school, help them\naffecting their learning/behaviour/social functioning and that\nreturn as soon as possible by creating a gradually increasing\nthere are things the teacher can do to help. reintegration schedule. During the reintegration period, the\nstudent should be excused from quizzes and exams."
  },
  {
    "id": 299,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "possible by creating a gradually increasing\nthere are things the teacher can do to help. reintegration schedule. During the reintegration period, the\nstudent should be excused from quizzes and exams. CHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 89\n\n90\nCMH 3\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Follow-up\nCMH 3 Follow-up\n1\nASSESS FOR IMPROVEMENT\nCLINICAL TIP\n»\nIs the person improving? If exposure to one or more types\nReassess and monitor the child/adolescent’s symptoms, of maltreatment was identified\nbehaviour, and functioning at every visit. in the assessment, assess ongoing\nexposure and risks to the child/\nadolescent. »\nContinue with management plan and follow-up\nuntil symptoms cease or remit. »\nProvide additional psychoeducation and advice on\n»\nparenting."
  },
  {
    "id": 300,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "assess ongoing\nexposure and risks to the child/\nadolescent. »\nContinue with management plan and follow-up\nuntil symptoms cease or remit. »\nProvide additional psychoeducation and advice on\n»\nparenting. P rovide additional psychoeducation and advice on parenting, as appropriate. » »\nIf on medication, consider gradually reducing R eview psychosocial interventions and revise management plan as needed. medication dose in consultation with a specialist. Involve child/adolescent and carers in decision-making, as appropriate. »\n»\nIf not on medication, decrease frequency of\nOffer regular follow-up. follow up once symptoms have subsided and the\nchild/adolescent is able to perform well in daily life."
  },
  {
    "id": 301,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "n-making, as appropriate. »\n»\nIf not on medication, decrease frequency of\nOffer regular follow-up. follow up once symptoms have subsided and the\nchild/adolescent is able to perform well in daily life. If NO improvement in symptoms and/or functioning in 6 months:\n»\nProvide additional interventions if available. »\nIncrease the frequency of follow-up visits as needed. »\nREFER TO SPECIALIST if available, for further assessment and management."
  },
  {
    "id": 302,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "tioning in 6 months:\n»\nProvide additional interventions if available. »\nIncrease the frequency of follow-up visits as needed. »\nREFER TO SPECIALIST if available, for further assessment and management. DEVELOPMENTAL DISORDERS EMOTIONAL DISORDERS\nIf no improvement, further deterioration, predicted danger to the If no improvement and the child/adolescent has received\nchild, or physical health is affected (such as nutritional problems), psychosocial treatment for at least 6 months\n» »\nREFER TO SPECIALIST for further assessment and advice on R EFER TO SPECIALIST. management plan. DO NOT initiate pharmacological treatment. DO NOT consider pharmacological treatment."
  },
  {
    "id": 303,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "least 6 months\n» »\nREFER TO SPECIALIST for further assessment and advice on R EFER TO SPECIALIST. management plan. DO NOT initiate pharmacological treatment. DO NOT consider pharmacological treatment. DEPRESSION\nADHD\nIf no improvement and the adolescent is 12 years or older and\nIf no improvement and the child is at least 6 years old and has has received psychosocial treatment for at least 6 months\nreceived psychosocial treatment for at least 6 months »\nR efer to or consult SPECIALIST for fluoxetine (but not other\n»\nRefer to or consult SPECIALIST for methylphenidate use. SSRIs or TCAs)."
  },
  {
    "id": 304,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "6 months\nreceived psychosocial treatment for at least 6 months »\nR efer to or consult SPECIALIST for fluoxetine (but not other\n»\nRefer to or consult SPECIALIST for methylphenidate use. SSRIs or TCAs). CLINICAL TIP\nCONDUCT DISORDERS\n»\nFor adolescents, plan to see If no improvemen or predicted danger to the adolescent\n»\nthe adolescent separately from their REFER TO SPECIALIST for further assessment and advice\non management plan. parent/carer for part of the follow-up\nDO NOT consider pharmacological treatment. visit. Clarify the confidential nature of\nthe health care discussion, including in\nwhat circumstances parents or other\n2\nadults will be given information. CONDUCT ROUTINE ASSESSMENTS\nAt every visit:\n» »\nFor children under 5 years, monitor child development."
  },
  {
    "id": 305,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "discussion, including in\nwhat circumstances parents or other\n2\nadults will be given information. CONDUCT ROUTINE ASSESSMENTS\nAt every visit:\n» »\nFor children under 5 years, monitor child development. Assess opportunities for the child/adolescent to participate\n» in family and social life. Assess for the presence of any new problem or symptom related\n»\nto mood, behaviour or development/learning. For adolescents, Assess carers’ needs and support available to the family. »\nassess for the presence of worsening mood (irritable, easily Monitor attendance at school. annoyed or frustrated, down or sad) or suicidal thoughts. »\nReview management plan and monitor adherence to\nGo back to Assessment Step 4 for worsening mood. Go to » SUI\npsychosocial interventions. for suicidal thoughts."
  },
  {
    "id": 306,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ed, down or sad) or suicidal thoughts. »\nReview management plan and monitor adherence to\nGo back to Assessment Step 4 for worsening mood. Go to » SUI\npsychosocial interventions. for suicidal thoughts. »\nIf on medication, review adherence, side-effects, and dosing. »\nExplore and address psychosocial stressors in the home, school\nor work environment, including exposure to violence or other\nforms of maltreatment. CHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS 91\n\n92\nCMH 3\nCHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Follow-up\n3\nMONITOR PHARMACOLOGICAL TREATMENT AS APPLICABLE\nAdditional monitoring if the adolescent Additional monitoring if the child has\nhas been prescribed fluoxetine been prescribed methylphenidate\nRecord prescription and administration details."
  },
  {
    "id": 307,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "APPLICABLE\nAdditional monitoring if the adolescent Additional monitoring if the child has\nhas been prescribed fluoxetine been prescribed methylphenidate\nRecord prescription and administration details. Record prescription and administration details. Weekly for the first month, then every month: Monitor potential for misuse and diversion. monitor for reported side-effects and changes in mood and\nEvery three months: monitor/record height, weight, blood\nother symptoms. pressure, reported side-effects, and changes in behaviour. Consult specialist if you identify severe medication side-\nConsult specialist if you observe medication side-effects\neffects or adverse events (e.g. new or worsening suicidal\n(e.g."
  },
  {
    "id": 308,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "anges in behaviour. Consult specialist if you identify severe medication side-\nConsult specialist if you observe medication side-effects\neffects or adverse events (e.g. new or worsening suicidal\n(e.g. failure to make expected gains in weight and height,\nthoughts, suicidal or self-harming behaviour, agitation,\nincreased blood pressure, agitation, anxiety, and severe\nirritability, anxiety or insomnia). insomnia). Advise the adolescent to continue the medication even if\nAfter one year of treatment: Consult specialist regarding\nthey feel better. The medication should be continued for\nthe continuation of methylphenidate. 9-12 months after the symptoms have resolved to reduce\nthe risk of relapse. Advise against suddenly stopping the medication."
  },
  {
    "id": 309,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "The medication should be continued for\nthe continuation of methylphenidate. 9-12 months after the symptoms have resolved to reduce\nthe risk of relapse. Advise against suddenly stopping the medication. If symptoms have been resolved for 9-12 months:\nDiscuss with adolescent and carer risks and benefits to taper\noff medication. Reduce treatment gradually over minimum 4\nweeks, monitor closely for symptom recurrence. DEMENTIA\nDementia is a chronic and progressive syndrome due to changes in emotional control, social behaviour, or motivation. People with\nin the brain. Although it can occur at any age, it is more common dementia may be totally unaware of these changes and may not\nin older people. Dementia is a significant cause of disability and seek help."
  },
  {
    "id": 310,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "he brain. Although it can occur at any age, it is more common dementia may be totally unaware of these changes and may not\nin older people. Dementia is a significant cause of disability and seek help. Family members may notice memory problems, changes\ndependency among older people worldwide; it has a physical, in personality or behaviour, confusion, wandering, or incontinence. psychological, social, and economic impact on carers, families, However some people with dementia and their carers may deny\nand society at large. or minimize the severity of memory loss and associated problems."
  },
  {
    "id": 311,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "cal, social, and economic impact on carers, families, However some people with dementia and their carers may deny\nand society at large. or minimize the severity of memory loss and associated problems. Dementia results in decline in cognitive functioning and usually\nThe conditions that cause dementia produce changes in a person’s interferes with activities of daily living, such as washing, dressing,\nmental ability, personality, and behaviour. People with dementia eating, personal hygiene, and toilet activities. Although there is no\ncommonly experience problems with memory and the skills needed cure, with early recognition and supportive treatment, the lives of\nto carry out everyday activities."
  },
  {
    "id": 312,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "et activities. Although there is no\ncommonly experience problems with memory and the skills needed cure, with early recognition and supportive treatment, the lives of\nto carry out everyday activities. Dementia is not part of normal people with dementia and their caregivers can be significantly\nageing. Alzheimer’s disease is the most common cause, however, improved, and the physical health, cognition, activity, and well-\ndementia can be caused by a variety of diseases and injuries to the being of the person with dementia can be optimized. brain. People with dementia often present with forgetfulness or\nfeeling depressed. Other common symptoms include deterioration\n93\n\n94\nDEM\nDEMENTIA\nDEM Quick Overview\nASSESSMENT MANAGEMENT\nA ssess for signs of dementia Management Protocols\n1."
  },
  {
    "id": 313,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "with forgetfulness or\nfeeling depressed. Other common symptoms include deterioration\n93\n\n94\nDEM\nDEMENTIA\nDEM Quick Overview\nASSESSMENT MANAGEMENT\nA ssess for signs of dementia Management Protocols\n1. Dementia – without behavioural/psychological symptoms\nAre there any other explanations for\n2. Dementia – with behavioural/psychological symptoms\nthe symptoms?"
  },
  {
    "id": 314,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "signs of dementia Management Protocols\n1. Dementia – without behavioural/psychological symptoms\nAre there any other explanations for\n2. Dementia – with behavioural/psychological symptoms\nthe symptoms? Psychosocial Interventions\n– Rule out delirium\n– Rule out depression (pseudodementia)\nPharmacological Interventions\nEvaluate for other medical issues\nAssess for behavioral or psychological\nsymptoms\nRule out other MNS conditions\nFOLLOW-UP\nEvaluate the needs of carers\n\nCLINICAL TIP:\nDEM 1 Assessment\nInterview the key informant\n(someone who knows the person\nwell) and ask about recent changes\nin thinking and reasoning, memory\nand orientation."
  },
  {
    "id": 315,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "uate the needs of carers\n\nCLINICAL TIP:\nDEM 1 Assessment\nInterview the key informant\n(someone who knows the person\nwell) and ask about recent changes\nin thinking and reasoning, memory\nand orientation. Occasional\nCOMMON PRESENTATIONS OF DEMENTIA\nmemory lapses are common in\nolder people, whereas some\nDecline or problems with memory (severe forgetfulness) and orientation\nproblems can be significant even\n(awareness of time, place, and person)\nif infrequent. Mood or behavioural problems such as apathy (appearing uninterested) or irritability\nAsk, for example, whether the\nLoss of emotional control-easily upset, irritable, or tearful\nperson often forgets where they\nDifficulties in carrying out usual work, domestic, or social activities put things."
  },
  {
    "id": 316,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "r example, whether the\nLoss of emotional control-easily upset, irritable, or tearful\nperson often forgets where they\nDifficulties in carrying out usual work, domestic, or social activities put things. Do they sometimes\nCLINICAL TIP\nforget what happened the day\nAssess directly by testing before? Does the person sometimes\n1\nmemory, orientation, and forget where they are? language skills with a general\nAsk the informant when these\nneurologic assessment, utilizing Assess for signs of dementia\nproblems started and whether they\nculturally adapted tools if\nhave been getting worse over time. available. See Essential Care &\nPractice (» ECP). Are there problems with memory and/or orientation? (e.g. forgetting what happened the previous day or not knowing where he or she is)\nDEMENTIA is unlikely."
  },
  {
    "id": 317,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "able. See Essential Care &\nPractice (» ECP). Are there problems with memory and/or orientation? (e.g. forgetting what happened the previous day or not knowing where he or she is)\nDEMENTIA is unlikely. Screen for other MNS conditions. Does the person have difficulties in performing key roles/activities? (e.g. with daily activities such as shopping, paying bills, cooking, etc.)\nDEMENTIA is unlikely. Screen for other MNS conditions. DDEEMMEENNTTIIAA 95\n\n96\nDEM 1\nDEMENTIA Assessment\n2\nCLINICAL TIP Are there any other explanations for the symptoms? Delirium: transient fluctuating mental\nstate characterized by disturbed attention\nthat develops over a short period of time Have the symptoms been present and slowly\nand tends to fluctuate during the course progressing for at least 6 months?"
  },
  {
    "id": 318,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ate characterized by disturbed attention\nthat develops over a short period of time Have the symptoms been present and slowly\nand tends to fluctuate during the course progressing for at least 6 months? of a day. It may result from acute organic\ncauses such as infections, medication,\nmetabolic abnormalities, substance\nAsk for ANY of the following:\nintoxication, or substance withdrawal. – Abrupt onset\n– Short duration (days to weeks)\n– Disturbance at night and associated\nwith impairment of consciousness\n– Disorientation of time and place\nCLINICAL TIP\nDoes the person have moderate\nCognitive impairment may be the result\nto severe DEPRESSION? Go to DEP. of depression – “Pseudodementia”\nSuspect DELIRIUM\nManage depression. Go to DEP. Once treated for depression, review criteria\nfor dementia."
  },
  {
    "id": 319,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "impairment may be the result\nto severe DEPRESSION? Go to DEP. of depression – “Pseudodementia”\nSuspect DELIRIUM\nManage depression. Go to DEP. Once treated for depression, review criteria\nfor dementia. Go to STEP 1 Evaluate for possible medical causes (toxic/metabolic/infectious). – Obtain urinalysis to evaluate for infection\nSuspect – Review medications, particularly those with significant anti-\nDEMENTIA cholinergic side effects (such as antidepressants, many antihistamines,\nand antipsychotics)\n– Evaluate for pain\n– Evaluate nutritional status, consider vitamin deficiency\nor electrolyte abnormality\n\n3\nEvaluate for other medical issues\nDoes the person have ANY of the following?"
  },
  {
    "id": 320,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ntipsychotics)\n– Evaluate for pain\n– Evaluate nutritional status, consider vitamin deficiency\nor electrolyte abnormality\n\n3\nEvaluate for other medical issues\nDoes the person have ANY of the following? Less than 60 years old prior to symptom onset Clinical history of goitre, slow pulse, dry skin (hypothyroidism)\nOnset of symptoms associated with head injury, stroke, History of sexually transmitted infection (STI),\nor altered or loss of consciousness including HIV/AIDS\nUnusual Features. »\nRefer to specialist. Does the person have poor dietary\nintake, malnutrition, or anaemia? Fortification of food and monitoring of\nweight is necessary. Does the person have cardiovascular risk factors?"
  },
  {
    "id": 321,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Refer to specialist. Does the person have poor dietary\nintake, malnutrition, or anaemia? Fortification of food and monitoring of\nweight is necessary. Does the person have cardiovascular risk factors? – Hypertension – Obesity\n– High cholesterol – Heart disease (chest pain, heart attack)\n– Diabetes – Previous stroke or transient ischaemic\n– Smoking attack (TIA)\nRefer to appropriate SPECIALIST. Reduce cardiovascular risk factors:\n– Advise person to stop smoking – Advise weight-reducing diet for obesity\n– Treat hypertension – Treat diabetes\nDEMENTIA 97\n\n98\nDEM 1\nDEMENTIA Assessment\nCLINICAL TIP\n4\nDetermine:\n– Who are the main carers? Evaluate the needs of the carers. – Who else provides care and\nwhat care do they provide? – What is difficult to manage?"
  },
  {
    "id": 322,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "DEM 1\nDEMENTIA Assessment\nCLINICAL TIP\n4\nDetermine:\n– Who are the main carers? Evaluate the needs of the carers. – Who else provides care and\nwhat care do they provide? – What is difficult to manage? Is the carer having difficulty coping or experiencing strain? E xplore psychosocial interventions about\nrespite care, activation of community support network,\nand family/individual therapy, if available. Is the carer experiencing depressed mood? For assessment of depression in care, go to » DEP. Try to address strain with support and psychoeducation. Problem-solving counselling or cognitive behavioural therapy. Is the carer facing loss of income and/or additional\nexpenses because of the needs for care? E xplore local financial support options,\nsuch as disability services."
  },
  {
    "id": 323,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ng or cognitive behavioural therapy. Is the carer facing loss of income and/or additional\nexpenses because of the needs for care? E xplore local financial support options,\nsuch as disability services. 5\nDoes the person have ANY of the following\nBEHAVIOURAL or PSYCHOLOGICAL symptoms of dementia? Behavioural symptoms, e.g. Psychological symptoms, e.g. Wandering Hallucinations\nNight-time disturbance Delusions\nAgitation Anxiety\nAggression Uncontrollable emotional outbursts\nGo to PROTOCOL 1\nGo to PROTOCOL 2\nIF THERE IS IMMINENT RISK OF SUICIDE,\nASSESS AND MANAGE before continuing\n»\nto Protocol. Go to SUI."
  },
  {
    "id": 324,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ns\nAgitation Anxiety\nAggression Uncontrollable emotional outbursts\nGo to PROTOCOL 1\nGo to PROTOCOL 2\nIF THERE IS IMMINENT RISK OF SUICIDE,\nASSESS AND MANAGE before continuing\n»\nto Protocol. Go to SUI. IF THE PERSON HAS OTHER CONCURRENT\nMNS CONDITIONS, ASSESS AND MANAGE\nbefore continuing to Protocol\nDEMENTIA 99\n\n100\nDEM 2\nDEMENTIA Management\nDEM 2 Management\nPROTOCOL PROTOCOL\n1 2\nDEMENTIA – without behavioural DEMENTIA – with behavioural\nand/or psychological symptoms and/or psychological symptoms\nProvide Psychoeducation to person and carers. (2.1) Follow PROTOCOL 1\nEncourage carers to conduct interventions to improve\n+\ncognitive functioning. (2.4)\nPromote independence, functioning, and mobility. (2.3)\nManage behavioral and psychological symptoms. (2.2)\nProvide carers with support."
  },
  {
    "id": 325,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "conduct interventions to improve\n+\ncognitive functioning. (2.4)\nPromote independence, functioning, and mobility. (2.3)\nManage behavioral and psychological symptoms. (2.2)\nProvide carers with support. (2.5)\nConsider medications only in settings where specific\ndiagnosis of Alzheimer’s Disease can be made AND where\nadequate support and supervision by specialists and If there is imminent risk to the person or carer:\nmonitoring (for side-effects) from carers is available. (2.6)\nConsider antipsychotic medications if symptoms persist\nor if there is imminent risk of harm. (2.7)\nRefer to speacialist when available. PSYCHOSOCIAL INTERVENTIONS\n2.1 Psychoeducation Consider environmental adaptations such as appropriate – Recommend making adaptations in the person’s home."
  },
  {
    "id": 326,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "m. (2.7)\nRefer to speacialist when available. PSYCHOSOCIAL INTERVENTIONS\n2.1 Psychoeducation Consider environmental adaptations such as appropriate – Recommend making adaptations in the person’s home. It can\nseating, safe wandering areas, signs (e.g. ‘no exit’ sign on be helpful to add hand-rails or ramps. Signs for key locations\nAsk people assessed with dementia whether they wish the street door or signpost to toilet). (e.g. toilet, bathroom, bedroom) can help ensure that the\nperson does not get lost or lose orientation while home. to know the diagnosis and with whom it should be\nEncourage soothing, calming, or distracting strategies. shared. Suggest an activity the person enjoys (e.g."
  },
  {
    "id": 327,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ot get lost or lose orientation while home. to know the diagnosis and with whom it should be\nEncourage soothing, calming, or distracting strategies. shared. Suggest an activity the person enjoys (e.g. going for a – Recommend physical activity and exercise to maintain\n– Tailor the explanation of the illness so that they walk, listening to music, engaging in conversation), mobility and reduce risk of falls. can understand and retain the information. especially when feeling agitated. – Advise recreational activities (tailored to stage and severity\nof dementia). – Give basic information. (Do not overload them with\ntoo much!) 2.3 Promote functioning in – Manage sensory deficits (such as low vision or poor\nKey Messages: activities of daily living (ADLs) hearing) with appropriate devices (e.g."
  },
  {
    "id": 328,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "t overload them with\ntoo much!) 2.3 Promote functioning in – Manage sensory deficits (such as low vision or poor\nKey Messages: activities of daily living (ADLs) hearing) with appropriate devices (e.g. magnifying glass,\nhearing aids). and community life\n– Dementia is an illness of the brain and tends to get\n– Refer for occupational therapy, if available. worse over time. For interventions that promote functioning in ADLs and\n– Although there is no cure, there is much that can be\n»\ncommunity life, go to ECP. done to help and support the person and the family. 2.4 Interventions to improve\nPlan for ADL in a way that maximises independent cognitive functioning\n– Many specific concerns and behaviors can be\nactivity, enhances function, helps to adapt and develop\nmanaged as they arise."
  },
  {
    "id": 329,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rove\nPlan for ADL in a way that maximises independent cognitive functioning\n– Many specific concerns and behaviors can be\nactivity, enhances function, helps to adapt and develop\nmanaged as they arise. A lot can be done to make the\nskills, and minimises the need for support. Facilitate\nperson more comfortable and to make providing Encourage carers to:\nfunctioning and participation in the community involving\nsupport less stressful for the carer. people and their carers in planning and implementation Provide regular orientation information (e.g. day, date, time,\nof these interventions. Assist in liaison with available names of people) so that the person can remain oriented. 2.2 M anage behavioral and social resources."
  },
  {
    "id": 330,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "tation information (e.g. day, date, time,\nof these interventions. Assist in liaison with available names of people) so that the person can remain oriented. 2.2 M anage behavioral and social resources. Use materials such as newspapers, radio, or TV programmes,\npsychological symptoms – Give advice to maintain independent toileting skills, inclu- family albums and household items to promote communication,\nding prompting and regulation of fluid intake. (If incon- to orient them to current events, to stimulate memories, and\ntinence occurs, all possible causes should be evaluated and to enable people to share and value their experiences. Identify and treat underlying physical health problems that\ntreatments trialed before concluding it is permanent). may affect behaviour."
  },
  {
    "id": 331,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ated and to enable people to share and value their experiences. Identify and treat underlying physical health problems that\ntreatments trialed before concluding it is permanent). may affect behaviour. Look for pain, infections, etc. on Use simple short sentences to make verbal communication clear. physical exam (Go to\n»\nECP). Refer to specialist if needed. – Keep the environment at home safe to reduce the risk of Try to minimize competing noises, such as radio, TV, or other\nfalling and injury. conversation. Listen carefully to what the person has to say. Identify events (e.g. shopping at busy market) or factors\n(e.g."
  },
  {
    "id": 332,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "minimize competing noises, such as radio, TV, or other\nfalling and injury. conversation. Listen carefully to what the person has to say. Identify events (e.g. shopping at busy market) or factors\n(e.g. going out alone) that may precede, trigger, or enhance – Inform family members that it is important to keep the Keep things simple, avoid changes to routine, and, as far\nproblem behaviours. Modify these triggers if possible. floor of the person’s home without clutter to reduce as possible, avoid exposing the person to unfamiliar and\nthe risk of falling. bewildering places."
  },
  {
    "id": 333,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "em behaviours. Modify these triggers if possible. floor of the person’s home without clutter to reduce as possible, avoid exposing the person to unfamiliar and\nthe risk of falling. bewildering places. DEMENTIA 101\n\n102\nDEM 2\nDEMENTIA Management\nPSYCHOSOCIAL (CONT.) PHARMACOLOGICAL INTERVENTIONS\n2.5 Carer support 2.6 For Dementia without 2.7 Antipsychotic medication for\nbehavioural and/or behavioural and/or psychological\nAssess the impact on the carer and the carer’s needs to\npsychological symptoms symptoms\nensure necessary support and resources for their family life,\n»\nemployment, social activities, and health (see DEM 1). Acknowledge that it can be extremely frustrating and Do not consider cholinesterase inhibitors (like P rovide psychosocial interventions first."
  },
  {
    "id": 334,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "»\nemployment, social activities, and health (see DEM 1). Acknowledge that it can be extremely frustrating and Do not consider cholinesterase inhibitors (like P rovide psychosocial interventions first. stressful to take care of people with dementia. Carers donepezil, galantamine and rivastigmine) or memantine\nI f there is imminent risk to person or carers, consider\nneed to be encouraged to respect the dignity of the routinely for all cases of dementia. »\nantipsychotic medication. Go to PSY 2, Management\nperson with dementia and avoid hostility towards,\nC onsider medications only in settings where specific for details about antipsychotic medication. or neglect of, the person."
  },
  {
    "id": 335,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": ". Go to PSY 2, Management\nperson with dementia and avoid hostility towards,\nC onsider medications only in settings where specific for details about antipsychotic medication. or neglect of, the person. diagnosis of Alzheimer’s Disease can be made AND where\nF ollow the principles of:\nEncourage the carers to seek help if they are experiencing adequate support and supervision by specialists and\ndifficulty or strain in caring for their loved one. monitoring (for side-effects and response) from carers is – “Start low, go slow” (titrate) and review the need regularly\navailable. (at least monthly). Provide information to the carer regarding dementia,\n– Use the lowest effective dose. keeping in mind the wishes of the person with dementia."
  },
  {
    "id": 336,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "d review the need regularly\navailable. (at least monthly). Provide information to the carer regarding dementia,\n– Use the lowest effective dose. keeping in mind the wishes of the person with dementia. If appropriate:\n– Monitor the person for extrapyramidal symptoms (EPS)\nProvide training and support in specific skills, e.g. F or dementia with suspected Alzhemer’s Disease,\nAvoid i.v. haloperidol\nmanaging difficult behaviour, if necessary. To be most and with CLOSE MONITORING, consider cholinesterase\neffective, elicit active participation, e.g. role play. inhibitors (e.g. donepezil, galantamine, rivastigmine) Avoid diazepam. OR memantine. Consider providing practical support when feasible,\ne.g. home-based respite care."
  },
  {
    "id": 337,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ve participation, e.g. role play. inhibitors (e.g. donepezil, galantamine, rivastigmine) Avoid diazepam. OR memantine. Consider providing practical support when feasible,\ne.g. home-based respite care. Another family or suitable F or dementia with associated vascular disease, consider\nperson can supervise and care for the person with memantine. dementia to provide the main carer with a period of relief\nto rest or carry out other activities. Explore whether the person qualifies for any disability\nbenefits or other social/financial support (government or\nnon-governmental). DEM 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n1 »\nFollow-up at minimum every\n3 months. »\nASSESS FOR IMPROVEMENT If on medications, recommend\nfollow-up monthly."
  },
  {
    "id": 338,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "vernment or\nnon-governmental). DEM 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n1 »\nFollow-up at minimum every\n3 months. »\nASSESS FOR IMPROVEMENT If on medications, recommend\nfollow-up monthly. Is the person stable (no worsening symptoms or decline\nin function; behavioural/psychological symptoms are\nimproving if present)? Continue management plan. If not on medications\nInitiate pharmacological intervention, if appropriate. Follow up at minimum every\n3 months. If on medications\nReview adherence, side effects and dosing. Adjust or\nconsider alternative medication as appropriate. Review psychosocial interventions. Evaluate for medical problems."
  },
  {
    "id": 339,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "every\n3 months. If on medications\nReview adherence, side effects and dosing. Adjust or\nconsider alternative medication as appropriate. Review psychosocial interventions. Evaluate for medical problems. DEMENTIA 103\n\n104\nDEM 3\nDEMENTIA Follow-up\n2\nCONDUCT ROUTINE ASSESSMENTS\nAt each visit, routinely assess and address the following:\nMedication side-effects Safety risks and offer appropriate behaviour modification\nIf on antipsychotics, check for extrapyramidal symptoms if disease has progressed (e.g. limit driving, cooking, etc.)\n»\n(Go to PSY). Stop or reduce dose if present. New behavioural or psychological symptoms\nMedical and MNS co-morbidities »\nSymptoms of depression (Go to DEP)\n»\nAbility to participate in activities of daily living and or imminent risk of self-harm/suicide (Go to SUI)."
  },
  {
    "id": 340,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "psychological symptoms\nMedical and MNS co-morbidities »\nSymptoms of depression (Go to DEP)\n»\nAbility to participate in activities of daily living and or imminent risk of self-harm/suicide (Go to SUI). any needs of care\nNeeds of the carers\n3\nPROVIDE PSYCHOSOCIAL INTERVENTIONS\n»\nContinue to promote functioning and provide psychosocial education. » »\nSee DEM 2.1-2.5 and ECP for details. DISORDERS DUE TO SUBSTANCE USE\nDisorders due to substance use include both drug and alcohol HARMFUL USE is a pattern of psychoactive substance use\nuse disorders and certain conditions including acute intoxication, that damages health. This damage may be physical, e.g. liver\noverdose and withdrawal. disease, or mental, e.g. episodes of depressive disorder. It is\noften associated with social consequences, e.g."
  },
  {
    "id": 341,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "n, that damages health. This damage may be physical, e.g. liver\noverdose and withdrawal. disease, or mental, e.g. episodes of depressive disorder. It is\noften associated with social consequences, e.g. family or\nACUTE INTOXICATION is a transient condition following intake of work problems. a psychoactive substance resulting in disturbances of consciousness,\ncognition, perception, affect, or behaviour. DEPENDENCE is a cluster of physiological, behavioural, and\ncognitive phenomena in which the use of a psychoactive substance\nOVERDOSE is the use of any drug in such an amount that acute takes on a much higher priority for a given individual than other\nadverse physical or mental effects are produced. behaviours that once had greater value."
  },
  {
    "id": 342,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "use of any drug in such an amount that acute takes on a much higher priority for a given individual than other\nadverse physical or mental effects are produced. behaviours that once had greater value. It is characterized by a\nstrong craving to use the substance and a loss of control over its\nWITHDRAWAL is the experience of a set of unpleasant symptoms use. It is often associated with high levels of substance use and\nfollowing the abrupt cessation or reduction in dose of a psychoactive the presence of a withdrawal state upon cessation. substance; it has been consumed in high enough doses and for a\nlong enough duration for the person to be physically or mentally\ndependent on it. Withdrawal symptoms are, essentially, opposite to\nthose that are produced by the psychoactive substance itself."
  },
  {
    "id": 343,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "for a\nlong enough duration for the person to be physically or mentally\ndependent on it. Withdrawal symptoms are, essentially, opposite to\nthose that are produced by the psychoactive substance itself. 105\n\n106\nSUB\nDISORDERS DUE TO SUBSTANCE USE\nSUB Quick Overview\nASSESSMENT MANAGEMENT\nE MERGENCY ASSESSMENT: Management Protocols\nIs intoxication or withdrawal suspected? 1. Harmful use\n2. Dependence\n– Does the person appear sedated? 3. Alcohol withdrawal\n– Does the person appear overstimulated, anxious, or agitated? 4. Opioid withdrawal\n– Does the person appear confused? 5. Opioid agonist maintenance treatment\n6. Benzodiazepine withdrawal\nDoes the person use psychoactive substances? Psychosocial Interventions\nIs there harmful use?"
  },
  {
    "id": 344,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "al\n– Does the person appear confused? 5. Opioid agonist maintenance treatment\n6. Benzodiazepine withdrawal\nDoes the person use psychoactive substances? Psychosocial Interventions\nIs there harmful use? Pharmacological Interventions\nDoes the person have substance\ndependence? FOLLOW-UP\n\nSUB EMERGENCY\nIf no emergency presentation present, go to SUB 1, Assessment."
  },
  {
    "id": 345,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ial Interventions\nIs there harmful use? Pharmacological Interventions\nDoes the person have substance\ndependence? FOLLOW-UP\n\nSUB EMERGENCY\nIf no emergency presentation present, go to SUB 1, Assessment. EMERGENCY PRESENTATIONS OF DISORDERS DUE TO SUBSTANCE USE\nAlcohol intoxication: Smell of alcohol on the Stimulant intoxication: Dilated pupils, excited, racing\nbreath, slurred speech, uninhibited behaviour; thoughts, disordered thinking, strange behaviour, recent\ndisturbance in the level of consciousness, cognition, use of psychoactive substances, raised pulse and blood\nperception, affect, or behaviour pressure, aggressive, erratic, or violent behaviour\nOpioid overdose: Unresponsive or minimally Delirium associated with substance use:\nresponsive, slow respiratory rate, pinpoint pupils Confusion, hallucination, racing thoughts, anxiety,\nagitation, disorientation, typically in association\nAlcohol or other sedative withdrawal: Tremor in\nwith either stimulant intoxication or alcohol (or other\nhands, sweating, vomiting, increased pulse and blood\nsedative) withdrawal\npressure, agitation, headache, nausea, anxiety;\nseizure and confusion in severe cases\nDISORDERS DUE TO SUBSTANCE USE 107\n\n108\nSUB\nDISORDERS DUE TO SUBSTANCE USE\nCLINICAL TIP\n1\n»\nSuspect sedative intoxication/\noverdose in anyone with\nDoes the person appear sedated?"
  },
  {
    "id": 346,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "usion in severe cases\nDISORDERS DUE TO SUBSTANCE USE 107\n\n108\nSUB\nDISORDERS DUE TO SUBSTANCE USE\nCLINICAL TIP\n1\n»\nSuspect sedative intoxication/\noverdose in anyone with\nDoes the person appear sedated? unexplained drowsiness and\nslow breathing. SSSKKKIIIPPP tttooo SSSTTTEEEPPP 11111200000\nSuspect SEDATIVE INTOXICATION\n(alcohol, opioids, other sedatives)\nCheck Airway, Breathing, Circulation (ABC). Provide initial respiratory support. Give oxygen. Is the person minimally responsive, unresponsive,\nor in respiratory failure? Supportive care. Monitor vital signs. Lay the person on their side to prevent aspiration. Give oxygen if available. Consider intravenous (i.v.), rehydration but do not give\nfluids orally while sedated. Observe the person until fully recovered or\ntransported to hospital."
  },
  {
    "id": 347,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "prevent aspiration. Give oxygen if available. Consider intravenous (i.v.), rehydration but do not give\nfluids orally while sedated. Observe the person until fully recovered or\ntransported to hospital. Check pupils. Normal pupils Pinpoint pupils\nSuspect\nOpioid overdose less likely –\nOPIOID OVERDOSE\nconsider overdose of alcohol,\nother sedatives, or other medical\ncauses (i.e. head injury, infection,\nor hypoglycemia). Give i.v., intramuscular (i.m.), intranasal\nor subcutaneous naloxone 0.4-2 mg. Continue respiratory support. Did the person respond to naloxone within 2 minutes? GIVE A SECOND DOSE Observe for 1-2 hours and repeat naloxone\nas needed. Observe the person until fully recovered\nor transported to hospital."
  },
  {
    "id": 348,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "pport. Did the person respond to naloxone within 2 minutes? GIVE A SECOND DOSE Observe for 1-2 hours and repeat naloxone\nas needed. Observe the person until fully recovered\nor transported to hospital. Continue to resuscitate and observe the person\nuntil fully recovered or transported to hospital. DISORDERS DUE TO SUBSTANCE USE 109\n\n110\nSUB\nDISORDERS DUE TO SUBSTANCE USE\n2\nDoes the person appear\noverstimulated, anxious, or agitated?"
  },
  {
    "id": 349,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e the person\nuntil fully recovered or transported to hospital. DISORDERS DUE TO SUBSTANCE USE 109\n\n110\nSUB\nDISORDERS DUE TO SUBSTANCE USE\n2\nDoes the person appear\noverstimulated, anxious, or agitated? SSSKKKIIIPPP tttooo SSSTTTEEEPPP 11111300000\nASSESS AND MANAGE A – D\nA Person has recently stopped MANAGE WITHDRAWAL\nSuspect\ndrinking or using sedatives and is – If the person has tremors, sweating, or vital sign changes then give\nALCOHOL or\nnow showing any of the following diazepam 10-20 mg orally (p.o.) and transfer to hospital or detoxification\nBENZODIAZEPINE\nsigns: Tremors, sweating, vomiting, facility if possible. WITHDRAWAL\nincreased blood pressure (BP) & heart\n– Observe and repeat doses as needed for continued signs of\nrate, and agitation."
  },
  {
    "id": 350,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "NZODIAZEPINE\nsigns: Tremors, sweating, vomiting, facility if possible. WITHDRAWAL\nincreased blood pressure (BP) & heart\n– Observe and repeat doses as needed for continued signs of\nrate, and agitation. withdrawal (tremors, sweating, increased BP and heart rate). – For alcohol withdrawal only: Give thiamine 100 mg daily for five days. TRANSFER IMMEDIATELY TO A HOSPITAL\nif the following are present:\n– Other serious medical problems, e.g. hepatic encephalopathy,\ngastrointestinal bleeding, or head injury. – Seizures: give diazepam 10-20 mg p.o., i.v. or rectum (p.r.) first. – Delirium: give diazepam 10-20 mg p.o., i.v. or p.r. first. If severe and not\nresponsive to diazepam, give an anti-psychotic medication such as\nhaloperidol 1-2.5 mg p.o. or i.m."
  },
  {
    "id": 351,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rectum (p.r.) first. – Delirium: give diazepam 10-20 mg p.o., i.v. or p.r. first. If severe and not\nresponsive to diazepam, give an anti-psychotic medication such as\nhaloperidol 1-2.5 mg p.o. or i.m. Continue to treat other signs of withdrawal\n(tremors, sweating, vital signs changes) with diazepam p.o., i.v. or p.r. B Person has recently used Suspect Give diazepam 5-10 mg p.o., i.v., or p.r. stimulants (cocaine, amphetamine ACUTE STIMULANT in titrated doses until the person is calm and lightly sedated. type stimulants) and is showing INTOXICATION If psychotic symptoms are not responsive to diazepam, consider\nany of the following signs: dilated antipsychotic medication such as haloperidol 1-2.5 mg p.o. or i.m.. pupils, anxiety, agitation, hyper- Treat until symptoms resolve."
  },
  {
    "id": 352,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "esponsive to diazepam, consider\nany of the following signs: dilated antipsychotic medication such as haloperidol 1-2.5 mg p.o. or i.m.. pupils, anxiety, agitation, hyper- Treat until symptoms resolve. If symptoms persist, go to PSY. excitable state, racing thoughts,\nFor management of persons with aggressive and/or agitated behaviour\nraised pulse and blood pressure. go to PSY, Table 5. If the person has chest pain, tachyarrythmias, or other\nneurological signs TRANSFER TO HOSPITAL. During the post-intoxication phase, be alert for suicidal thoughts\nor actions. If suicidal thoughts are present, go to SUI."
  },
  {
    "id": 353,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "est pain, tachyarrythmias, or other\nneurological signs TRANSFER TO HOSPITAL. During the post-intoxication phase, be alert for suicidal thoughts\nor actions. If suicidal thoughts are present, go to SUI. C Person has recently stopped using Suspect MANAGE OPIOID WITHDRAWAL\nopioids and is showing any of the ACUTE OPIOID – Methadone 20 mg, with a supplemental dose of 5-10 mg 4 hours\nfollowing signs: dilated pupils, WITHDRAWAL later if necessary. muscle aches, abdominal cramps,\n– Buprenorphine 4-8 mg, with a supplementary dose 12 hours later if\nheadache, nausea, vomiting,\nnecessary. diarrhea, runny eyes and nose,\n– If methadone or buprenorphine are not available, any opioid can\nanxiety, restlessness. be used in the acute setting, i.e."
  },
  {
    "id": 354,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ter if\nheadache, nausea, vomiting,\nnecessary. diarrhea, runny eyes and nose,\n– If methadone or buprenorphine are not available, any opioid can\nanxiety, restlessness. be used in the acute setting, i.e. morphine sulphate 10-20 mg as an\ninitial dose with a 10 mg extra dose if needed. Also consider an alpha\nadrenergic agonists, i.e. clonidine or lofexidine. Once stable, go to SUB 2\nD\nRULE OUT OTHER MEDICAL CAUSES\nAND PRIORITY MNS CONDITIONS. DISORDERS DUE TO SUBSTANCE USE 111\n\n112\nSUB\nDISORDERS DUE TO SUBSTANCE USE\n3\nDoes the person appear confused?"
  },
  {
    "id": 355,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ine. Once stable, go to SUB 2\nD\nRULE OUT OTHER MEDICAL CAUSES\nAND PRIORITY MNS CONDITIONS. DISORDERS DUE TO SUBSTANCE USE 111\n\n112\nSUB\nDISORDERS DUE TO SUBSTANCE USE\n3\nDoes the person appear confused? SSSKKKIIIPPP tttooo SSSTTUEEBPP 1 1111 A0000ssessment\nAre there any medical conditions which might\nexplain the confusion, including:\n– head trauma – hepatic encephalopathy\n– hypoglycaemia – cerebrovascular accidents (CVA)\n– pneumonia or other infections\nManage the physical condition\nASSESS AND MANAGE A – C and refer the person to hospital."
  },
  {
    "id": 356,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rauma – hepatic encephalopathy\n– hypoglycaemia – cerebrovascular accidents (CVA)\n– pneumonia or other infections\nManage the physical condition\nASSESS AND MANAGE A – C and refer the person to hospital. A Person has stopped drinking in the Suspect If the person is showing other signs of alcohol\nlast week: confusion, hallucination, withdrawal (tremors, sweating, vital signs changes)\nALCOHOL OR\nracing thoughts, anxiety, agitation, – Treat with diazepam 10-20 mg p.o. BENZODIAZEPINE\ndisorientation, typically in association\nWITHDRAWAL – TRANSFER TO HOSPITAL. with either stimulant intoxication or\nDELIRIUM Manage delirium with antipsychotics such as\nalcohol (or other sedative) withdrawal. haloperidol 1-2.5 mg p.o. or i.m."
  },
  {
    "id": 357,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "WITHDRAWAL – TRANSFER TO HOSPITAL. with either stimulant intoxication or\nDELIRIUM Manage delirium with antipsychotics such as\nalcohol (or other sedative) withdrawal. haloperidol 1-2.5 mg p.o. or i.m. B Person has been drinking heavily Suspect Treat with thiamine 100-500 mg 2-3 times daily i.v. or i.m. for 3-5 days. in the last few days AND has any WERNICKE’S TRANSFER TO HOSPITAL. of the folllowing signs:\nENCEPHALOPATHY\n– nystagmus (involuntary, rapid and\nrepetitive movement of the eyes)\n– ophthalmoplegia\n(weakness/paralysis of one or more\nof the muscles that control eye\nmovement)\n– ataxia (uncoordinated movements). C Person has used stimulants in the Suspect Treat with diazepam 5-10 mg p.o., i.v. or p.r."
  },
  {
    "id": 358,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "akness/paralysis of one or more\nof the muscles that control eye\nmovement)\n– ataxia (uncoordinated movements). C Person has used stimulants in the Suspect Treat with diazepam 5-10 mg p.o., i.v. or p.r. until the patient is\nlast few days: Dilated pupils, excited, STIMULANT lightly sedated. racing thoughts, disordered thinking,\nINTOXICATION If psychotic symptoms do not respond to diazepam, consider\nstrange behaviour, recent use of\nan antipsychotic such as haloperidol 1-2.5 mg p.o. or i.m. psychoactive substances, raised pulse\nIf psychotic symptoms persist, go to PSY\nand blood pressure, aggressive,\nerratic, or violent behaviour. CLINICAL TIP\n»\nFollowing the management of emergency\npresentation, GO to SUB 1 assessment\nand SUB 2 management protocols 1 to 6\nas appropriate."
  },
  {
    "id": 359,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ood pressure, aggressive,\nerratic, or violent behaviour. CLINICAL TIP\n»\nFollowing the management of emergency\npresentation, GO to SUB 1 assessment\nand SUB 2 management protocols 1 to 6\nas appropriate. DISORDERS DUE TO SUBSTANCE USE 113\n\n114\nSUB 1\nDISORDERS DUE TO SUBSTANCE USE Assessment\nSUB 1 Assessment\nCOMMON PRESENTATIONS OF DISORDERS DUE TO SUBSTANCE USE\nAppearing affected by alcohol or other substance (e.g. smell I ncidental findings: macrocytic anaemia, low platelet count,\nof alcohol, slurred speech, sedated, erratic behaviour) elevated mean corpuscular volume (MCV)\nSigns of recent drug use (recent injection marks, skin infection) E mergency presentation due to substance withdrawal\noverdose, or intoxication."
  },
  {
    "id": 360,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ratic behaviour) elevated mean corpuscular volume (MCV)\nSigns of recent drug use (recent injection marks, skin infection) E mergency presentation due to substance withdrawal\noverdose, or intoxication. Person may appear sedated,\nSigns and symptoms of acute behavioural effects, withdrawal\noverstimulated, agitated, anxious or confused\nfeatures or effects of prolonged use (see Box 1)\nP ersons with disorders due to substance use may not\nDeterioration of social functioning (i.e. difficulties at work\nreport any problems with substance use."
  },
  {
    "id": 361,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ures or effects of prolonged use (see Box 1)\nP ersons with disorders due to substance use may not\nDeterioration of social functioning (i.e. difficulties at work\nreport any problems with substance use. Look for:\nor home, unkempt appearance)\n– Recurrent requests for psychoactive medications including\nSigns of chronic liver disease (abnormal liver enzymes),\nanalgesics\njaundiced (yellow) skin and eyes, palpable and tender liver\nedge (in early liver disease), ascites (distended abdomen is filled – Injuries\nwith fluid), spider naevi (spider-like blood vessels visible on\n– Infections associated with intravenous drug use (HIV/AIDS,\nthe surface of the skin), and altered mental status (hepatic\nHepatitis C)\nencephalopathy)\nProblems with balance, walking, coordinated movements,\nand nystagmus\nCLINICAL TIP\n»\nAvoid stereotyping!"
  },
  {
    "id": 362,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "/AIDS,\nthe surface of the skin), and altered mental status (hepatic\nHepatitis C)\nencephalopathy)\nProblems with balance, walking, coordinated movements,\nand nystagmus\nCLINICAL TIP\n»\nAvoid stereotyping! All persons presenting to\nhealth care facilities should be asked about\ntheir tobacco and alcohol use."
  },
  {
    "id": 363,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ems with balance, walking, coordinated movements,\nand nystagmus\nCLINICAL TIP\n»\nAvoid stereotyping! All persons presenting to\nhealth care facilities should be asked about\ntheir tobacco and alcohol use. BOX 1: PSYCHOACTIVE SUBSTANCES: ACUTE BEHAVIOURAL EFFECTS, WITHDRAWAL FEATURES, AND EFFECTS OF PROLONGED USE\nACUTE BEHAVIOURAL EFFECTS WITHDRAWAL FEATURES EFFECTS OF PROLONGED USE\nAlcohol Smell of alcohol on breath, slurred speech, disinhibited Tremors, shaking, nausea/vomiting, increased heart rate Loss of brain volume, reduction in cognitive capacity,\nbehavior, agitation, vomiting, unsteady gait and blood pressure, seizures, agitation, confusion, impaired judgement, loss of balance, liver fibrosis,\nhallucinations gastritis, anaemia, increased risk of some cancers and a\nCan be life-threatening range of other medical problems\nBenzodiazepines Slurred speech, disinhibited behavior, unsteady gait Anxiety, insomnia, tremors, shaking, nausea/vomiting, Memory impariment, increased risk of falls in the elderly,\nincreased heart rate and blood pressure, seizures, risk of fatal sedative overdose\nagitation, confusion, hallucinations\nCan be life-threatening\nOpioids Pinpoint pupils, drowsiness and falling asleep, decreased Dilated pupils, anxiety, nausea/vomiting/diarrhea, Constipation, risk of fatal sedative overdose, hypogonadism,\nawareness, slow speech abdominal cramps, muscle aches and pains, headaches, adaptations in reward, learning and stress responses\nrunny eyes and nose, yawning, hair standing up on\narms, increased heart rate and blood pressure\nTobacco Arousal, increased attention, concentration and memory; Irritibility, hostility, anxiety, dysphoria, depresed mood, Lung disease (in tobacco smokers), cardiovascular disease,\ndecreased anxiety and appetite; stimulant-like effects increased heart rate, increased appetite risk of cancers and other health effects\nCocaine, Methamphetamines & Dilated pupils, increased blood pressure and heart rate, Fatigue, increased appetite, depressed, irritable mood Hypertension, increased risk of cerebrovascular accidents\nAmphetamine-type stimulants excited, euphoric, hyperactivity, rapid speech, racing Watch out for suicidal thoughts (CVAs), arrythmias, heart disease, anxiety, depression\nthoughts, disordered thinking, paranoia, aggressive,\nerratic, violent\nKhat Alertness, euphoria, and mild excitation Lethargy, depressed mode, irritability Khat users often spend a significant portion of the\nday chewing khat; consti-pation, risk of mental health\nproblems such as psychosis\nCannabis Normal pupils, red conjunctivae, delayed Depressed or labile mood, anxiety, irritability, sleep Increased risk of mental health problems including\nresponsiveness, euphoria, relaxation disturbance (there may not be any clearly observable anxiety, paranoia and psychosis, lack of motivation,\nfeatures) difficulty in concentration, increased risk of vasospasm\nleading to myocardial infarction and stroke\nTramadol Opioid effects (sedation, euphoria, etc.) followed by Predominantly opioid withdrawal effects but also some Opioid dependence, risk of seizures, disturbed sleep\nstimulant effects (excitation and in high doses seizures serotonin norepinephrine reuptake inhibitor (SNRI)\nwithdrawal symptoms (depressed mood, lethargy)\nVolatile solvents Dizziness, disorientation, euphoria, light-headedness, Increased susceptibility to seizures Decreased cognitive function and dementia, peripheral\nincreased mood, hallucinations, delusions, incoord- neuropathy, other neurological sequelae, increased risk of\nination, visual disturbances, anxiolysis, sedation arrythmias causing sudden death\nHallucinogens Increased heart rate, blood pressure, body temperature, No evidence Acute or chronic psychotic episodes, flashbacks or re-\ndecreased appetite, nausea, vomiting, motor experiencing of drug effects long after termination of use\nincoordination, papillary dilatation, hallucinations\nMDMA Increased self-confidence, empathy, understanding, Nausea, muscle stiffness, headache, loss of appetite, Neurotoxic, leads to behavioral and physiological\nsensation of intimacy, communication, euphoria, energy blurred vision, dry mouth, insomnia, depression, anxiety, consequences, depression\nfatigue, difficulty concentrating\nDISORDERS DUE TO SUBSTANCE USE 115\n\n116 SUB 1\nDISORDERS DUE TO SUBSTANCE USE Assessment\n1\nCLINICAL TIP\nDoes the person use substances?"
  },
  {
    "id": 364,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "xiety, consequences, depression\nfatigue, difficulty concentrating\nDISORDERS DUE TO SUBSTANCE USE 115\n\n116 SUB 1\nDISORDERS DUE TO SUBSTANCE USE Assessment\n1\nCLINICAL TIP\nDoes the person use substances? While taking a history, ask:\nHow the person started using\nsubstances? Ask about use of tobacco, alcohol, and psychoactive prescription\nWhen they started using them? medicines. Depending on the setting and the presentation, consider What was happening in their\nasking about cannabis and other substance use. life at that time? If anyone in their family or\nsocial circle use substances? If they have tried to reduce their\nuse? Why? What happened? Emphasise the health benefits of not\nusing psychoactive substances. EXIT MODULE\n2\nIs the substance use harmful?"
  },
  {
    "id": 365,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ocial circle use substances? If they have tried to reduce their\nuse? Why? What happened? Emphasise the health benefits of not\nusing psychoactive substances. EXIT MODULE\n2\nIs the substance use harmful? For each substance used assess:\nA Frequency and quantity of use. (Hint: Ask “How many days per week do you use this substance? How much do you use per day?”)\nB Harmful behaviours."
  },
  {
    "id": 366,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "bstance use harmful? For each substance used assess:\nA Frequency and quantity of use. (Hint: Ask “How many days per week do you use this substance? How much do you use per day?”)\nB Harmful behaviours. (Hint: Ask “Does your substance use cause you any problems?”)\n– Injuries and accidents – Sexual activity while intoxicated that was risky – Violence towards others\n– Driving while intoxicated or later regretted – Poor performance in education, employment roles\n– Drug injection, sharing needles, reusing needles – Legal or financial problems – Poor performance in expected social roles\n– Relationship problems as a result of use – Inability to care for children responsibly (e.g. parenting)\nRemember answers for use\nlater during assessment. 3\nIs DEPENDENCE likely?"
  },
  {
    "id": 367,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "expected social roles\n– Relationship problems as a result of use – Inability to care for children responsibly (e.g. parenting)\nRemember answers for use\nlater during assessment. 3\nIs DEPENDENCE likely? For each substance used ask about the following features of dependence:\n– High levels of frequent substance use – Difficulty self regulating the use of that substance\n– A strong craving or sense of compulsion to despite the risks and harmful consequences\nuse the substance – Increasing levels of use tolerance and withdrawal\nsymptoms on cessation\nCLINICAL TIP\nProceed to PROTOCOL 2\nPatterns of substance use that suggest dependence include:\nTOBACCO: several times a day, often starting in the morning. ALCOHOL: more than 6 standard drinks at a time, and daily use."
  },
  {
    "id": 368,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "eed to PROTOCOL 2\nPatterns of substance use that suggest dependence include:\nTOBACCO: several times a day, often starting in the morning. ALCOHOL: more than 6 standard drinks at a time, and daily use. IF THERE IS IMMINENT RISK OF\nPRESCRIPTION PILLS: taking a higher dose of medication than SUICIDE, ASSESS AND MANAGE\nprescribed and lying to get prescriptions. before continuing to Protocol\nCANNABIS: at least 1 g of cannabis daily. (Go to SUI)\nIs the substance use harmful? See answer in step 2, above. Provide psychoeducation about the risks Proceed to PROTOCOL 1\nof different levels of each substance used."
  },
  {
    "id": 369,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "1 g of cannabis daily. (Go to SUI)\nIs the substance use harmful? See answer in step 2, above. Provide psychoeducation about the risks Proceed to PROTOCOL 1\nof different levels of each substance used. EXIT MODULE\nIF THERE IS IMMINENT RISK OF\nSUICIDE, ASSESS AND MANAGE\nbefore continuing to Protocol\n(Go to SUI)\nDISORDERS DUE TO SUBSTANCE USE 117\n\n118\nSUB 2\nDISORDERS DUE TO SUBSTANCE USE Management\nSUB 2 Management\nPROTOCOL\n1\nHarmful Use\n»\nProvide psychoeducation and emphasize that the level/pattern of substance use is causing harm to health. »\nExplore the person’s motivations for substance use. Conduct motivational interviewing. (See BRIEF PSYCHOSOCIAL INTERVENTION – MOTIVATIONAL INTERVIEWING (2.2))."
  },
  {
    "id": 370,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "bstance use is causing harm to health. »\nExplore the person’s motivations for substance use. Conduct motivational interviewing. (See BRIEF PSYCHOSOCIAL INTERVENTION – MOTIVATIONAL INTERVIEWING (2.2)). »\nAdvise stopping the substance completely or consuming it at a non-harmful level, if one exists. Verbalise your intention to support the person to do this. Ask them if they are ready to make this change. »\nExplore STRATEGIES FOR REDUCING OR STOPPING USE (2.3) and\nSTRATEGIES FOR REDUCING HARM (2.5). »\nAddress food, housing, and employment needs. »\nFollow up\n»\nIf the person is an adolescent or a woman of child-bearing age, pregnant, or breastfeeding,\nsee SPECIAL POPULATIONS."
  },
  {
    "id": 371,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "R REDUCING HARM (2.5). »\nAddress food, housing, and employment needs. »\nFollow up\n»\nIf the person is an adolescent or a woman of child-bearing age, pregnant, or breastfeeding,\nsee SPECIAL POPULATIONS. PROTOCOL\n2\nDependence\nIF THE PERSON IS DEPENDENT ON OPIOIDS: FOR ALL OTHER SUBSTANCES:\n» »\nMaintenance treatment is generally more effective than detoxification. Advise stopping the substance completely and verbalise your intention to support\n» the person in doing so. Ask them if they are ready to do this. Assess the severity of dependence and, if appropriate, provide or refer the person for\n»\nopioid agonist maintenance treatment, also known as opioid substitution therapy (OST), Explore STRATEGIES FOR REDUCING OR STOPPING USE and STRATEGIES FOR\nafter detoxification."
  },
  {
    "id": 372,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "r refer the person for\n»\nopioid agonist maintenance treatment, also known as opioid substitution therapy (OST), Explore STRATEGIES FOR REDUCING OR STOPPING USE and STRATEGIES FOR\nafter detoxification. Go to PROTOCOL 5 (Opioid Agonist Maintenance Treatment). REDUCING HARM. » »\nIn the remainder of cases arrange planned detoxification, if necessary. Consider referral to peer help groups or rehabilitation/residential therapeutic\nGo to PROTOCOL 4 (Opioid Withdrawal). communities, if available. »\nAddress food, housing, and employment needs. IF THE PERSON IS DEPENDENT ON BENZODIAZEPINES: »\nAssess and treat any physical or mental health co-morbidity, ideally after 2-3 weeks of\n»\nSudden cessation can lead to seizures and delirium."
  },
  {
    "id": 373,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nt needs. IF THE PERSON IS DEPENDENT ON BENZODIAZEPINES: »\nAssess and treat any physical or mental health co-morbidity, ideally after 2-3 weeks of\n»\nSudden cessation can lead to seizures and delirium. Consider gradually reducing the abstinence, as some problems will resolve with abstinence. dose of benzodiazepine with supervised dispensing or a more rapid reduction in an\ninpatient setting. Go to PROTOCOL 6 (Benzodiazepine Withdrawal). IN ALL CASES:\n»\nProvide psychoeducation. IF THE PERSON IS DEPENDENT ON ALCOHOL:\n»\n» Arrange for detoxification services if necessary or treatment in an inpatient facility where\nSudden alcohol cessation can lead to seizures and delirium; however, if the person is\navailable. Treat withdrawal symptoms as needed. willing to stop using alcohol, facilitate this."
  },
  {
    "id": 374,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ent facility where\nSudden alcohol cessation can lead to seizures and delirium; however, if the person is\navailable. Treat withdrawal symptoms as needed. willing to stop using alcohol, facilitate this. Determine the appropriate setting to cease\n»\nalcohol use, and arrange inpatient detoxification, if necessary. Go to PROTOCOL 3 Provide a brief intervention using motivational interviewing to encourage the person to\n(Alcohol Withdrawal). engage in treatment of their substance dependence. » »\nAdvise consumption of thiamine at a dose of 100 mg/day p.o.. Consider longer-term psychosocial treatment for persons with ongoing problems\n» related to their substance use, if they do not respond to the initial brief interventions."
  },
  {
    "id": 375,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "at a dose of 100 mg/day p.o.. Consider longer-term psychosocial treatment for persons with ongoing problems\n» related to their substance use, if they do not respond to the initial brief interventions. Consider pharmacologic intervention to prevent relapse in alcohol dependence;\nEvidence-based psychological therapies for disorders due to substance use include\nmedications include acamprosate, naltrexone and disulfiram. Baclofen can also be used,\nstructured individual and group programmes that are run over 6-12 weeks or more, and\nhowever, its sedating effects and risk of abuse make it best reserved for specialist settings."
  },
  {
    "id": 376,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "en can also be used,\nstructured individual and group programmes that are run over 6-12 weeks or more, and\nhowever, its sedating effects and risk of abuse make it best reserved for specialist settings. that use techniques such as cognitive behavioural therapy, motivational enhancement\nWith these medications, an effective response may include a reduction in the quantity\ntherapy, contingency management therapy, community reinforcement approach, and\nand frequency of alcohol consumption, if not complete abstinence. Go to Table 1. family therapy. Evidence-based social support approaches include employment and\naccommodation support."
  },
  {
    "id": 377,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nt approach, and\nand frequency of alcohol consumption, if not complete abstinence. Go to Table 1. family therapy. Evidence-based social support approaches include employment and\naccommodation support. DISORDERS DUE TO SUBSTANCE USE 119\n\n120\nSUB 2\nDISORDERS DUE TO SUBSTANCE USE Management\nPROTOCOL\n3\nAlcohol Withdrawal\n»\nProvide as quiet and non-stimulating an environment as possible; well-lit during the day\nand lit enough at night to prevent falls if the person wakes up at night. PREVENTING AND TREATING WERNICKE’S ENCEPHALOPATHY:\n» »\nEnsure adequate fluid intake and that electrolyte requirements are met, such as potassium Chronic heavy users of alcohol are at risk for Wernicke’s encephalopathy,\nand magnesium."
  },
  {
    "id": 378,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "S ENCEPHALOPATHY:\n» »\nEnsure adequate fluid intake and that electrolyte requirements are met, such as potassium Chronic heavy users of alcohol are at risk for Wernicke’s encephalopathy,\nand magnesium. a thiamine deficiency syndrome characterized by confusion, nystagmus,\n» ophthalmoplegia (trouble with eye movements), and ataxia (uncoordinated\nADDRESS DEHYDRATION: Maintain adequate hydration including i.v. hydration,\nmovements). if needed, and encourage oral fluid intake. Be sure to give thiamine before glucose to avoid\n»\nprecipitating Wernicke’s encephalopathy. To prevent this syndrome, all persons with a history of chronic\n» alcohol use should be given thiamine 100 mg p.o. per day."
  },
  {
    "id": 379,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "thiamine before glucose to avoid\n»\nprecipitating Wernicke’s encephalopathy. To prevent this syndrome, all persons with a history of chronic\n» alcohol use should be given thiamine 100 mg p.o. per day. Pharmacological Intervention:\nGive thiamine prior to administering glucose to avoid precipitating\nWhen appropriate, treat alcohol withdrawal symptoms. In the case of planned detoxification,\nWernicke’s encephalopathy. prevent withdrawal symptoms using diazepam. The dose and duration of diazepam treatment\nvaries according to the severity of the withdrawal. – Administer diazepam at an initial dose of up to 40 mg daily (10 mg four times a day or 20 mg\ntwice a day) for 3-7 days, p.o. Gradually decrease the dose and/or frequency as soon as\nsymptoms improve."
  },
  {
    "id": 380,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "– Administer diazepam at an initial dose of up to 40 mg daily (10 mg four times a day or 20 mg\ntwice a day) for 3-7 days, p.o. Gradually decrease the dose and/or frequency as soon as\nsymptoms improve. Monitor the person frequently, as each person may respond differently to\nthis medication. CLINICAL TIP\n– In the hospital setting, diazepam can be given more frequently, (i.e. hourly), and at\nFor planned alcohol cessation, assess the person’s risk for severe withdrawal. higher daily doses, up to 120 mg daily for the first 3 days p.o., if necessary, and based on\nAsk:\nfrequent assessment of the person’s withdrawal symptoms and mental status. Have there been past episodes of severe withdrawal symptoms, including\n– In persons with impaired hepatic metabolism, (i.e."
  },
  {
    "id": 381,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": ":\nfrequent assessment of the person’s withdrawal symptoms and mental status. Have there been past episodes of severe withdrawal symptoms, including\n– In persons with impaired hepatic metabolism, (i.e. persons with signs of liver disease seizures or delirium? or the elderly), use a single low dose initially of 5-10 mg p.o., as benzodiazepines may Are there other significant medical or psychiatric issues? have a longer duration of action in these populations. Alternatively, a shorter acting Do significant withdrawal features develop within 6 hours of the person’s last drink? benzodiazepine such as oxazepam may be used instead of diazepam. See Table 1. Have outpatient cessation attempts failed in the past? Is the person homeless or without any social support?"
  },
  {
    "id": 382,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "s last drink? benzodiazepine such as oxazepam may be used instead of diazepam. See Table 1. Have outpatient cessation attempts failed in the past? Is the person homeless or without any social support? – CAUTION\nUse caution when initiating or increasing the dose of benzodiazepines, as If risk is high, inpatient detoxification is preferable to outpatient detoxification. they can cause respiratory depression. Use caution in persons with respiratory\ndisease and/or hepatic encephalopathy. CLINICAL TIP: General principles to apply during management of any withdrawal:\nMaintain hydration. Depressive symptoms may occur in the post-intoxication period,\nManage specific withdrawal symptoms as they emerge, i.e."
  },
  {
    "id": 383,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ral principles to apply during management of any withdrawal:\nMaintain hydration. Depressive symptoms may occur in the post-intoxication period,\nManage specific withdrawal symptoms as they emerge, i.e. treat during or after withdrawal, and/or the person may have pre-existing\nnausea with anti-emetics, pain with simple analgesics, and insomnia depression. Be alert to the risk of suicide. with light sedatives. Offer all persons continued treatment, support, and monitoring after\nAllow the person to leave the treatment facility if they wish to do so. successful detoxification, regardless of the setting in which detoxification\nContinue treatment and support after detoxification. was delivered."
  },
  {
    "id": 384,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "to leave the treatment facility if they wish to do so. successful detoxification, regardless of the setting in which detoxification\nContinue treatment and support after detoxification. was delivered. PROTOCOL\n4\nOpioid Withdrawal\n» »\nCAUTION is advised before embarking upon withdrawal from opioids, especially when Methadone: Methadone is given orally at an initial dose of 15-20 mg, increasing, if\nthere has been injection use. When a decision is made to initiate withdrawal, inform the necessary, to 30 mg per day. Then gradually decrease the dose, until tapered off\nperson about what to expect, including symptoms and their duration. For example, completely, over 3-10 days. As with buprenorphine, special care should be taken for\nwithdrawal results in lower tolerance to opioids."
  },
  {
    "id": 385,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "hat to expect, including symptoms and their duration. For example, completely, over 3-10 days. As with buprenorphine, special care should be taken for\nwithdrawal results in lower tolerance to opioids. This means that if the person resumes individuals taking other sedating medications. opioid use at their usual dose after withdrawal that they are at an increased risk of »\nClonidine or Lofexidine: If opioid substitution medications are not available, clonidine or\noverdosing. Due to these risks, withdrawal is best undertaken when there is a plan for\nlofexidine can be used to manage some opioid withdrawal symptoms, namely hyperarousal. admission to a residential rehabilitation or other psychosocial support programme. They are given at dose ranges of 0.1-0.15 mg 3 times daily p.o."
  },
  {
    "id": 386,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "some opioid withdrawal symptoms, namely hyperarousal. admission to a residential rehabilitation or other psychosocial support programme. They are given at dose ranges of 0.1-0.15 mg 3 times daily p.o. and are dosed according to\nAlternatively, the person may be considered for opioid substitution therapy with either\nbody weight. Light-headedness and sedation may result. Monitor blood pressure closely. methadone or buprenorphine; see the opioid agonist maintenance treatment section (see\nOther symptoms of withdrawal should also be treated, i.e. nausea with anti-emetics, pain\nprotocol 5), and select one of the following pharmacological options for management:\nwith simple analgesics, and insomnia with light sedatives."
  },
  {
    "id": 387,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "uld also be treated, i.e. nausea with anti-emetics, pain\nprotocol 5), and select one of the following pharmacological options for management:\nwith simple analgesics, and insomnia with light sedatives. »\nBuprenorphine: Buprenorphine is given sublingually at a dose range of 4-16 mg per day »\nMorphine sulphate: 10-20 mg as an initial dose with 10 mg extra dose if needed. for 3-14 days for withdrawal management. Before initiating buprenorphine treatment, it is\nSedation and respiratory depression which canbe life threatening. Prolonged use can lead\nimportant to wait until signs and symptoms of opioid withdrawal become evident - at least\nto dependence. For more details go to Table 1."
  },
  {
    "id": 388,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "depression which canbe life threatening. Prolonged use can lead\nimportant to wait until signs and symptoms of opioid withdrawal become evident - at least\nto dependence. For more details go to Table 1. 8 hours after the last dose of heroin and 24-48 hours after the last dose of methadone;\notherwise, there is a risk that buprenorphine itself will precipitate a withdrawal syndrome. Special care should be taken for individuals taking other sedating medications."
  },
  {
    "id": 389,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "the last dose of methadone;\notherwise, there is a risk that buprenorphine itself will precipitate a withdrawal syndrome. Special care should be taken for individuals taking other sedating medications. DISORDERS DUE TO SUBSTANCE USE 121\n\n122\nSUB 2\nDISORDERS DUE TO SUBSTANCE USE Management\nPROTOCOL PROTOCOL\n5 6\nOpioid Agonist Maintenance Treatment Benzodiazepine Withdrawal\n» »\nOpioid agonist maintenance treatment requires the presence of an Benzodiazepine withdrawal can be managed by switching to a long-\nestablished and regulated national framework. It is characterized by the acting benzodiazepine and gradually decreasing the dose, tapered over\nprescription of long-acting opioid agonists (or partial agonists), such as 8-12 weeks, and in conjunction with psychosocial support."
  },
  {
    "id": 390,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ting benzodiazepine and gradually decreasing the dose, tapered over\nprescription of long-acting opioid agonists (or partial agonists), such as 8-12 weeks, and in conjunction with psychosocial support. More rapid\nmethadone or buprenorphine, generally on a daily, supervised basis. tapering is possible only if the person is in an inpatient setting in a\nThere is strong evidence that agonist maintenance treatment with hospital or detoxification facility. methadone or buprenorphine effectively reduces illicit drug use, the »\nIf severe, uncontrolled benzodiazepine withdrawal develops or occurs\nspread of HIV, mortality, and criminality, as well as improving physical\ndue to a sudden or unplanned cessation, consult a specialist or other\nhealth, mental health, and social functioning."
  },
  {
    "id": 391,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "or occurs\nspread of HIV, mortality, and criminality, as well as improving physical\ndue to a sudden or unplanned cessation, consult a specialist or other\nhealth, mental health, and social functioning. available resource person immediately to start a high-dose benzodiazepine\n»\nMonitoring: Medications used for opioid agonist maintenance treatment sedation regime and to hospitalise the person. Be cautious with\nare open to misuse and diversion, hence, programmes should use various unsupervised dispensing of benzodiazepines to unknown patients. methods of limiting the risk of diversion, including supervised\nconsumption. »\nFor more details please see Table 1. PSYCHOSOCIAL INTERVENTIONS\n2.1 Psychoeducation Throughout the discussion it is important to include all parts 6."
  },
  {
    "id": 392,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "of diversion, including supervised\nconsumption. »\nFor more details please see Table 1. PSYCHOSOCIAL INTERVENTIONS\n2.1 Psychoeducation Throughout the discussion it is important to include all parts 6. Have a discussion with the person based on the state-\nof the process: expressing empathy and building an atmosphere ments about their substance use, its causes, consequences\nof trust, while also pointing out contradictions in their and their personal goals, allowing exploration of apparent\nDisorders due to substance use can often be effectively\nnarrative, and challenging false beliefs. Avoid arguing with inconsistencies between the consequences of substance\ntreated, and people can and do get better. the person."
  },
  {
    "id": 393,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e use can often be effectively\nnarrative, and challenging false beliefs. Avoid arguing with inconsistencies between the consequences of substance\ntreated, and people can and do get better. the person. They should feel that the practitioner is there to use and the person’s stated goals. Discussing substance use can bring about feelings of support them and not to criticize them. If the person is unable\n7. D iscuss options for change based on the choice of realistic\nembarrassment or shame for many people. Always use a to commit to ending their harmful pattern of substance use at\ngoals and try to find a mutually agreed course of action. non-judgmental approach when speaking with people about this time, discuss why this is the case, rather than forcing the\nsubstance use."
  },
  {
    "id": 394,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "use at\ngoals and try to find a mutually agreed course of action. non-judgmental approach when speaking with people about this time, discuss why this is the case, rather than forcing the\nsubstance use. When people feel judged, they may be less person to say what they think is expected. 8. Support the person to enact these changes by commu-\nopen to speaking with you. Try not to express surprise at any nicating your confidence in them to make positive changes in\nresponses given. Techniques for more in depth discussions: their life, by provide information on the next steps as needed\n(further review, detoxification, psycho-social support), and by\nCommunicate confidently that it is possible to stop or reduce 1."
  },
  {
    "id": 395,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ussions: their life, by provide information on the next steps as needed\n(further review, detoxification, psycho-social support), and by\nCommunicate confidently that it is possible to stop or reduce 1. Provide personalised feedback to the person about the\nproviding the person with take-home materials if available. hazardous or harmful alcohol use and encourage the person risks associated with their pattern of substance use,\nto come back if he or she wants to discuss the issue further. whether or not they have a pattern of HARMFUL USE or\nExamples of questions to ask. Non-judgmentally elicit\nDEPENDENCE, and the specific harms they may be\nA person is more likely to succeed in reducing or stopping from the person their own thoughts about their substance\nexperiencing or causing to others."
  },
  {
    "id": 396,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "it\nDEPENDENCE, and the specific harms they may be\nA person is more likely to succeed in reducing or stopping from the person their own thoughts about their substance\nexperiencing or causing to others. substance use if the decision is their own. use by asking the following questions:\n2. Encourage the person to take responsibility for their\n1. Reasons for their substance use. (Ask: “Have you ever\nsubstance use choices, and the choice of whether or not to\nthought about why you use [substance]?”)\n2.2 Motivational Interviewing seek assistance for their substance use. Do this by asking\nthem how concerned THEY are about their substance use. 2. What they perceive as the benefits from their use. (Brief Intervention)\n(Ask: “What does [substance] do for you? Does it cause\n3."
  },
  {
    "id": 397,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "is by asking\nthem how concerned THEY are about their substance use. 2. What they perceive as the benefits from their use. (Brief Intervention)\n(Ask: “What does [substance] do for you? Does it cause\n3. Ask the person the reasons for their substance use,\nyou any problems?”)\nincluding as a response to other issues such as mental health\nBrief interventions using motivational interviewing is an\nproblems or specific stressors, and the perceived benefits 3. What they perceive as the actual and potential harms from\napproach to discussing substance use in a non-judgemental\nthey have from substance use, even if only in the short term. the substance use. (Ask: “Has [substance] use caused you\nway. It encourages a person to reflect on their own\nany harm?"
  },
  {
    "id": 398,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "n a non-judgemental\nthey have from substance use, even if only in the short term. the substance use. (Ask: “Has [substance] use caused you\nway. It encourages a person to reflect on their own\nany harm? Can you see it causing harm in the future?”)\nsubstance use choices. It can be used as part of a very brief 4. Ask about their perception of both the positive and\nencounter for addressing risks or harmful substance use. It negative consequences of their substance use and, if 4. What is most important to the person. can also be used as part of a longer discussion that takes necessary, challenge any overstatement of the benefits (Ask: “What is most important to you in your life?”)\nplace over several sessions that address dependent patterns and understatement of the risks/harms."
  },
  {
    "id": 399,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ary, challenge any overstatement of the benefits (Ask: “What is most important to you in your life?”)\nplace over several sessions that address dependent patterns and understatement of the risks/harms. of substance use; this is referred to as Motivational\n5. Ask about the person’s personal goals, and whether or\nEnhancement Therapy. not their substance use is helping them or preventing\nthem from reaching these goals. DISORDERS DUE TO SUBSTANCE USE 123\n\n124\nSUB 2\nDISORDERS DUE TO SUBSTANCE USE Management\n2.3 S trategies for Reducing and\nIf the person injects drugs: Provide information and education about disorders due\nStopping Use Inform the person about the risks of intravenous drug use, to substance use."
  },
  {
    "id": 400,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "trategies for Reducing and\nIf the person injects drugs: Provide information and education about disorders due\nStopping Use Inform the person about the risks of intravenous drug use, to substance use. which include: being at higher risk of infections such as Offer an assessment of their personal, social, and mental health\nSteps to reducing or stopping the use of all substances: HIV/AIDS, Hepatitis B and C, skin infections that can cause needs. Offer treatment for any priority mental health disorders. If the person is interested in reducing their substance use, septicaemia, endocarditis, spinal abscesses, meningitis,\ndiscuss the following steps with them. and even death. Inform them about and help them access support groups for\nfamilies and carers (if available) and other social resources."
  },
  {
    "id": 401,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "l abscesses, meningitis,\ndiscuss the following steps with them. and even death. Inform them about and help them access support groups for\nfamilies and carers (if available) and other social resources. Identify triggers for use and ways to avoid them. For Considering that the person may not stop injecting drugs\nexample: pubs where people are drinking or areas where the right away, provide information on less risky injection\nperson used to obtain drugs, etc. techniques. Emphasize the importance of using sterile CLINICAL TIP:\nneedles and syringes each time they inject and to never HIV/TB/HEPATITIS and SUBSTANCE USE\nIdentify emotional cues for use and ways to cope with them\nshare injecting equipment with others. (i.e. relationship problems, difficulties at work, etc.)."
  },
  {
    "id": 402,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "to never HIV/TB/HEPATITIS and SUBSTANCE USE\nIdentify emotional cues for use and ways to cope with them\nshare injecting equipment with others. (i.e. relationship problems, difficulties at work, etc.). P eople who inject drugs are at increased risk of HIV/AIDS and\nProvide information on how to access needle and syringe\nEncourage the person not to keep substances at home. hepatitis, particularly if they do not use sterile injection\nexchange programs where they exist or other sources of\nequipment or have unsafe sex in exchange for drugs; once\n2.4 M utual Help Groups\nsterile injection equipment. infected, they also have a worse prognosis."
  },
  {
    "id": 403,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "programs where they exist or other sources of\nequipment or have unsafe sex in exchange for drugs; once\n2.4 M utual Help Groups\nsterile injection equipment. infected, they also have a worse prognosis. HIV/AIDS also\nEncourage and offer, at minimum, annual testing for increases the risk of TB infection, and active TB is a main\nMutual help groups such as Alcoholics Anonymous, blood-borne viral illnesses, including HIV/AIDS and cause of death in people living with HIV/AIDS. People who\nNarcotics Anonymous, or Smart Recovery can be helpful Hepatitis B and C. use alcohol and drugs heavily are also at increased risk for TB. referrals for persons with disorders due to substance use."
  },
  {
    "id": 404,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "who\nNarcotics Anonymous, or Smart Recovery can be helpful Hepatitis B and C. use alcohol and drugs heavily are also at increased risk for TB. referrals for persons with disorders due to substance use. Therefore, a common presentation is of a person who has a\n– Encourage Hepatitis B vaccination\nThey provide information, structured activities, and peer combination of drug use, particularly i.v. heroin use, and\n– Ensure condom availability\nsupport in a non-judgmental environment. Find out what infection with TB, HIV/AIDS, and hepatitis at the same time. – Ensure availability of treatment for people with\nmutual help groups are available locally."
  },
  {
    "id": 405,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "in a non-judgmental environment. Find out what infection with TB, HIV/AIDS, and hepatitis at the same time. – Ensure availability of treatment for people with\nmutual help groups are available locally. HIV/AIDS and hepatitis S ervices that treat people who use drugs and alcohol\nshould regularly test all people who inject drugs for\n2.5 S trategies for Preventing Harm\nTreatment of co-morbidities: HIV/AIDS and hepatitis, and should have a high level\nof suspicion for TB in any person with a cough, fever,\nfrom Drug Use and Treating\nHave a low threshold for screening for TB in people who\nnight sweats, or weight loss. have disorders due to substance use."
  },
  {
    "id": 406,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "uspicion for TB in any person with a cough, fever,\nfrom Drug Use and Treating\nHave a low threshold for screening for TB in people who\nnight sweats, or weight loss. have disorders due to substance use. Related Conditions\nT reatment of HIV/AIDS and TB requires taking daily medica-\nConsider investigations for and treatment of sexually\ntions, where every single day is important. Directly obser-\ntransmitted diseases. Encourages the person to engage in less risky behaviour. ving the treatment can improve treatment adherence. If the\n– Advise not to drive if intoxicated."
  },
  {
    "id": 407,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "portant. Directly obser-\ntransmitted diseases. Encourages the person to engage in less risky behaviour. ving the treatment can improve treatment adherence. If the\n– Advise not to drive if intoxicated. person is also opioid dependent, providing daily observed\n2.4 C arer Support\nmethadone or buprenorphine treatment at the same place\n– If the person uses opioids, provide intramuscular or\nand time will further facilitate treatment adherence. intranasal naloxone for family members, which family\nSupporting family and carers:\nmembers can keep and use if the person has overdosed H epatitis treatments occur daily or weekly. Patients\nwhile waiting for help to arrive or en route to hospital."
  },
  {
    "id": 408,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "amily\nSupporting family and carers:\nmembers can keep and use if the person has overdosed H epatitis treatments occur daily or weekly. Patients\nwhile waiting for help to arrive or en route to hospital. Discuss the impact of disorders due to substance use on with Hepatitis B or C should be advised to avoid alcohol\nother family members, including children, with the person’s completely. family and/or carers."
  },
  {
    "id": 409,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "s the impact of disorders due to substance use on with Hepatitis B or C should be advised to avoid alcohol\nother family members, including children, with the person’s completely. family and/or carers. EPI 2\nSUBSTANCE USE DISORDERS Management\nSpecial populations\nADOLESCENTS W OMEN WHO ARE OF CHILD-BEARING AGE, PREGNANT,\nOR BREASTFEEDING\nHow to Assess the Adolescent:\nClarify the confidential nature of the health care discussion, Alcohol Use Drug Use\nincluding in what circumstances the adolescent’s parents or\nAdvise women who are pregnant or considering becoming Inquire about the woman’s menstrual cycle and inform her\ncarers will be given any information. pregnant to avoid alcohol completely."
  },
  {
    "id": 410,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "’s parents or\nAdvise women who are pregnant or considering becoming Inquire about the woman’s menstrual cycle and inform her\ncarers will be given any information. pregnant to avoid alcohol completely. that substance use can interfere with the menstrual cycle,\nAsk what else is going on in the adolescent’s life? Identify sometimes creating the false impression that pregnancy is\nInform women that consuming even small amounts of alcohol\nthe most important underlying issues for the adolescent. not possible. early in pregnancy can harm the developing fetus, and that\nKeep in mind that adolescents may not be able to fully\nlarger amounts of alcohol can result in a syndrome of severe Discuss the harmful effects of illicit drugs on fetal\narticulate what is bothering them."
  },
  {
    "id": 411,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "in mind that adolescents may not be able to fully\nlarger amounts of alcohol can result in a syndrome of severe Discuss the harmful effects of illicit drugs on fetal\narticulate what is bothering them. developmental problems (Fetal Alcohol Syndrome). development and ensure that the woman has access to\nOpen-ended questions may be helpful in eliciting information effective contraception. Advise women who are breastfeeding to avoid alcohol\nin the following areas: Home, Education & Employment,\ncompletely. Advise and support women who are pregnant to stop\nEating, Activities, Drugs and Alcohol, Sexuality, Safety, and\nusing all illicit drugs. Pregnant opioid dependent women\nSuicide/Depression. Allow sufficient time for discussion."
  },
  {
    "id": 412,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ho are pregnant to stop\nEating, Activities, Drugs and Alcohol, Sexuality, Safety, and\nusing all illicit drugs. Pregnant opioid dependent women\nSuicide/Depression. Allow sufficient time for discussion. Given the benefits of exclusive breastfeeding (particularly in\nshould generally be advised to take an opioid agonist such as\nAlso assess for other priority mental health conditions. If the first 6 months), if mothers continue to drink alcohol they\nmethadone. any priority conditions are identified, see CMH."
  },
  {
    "id": 413,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "d agonist such as\nAlso assess for other priority mental health conditions. If the first 6 months), if mothers continue to drink alcohol they\nmethadone. any priority conditions are identified, see CMH. should be advised to limit their alcohol consumption, and to\nminimise the alcohol content of their breast milk, such as by Screen babies of mothers with drug use disorders for\nPsychoeducation for the Adolescent:\nbreastfeeding before drinking alcohol and not again until withdrawal symptoms (also known as Neonatal Abstinence\nafter blood levels fall to zero (allowing approximately 2 hours Syndrome). Neonatal Abstinence Syndrome due to maternal\nProvide the adolescent and their parents with information on\nfor each drink consumed, i.e."
  },
  {
    "id": 414,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "d levels fall to zero (allowing approximately 2 hours Syndrome). Neonatal Abstinence Syndrome due to maternal\nProvide the adolescent and their parents with information on\nfor each drink consumed, i.e. 4 hours if two drinks are opioid use should be treated with low doses of opioids (such\nthe effects of alcohol and other substances on individual\nconsumed), or by using expressed breast milk. as morphine) or barbiturates. For more details please refer\nhealth and social functioning."
  },
  {
    "id": 415,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "(such\nthe effects of alcohol and other substances on individual\nconsumed), or by using expressed breast milk. as morphine) or barbiturates. For more details please refer\nhealth and social functioning. to Guidelines for the identification and management of\nEncourage a change in the adolescent’s environment and activi- CAUTION substance use and substance use disorders in pregnancy\nties, rather than focusing on the adolescent’s behaviour as being a All mothers with harmful substance use and young Available on http://apps.who.int/iris/bitstream/10665/\n“problem.” Encourage participation in school or work and activi- children should be offered any social support services 107130/1/9789241548731_eng.pdf. ties that occupy the adolescent’s time."
  },
  {
    "id": 416,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "m/10665/\n“problem.” Encourage participation in school or work and activi- children should be offered any social support services 107130/1/9789241548731_eng.pdf. ties that occupy the adolescent’s time. Encourage participation in that are available, including additional postnatal\nAdvise and support breastfeeding mothers not to use\ngroup activities that are safe and facilitate the adolescent’s build- visits, parenting training, and child care during\nany illicit drugs. ing of skills and contribution to their communities. It is important medical visits. that adolescents take part in activities which interest them."
  },
  {
    "id": 417,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ng training, and child care during\nany illicit drugs. ing of skills and contribution to their communities. It is important medical visits. that adolescents take part in activities which interest them. Advise and support mothers with disorders due to substance\nuse to breastfeed exclusively for at least the first 6 months,\nEncourage parents and/or carers to know where the adolescent\nunless there is specialist advice not to breastfeed. is, who they are with, what they are doing, when they will\nbe home, and to expect the adolescent to be accountable\nfor their activities."
  },
  {
    "id": 418,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "adolescent\nunless there is specialist advice not to breastfeed. is, who they are with, what they are doing, when they will\nbe home, and to expect the adolescent to be accountable\nfor their activities. DISORDERS DUE TO SUBSTANCE USE 125\n\n126\nSUB 2\nDISORDERS DUE TO SUBSTANCE USE Management\nPHARMACOLOGICAL INTERVENTIONS\nTABLE 1: Medication Chart\nCLASS / INDICATION MEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nBENZODIAZEPINES Diazepam 10-20 mg for observable features of alcohol with- Sedation and respiratory depression which can Do not use in people who are sedated. Beware of\ndrawal or stimulant intoxication every 2 hours until be life threatening. Prolonged use can lead to combining with other sedatives."
  },
  {
    "id": 419,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "depression which can Do not use in people who are sedated. Beware of\ndrawal or stimulant intoxication every 2 hours until be life threatening. Prolonged use can lead to combining with other sedatives. Patients should not\nTo treat alcohol withdrawal,\nfeatures of alcohol withdrawal/stimulant intoxication dependence. drive. Duration of effect may be prolonged in persons\nstimulant intoxication, and\nare no longer observable or the person is lightly with severe liver disease. Supervise dosing to minimise\npsychosis\nsedated. Lower doses (up to 10 mg four times a day) the risk of: diversion (i.e. selling the medication to\nfor alcohol withdrawal in an outpatient setting. somebody else). OPIOID ANTAGONISTS Naloxone 0.4-2 mg i.v., i.m., subcutaneous or intranasal."
  },
  {
    "id": 420,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ay) the risk of: diversion (i.e. selling the medication to\nfor alcohol withdrawal in an outpatient setting. somebody else). OPIOID ANTAGONISTS Naloxone 0.4-2 mg i.v., i.m., subcutaneous or intranasal. Discomfort or withdrawal symptoms may result. Repeat doses as needed. To treat opioid overdose\nVITAMINS Thiamine 100 mg p.o. daily for 5 days to prevent Wernicke’s\n(Vitamin B1) encephalopathy. To prevent or treat Wernicke’s\n100 mg – 500 mg i.v. or i.m. two to three times\nencephalopathy\ndaily for 3-5 days to treat Wernicke’s encephalopathy."
  },
  {
    "id": 421,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "to prevent Wernicke’s\n(Vitamin B1) encephalopathy. To prevent or treat Wernicke’s\n100 mg – 500 mg i.v. or i.m. two to three times\nencephalopathy\ndaily for 3-5 days to treat Wernicke’s encephalopathy. OPIOID AGONISTS Methadone Opioid withdrawal: Methadone initial dose Sedation, confusion, nausea, vomiting, consti- Use with caution in patients with cardiac or\n20 mg, with a supplemental dose of 5-10 mg pation, possible hormonal changes, decreased respiratory disease. To treat opioid withdrawal and 4 hours later if necessary. sex drive, ECG changes such as prolonged QT\ndependence interval or bradycardia, hypotension, respiratory\nOpioid maintenance: initial dose 10-20 mg with\ndepression."
  },
  {
    "id": 422,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "awal and 4 hours later if necessary. sex drive, ECG changes such as prolonged QT\ndependence interval or bradycardia, hypotension, respiratory\nOpioid maintenance: initial dose 10-20 mg with\ndepression. supplementary dose of 10 mg if needed, increasing\nthe daily dose by 5-10 mg every few days if needed\nuntil the person is no longer experiencing opioid\nwithdrawal and not using illicit opioids. Maintain\nuntil ready to cease opioid agonist treatment. Buprenorphine Initial dose of 4-8 mg, increasing by 4-8 mg each day as Sedation, dizziness, ataxia, nausea, vomiting, – Use with caution in congestive heart failure,\nneeded until the person is no longer experiencing constipation, respiratory depression. respiratory disease, or liver disease. opioid withdrawal and not using illicit opioids."
  },
  {
    "id": 423,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ongestive heart failure,\nneeded until the person is no longer experiencing constipation, respiratory depression. respiratory disease, or liver disease. opioid withdrawal and not using illicit opioids. Maintain – Potential for abuse. until ready to cease opioid agonist treatment. – Abrupt cessation can cause withdrawal symptoms. Morphine 10-20 mg as an initial dose with 10 mg extra dose Sedation and respiratory depression which can Do not use in people who are sedated. Beware of\nsulphate if needed. be life threatening. Prolonged use can lead to combining with other sedatives. The person should not\ndependence. drive. Supervise dosing to minimise the risk of diversion. Give longer acting opioids, such as methadone or bupre-\nnorphine, once per day to outpatients, when available."
  },
  {
    "id": 424,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "person should not\ndependence. drive. Supervise dosing to minimise the risk of diversion. Give longer acting opioids, such as methadone or bupre-\nnorphine, once per day to outpatients, when available. CLASS / INDICATION MEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nALPHA ADRENERGIC Clonidine Start 0.1 mg 2-3 times daily. Increase as tolerated Sedation, light-headedness, dizziness, headache, Use caution in cardiac, cerebrovascular, and liver\nAGONISTS in divided doses to manage withdrawal symptoms, nausea/vomiting, dry mouth, constipation, sexual disease. Use lower doses in kidney disease. to a maximum of 1 mg daily. dysfunction, depression, agitation, low blood Be aware of the potential for abuse. Monitor vital\npressure, tachycardia, sinus bradycardia, and signs closely."
  },
  {
    "id": 425,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "idney disease. to a maximum of 1 mg daily. dysfunction, depression, agitation, low blood Be aware of the potential for abuse. Monitor vital\npressure, tachycardia, sinus bradycardia, and signs closely. To treat opioid withdrawal\nAV block. DO NOT stop abruptly, as withdrawal can cause\nrebound hypertension. Avoid in women who are\npregnant or breastfeeding. Lofexidine Start 0.4 - 0.6 mg twice daily. Increase Sedation, light-headedness, low blood Use caution in cardiac, cerebrovascular, and renal\nas needed by 0.4-0.8 mg daily. Maximum single pressure, ECG changes such as prolonged disease. Avoid in patients with prolonged QT\ndose: 0.8 mg. Maximum daily dose: 2.4 mg QT interval and sinus bradycardia. syndrome, metabolic disarray, or if they are taking\n(in 2-4 divided doses)."
  },
  {
    "id": 426,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ged disease. Avoid in patients with prolonged QT\ndose: 0.8 mg. Maximum daily dose: 2.4 mg QT interval and sinus bradycardia. syndrome, metabolic disarray, or if they are taking\n(in 2-4 divided doses). any other QT-prolonging medications. Monitor vital signs closely. DO NOT stop medication abruptly, as withdrawal\nmay cause rebound hypertension. MEDICATIONS TO Acamprosate Start 2 tablets of 333 mg p.o. each 3 times per day Diarrhoea, flatulence, nausea/vomiting, abdominal In moderate kidney disease, give a lower dose,\nPREVENT RELAPSE for 12 months. If the person weighs less than 60 kg, pain, depression, anxiety, suicidality, itching. 333 mg p.o. 3 times per day. IN ALCOHOL give 2 tablets 2 times per day p.o. for 12 months."
  },
  {
    "id": 427,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "RELAPSE for 12 months. If the person weighs less than 60 kg, pain, depression, anxiety, suicidality, itching. 333 mg p.o. 3 times per day. IN ALCOHOL give 2 tablets 2 times per day p.o. for 12 months. Occasionally, a maculopapular rash can occur, and\nDEPENDENCE rarely, bullous skin reactions. CONTRAINDICATED in severe kidney disease\nand liver disease. Naltrexone Start 50 mg daily for 6-12 months. In opioid Sedation, dizziness, nausea/vomiting, abdominal Risk of FATAL OVERDOSE in patients who use\nTo suppress the urge to drink\ndependence, ensure that there has been no opioid pain, insomnia, anxiety, reduced energy, joint opioids more than 24 hours after their last dose of\nuse in the last 7 days (for example by administration and muscle pain."
  },
  {
    "id": 428,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "that there has been no opioid pain, insomnia, anxiety, reduced energy, joint opioids more than 24 hours after their last dose of\nuse in the last 7 days (for example by administration and muscle pain. Monitor liver function due to naltrexone, due to the rapid loss of antagonistic effect. of dose of naloxone). risk of liver toxicity. DO NOT use in patients with liver failure or acute\nhepatitis. Disulfiram Start 200-400 mg daily. Drowsiness, dizziness, headache, flushing, Tricyclic antidepressants (TCAs), monamine oxidase\nsweating, dry mouth, nausea/vomiting, tremor, inhibitors (MAOIs), antipsychotics, vasodilators, and\nfoul body odour, sexual dysfunction. Rarely, alpha or beta adrenergic antagonists make the\npsychotic reactions, allergic dermatitis, disulfiram-alcohol reaction more serious."
  },
  {
    "id": 429,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "hotics, vasodilators, and\nfoul body odour, sexual dysfunction. Rarely, alpha or beta adrenergic antagonists make the\npsychotic reactions, allergic dermatitis, disulfiram-alcohol reaction more serious. Sensitisation\nperipheral neuritis, or hepatic cell damage can to alcohol continues 6-14 days after taking disulfiram,\noccur. Severe reactions can lead to confusion, even if in small amounts. cardiovascular collapse, and death. DO NOT use with alcohol, as reactions can be\nlife-threatening or fatal. DO NOT use in women who are pregnant or\nbreastfeeding. CONTRAINDICATED in people with hypertension,\nheart, liver, or kidney disease, a history of cerebro-\nvascular accidents, psychosis, impulsivity, or if at risk\nof suicide."
  },
  {
    "id": 430,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "are pregnant or\nbreastfeeding. CONTRAINDICATED in people with hypertension,\nheart, liver, or kidney disease, a history of cerebro-\nvascular accidents, psychosis, impulsivity, or if at risk\nof suicide. DISORDERS DUE TO SUBSTANCE USE 127\n\n128\nSUB 3\nDISORDERS DUE TO SUBSTANCE USE Follow-up\nSUB 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n1 »\nHarmful use: Follow-up in one\nmonth. Follow-up as needed\nASSESS FOR IMPROVEMENT thereafter. »\nDependence: Follow-up several\ntimes per week in the first two\nweeks, then weekly in the first\nAt every visit, assess:\nmonth. Once improving,\n» decrease frequency to monthly\nQuantity and frequency of substance use, mental health, physical\nand as needed thereafter. health, risk and protective factors (e.g."
  },
  {
    "id": 431,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "sit, assess:\nmonth. Once improving,\n» decrease frequency to monthly\nQuantity and frequency of substance use, mental health, physical\nand as needed thereafter. health, risk and protective factors (e.g. relationships, accommodation,\nemployment, etc.)\n»\nAsk about factors that lead to substance use and consequences\nof substance use\nRECENT CESSATION OF USE LONG TERM CESSATION OR\nONGOING SUBSTANCE USE OR SHIFT TO NON-HARMFUL USE NON-HARMFUL USE\n»\nD evelop strategies to reduce harm\n»\nC onsider urine testing to confirm abstinence\n»\nC onsider occasional urine testing to confirm\n»\nT reat health problems\n»\nG ive positive feedback to encourage the\nnon-use\n»\nD evelop strategies to reduce use\nmaintenance of abstinence/non-harmful use\n»\nP ositive feedback\n»\nA rrange detoxification or maintenance\n»\nT reat other medical problems\n»\nS upport factors which reduce the risk of\ntreatment if client agrees\n»\nC onsider relapse prevention medications for\nrelapse (such as housing and employment)\n»\nC onduct frequent review and outreach\nalcohol and opioid dependence\n»\nT reat other medical problems\n»\nC onsider psychosocial therapies to prevent\n»\nE ncourage participation in mutual help groups\nrelapse and mutual help groups »\nL ess frequent review\n»\nS upport factors which reduce the risk of relapse\nsuch as housing and employment\n\nBOX 2."
  },
  {
    "id": 432,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "event\n»\nE ncourage participation in mutual help groups\nrelapse and mutual help groups »\nL ess frequent review\n»\nS upport factors which reduce the risk of relapse\nsuch as housing and employment\n\nBOX 2. SIGNS OF CHRONIC SUBSTANCE USE & INVESTIGATIONS TO CONSIDER\nSIGNS OF CHRONIC, HEAVY ALCOHOL CONSUMPTION: SIGNS OF CHRONIC DRUG USE:\nLiver disease: look for jaundiced (yellow) skin and eyes, palpable and tender liver Difficulty caring for self, poor dentition, parasitic skin infections such as lice or scabies,\nedge (in early liver disease), ascites (distended abdomen filled with fluid), spider naevi and malnutrition."
  },
  {
    "id": 433,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ficulty caring for self, poor dentition, parasitic skin infections such as lice or scabies,\nedge (in early liver disease), ascites (distended abdomen filled with fluid), spider naevi and malnutrition. (spider-like blood vessels visible on the surface of the skin), and altered mental status\nSigns of injection: look for injection sites on arms or legs, with both new and old\n(hepatic encephalopathy). marks visible. Ask the person where they inject and inspect the sites to make sure there\nCerebellar damage: Look for problems with balance, walking, coordinating movements, are no signs of local infection. and nystagmus."
  },
  {
    "id": 434,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "he person where they inject and inspect the sites to make sure there\nCerebellar damage: Look for problems with balance, walking, coordinating movements, are no signs of local infection. and nystagmus. Common health complications of injecting drug use: people who inject drugs have a\nInvestigations to consider: higher risk of contracting infections such as HIV/AIDS, Hepatitis B and C, and tuberculosis. They are also at high risk for skin infections at their injection sites. In some cases, this\n– Liver enzymes: elevated liver enzymes and elevated ammonia indicate liver disease. can spread through the blood and cause septicaemia, endocarditis, spinal abscesses,\n– Complete blood count: look for macrocytic anaemia and low platelets. meningitis, or even death."
  },
  {
    "id": 435,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ate liver disease. can spread through the blood and cause septicaemia, endocarditis, spinal abscesses,\n– Complete blood count: look for macrocytic anaemia and low platelets. meningitis, or even death. Investigations to consider:\n– Urine drug screen: for emergency cases, a urine drug screen should be conducted\nwhenever intoxication, withdrawal, or overdose is suspected, especially in cases when\nthe person is unable to convey what they have ingested. – If the person has been injecting drugs, offer serological testing for blood-borne viruses,\nHIV/AIDS and Hepatitis B and C, etc. – If the person has had unprotected sex, offer testing for sexually transmitted infections,\nincluding HIV, syphilis, chlamydia, gonorrhoea, and human papilloma virus (HPV)."
  },
  {
    "id": 436,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "and Hepatitis B and C, etc. – If the person has had unprotected sex, offer testing for sexually transmitted infections,\nincluding HIV, syphilis, chlamydia, gonorrhoea, and human papilloma virus (HPV). – Obtain a tuberculosis test, sputum sample, and a chest x-ray if tuberculosis is\nsuspected. Look for signs and symptoms such as chronic productive cough, fevers,\nchills, and weight loss. DISORDERS DUE TO SUBSTANCE USE 129\n\n130\nDISORDERS DUE TO SUBSTANCE USE\n\nSELF-HARM / SUICIDE\nSuicide is the act of deliberately killing oneself. Self-harm is a Evaluate for thoughts, plans and acts of self-harm during the\nbroader term referring to intentional self-inflicted poisoning or initial assessment and periodically thereafter, as required."
  },
  {
    "id": 437,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "f-harm is a Evaluate for thoughts, plans and acts of self-harm during the\nbroader term referring to intentional self-inflicted poisoning or initial assessment and periodically thereafter, as required. Attend\ninjury, which may or may not have a fatal intent or outcome. to the person’s mental state and emotional distress. Any person over 10 years of age experiencing any of the following\nconditions should be asked about thoughts or plans of self-harm\nin the last month, and about acts of self-harm in the last year: CLINICAL TIP:\nAsking about self-harm does NOT provoke acts of self-harm. It often reduces\n»\nAny of the priority MNS conditions. See Master Chart ( MC) anxiety associated with thoughts or acts of self-harm and helps the person feel\n» Chronic pain understood."
  },
  {
    "id": 438,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "s of self-harm. It often reduces\n»\nAny of the priority MNS conditions. See Master Chart ( MC) anxiety associated with thoughts or acts of self-harm and helps the person feel\n» Chronic pain understood. However, try to establish a relationship with the person before asking\n» questions about self-harm. Ask the person to explain their reasons for harming\nAcute emotional distress\nthemselves. 131\n\n132\nSUI\nSELF HARM / SUICIDE\nSUI Quick Overview\nASSESSMENT MANAGEMENT\nA ssess if the person has attempted Management Protocols\na medically serious act of self-harm\n1. Medically serious act of self-harm\n2. Imminent risk of self-harm/suicide\nAssess for imminent risk of\n3."
  },
  {
    "id": 439,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "A ssess if the person has attempted Management Protocols\na medically serious act of self-harm\n1. Medically serious act of self-harm\n2. Imminent risk of self-harm/suicide\nAssess for imminent risk of\n3. Risk of self-harm/suicide\nself-harm/suicide\nGeneral Management and\nAssess for any of the priority MNS conditions\nPsychosocial Interventions\nAssess for chronic pain\nAssess for severity of emotional symptoms\nFOLLOW-UP\n\nSUI 1\nSUI 1 Assessment\nASSESS FOR SELF-HARM/SUICIDE IF THE PERSON PRESENTS WITH EITHER:\nE xtreme hopelessness and despair, current thoughts/plan/act of self-harm suicide or history\nthereof, act of self-harm with signs of poisoning/intoxication, bleeding from self-inflicted wound,\nloss of consciousness and/or extreme lethargy, OR\nA ny of the priority MNS conditions, chronic pain or extreme emotional distress\n1\nHas the person attempted a medically serious act of self-harm?"
  },
  {
    "id": 440,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ound,\nloss of consciousness and/or extreme lethargy, OR\nA ny of the priority MNS conditions, chronic pain or extreme emotional distress\n1\nHas the person attempted a medically serious act of self-harm? Assess if there is evidence of self-injury and/or\nsigns/symptoms requiring urgent medical treatment:\n– Signs of poisoning or intoxication – Loss of consciousness\n– Bleeding from self-inflicted wound – Extreme lethargy\nCLINICAL TIP\nManagement for the medically serious act of\nIf medically stable, perform appropriate self-harm is required. management, as needed. Go to PROTOCOL 1\nR eturn to STEP 2 2 once person is medically stable. SELF-HARM /SUICIDE 133\n\n134\nSUI 1\nSELF HARM / SUICIDE Assessment\n2\nIs there an imminent risk of self-harm/suicide?"
  },
  {
    "id": 441,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ent, as needed. Go to PROTOCOL 1\nR eturn to STEP 2 2 once person is medically stable. SELF-HARM /SUICIDE 133\n\n134\nSUI 1\nSELF HARM / SUICIDE Assessment\n2\nIs there an imminent risk of self-harm/suicide? Ask the person and carers if there are ANY of the following:\n– Current thoughts or plan of self-harm/suicide\n– History of thoughts or plan of self-harm in the past month or act of self-harm in the past year\nin a person who is now extremely agitated, violent, distressed or lacks communication\nIMMINENT RISK OF\nSELF-HARM/SUICIDE is likely\nG o to PROTOCOL 2, manage,\nand then continue to STEP 3 3\nIs there a history of thoughts or plan\nof self-harm in the past month or act of\nself-harm in the past year? Imminent risk of self-harm/suicide is\nunlikely, but a risk may still persist."
  },
  {
    "id": 442,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ue to STEP 3 3\nIs there a history of thoughts or plan\nof self-harm in the past month or act of\nself-harm in the past year? Imminent risk of self-harm/suicide is\nunlikely, but a risk may still persist. G o to PROTOCOL 3, manage,\nRisk of self-harm/suicide is unlikely. and then continue to STEP 33\n\n3\nDoes the person have concurrent MNS conditions? – Depression – Child & adolescent mental – Psychoses\n– Disorders due to substance use and behavioral disorders – Epilepsy\nM anage the concurrent conditions. See relevant modules. 4\nDoes the person have chronic pain? M anage the pain and treat any\nrelevant medical conditions. 5\nDoes the person have emotional symptoms severe enough to warrant clinical management?"
  },
  {
    "id": 443,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "levant modules. 4\nDoes the person have chronic pain? M anage the pain and treat any\nrelevant medical conditions. 5\nDoes the person have emotional symptoms severe enough to warrant clinical management? – Difficulty carrying out usual work, school, – Repeated self-medication for emotional – Marked distress or repeated help-seeking\ndomestic or social activities distress, or unexplained physical symptoms\nManage the emotional symptoms. Go to SUI 3 (Follow-up)\nGo to OTH\nSELF-HARM /SUICIDE 135\n\n136\nSUI 2\nSELF HARM / SUICIDE Management\nSUI 2 Management\nPROTOCOL PROTOCOL PROTOCOL\n1 2 3\nMedically Serious Act of Self-Harm Imminent Risk of Self-Harm/Suicide Risk of Self-Harm/Suicide\n» » »\nFor all cases: Place the person in a Remove means of self-harm/suicide. Offer and activate psychosocial support."
  },
  {
    "id": 444,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ous Act of Self-Harm Imminent Risk of Self-Harm/Suicide Risk of Self-Harm/Suicide\n» » »\nFor all cases: Place the person in a Remove means of self-harm/suicide. Offer and activate psychosocial support. secure and supportive environment at a » (2.3)\nCreate a secure and supportive environment;\nhealth facility. »\nif possible, offer a separate, quiet room while Consult a mental health specialist, if available. »\nDO NOT leave the person alone. waiting for treatment. »\nMaintain regular contact and Follow-Up. » »\nMedically treat injury or poisoning. DO NOT leave the person alone. If there is acute pesticide intoxication, follow »\nSupervise and assign a named staff or family\n“Management of pesticide intoxication”. (2.1)\nmember to ensure person’s safety at all times."
  },
  {
    "id": 445,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "rson alone. If there is acute pesticide intoxication, follow »\nSupervise and assign a named staff or family\n“Management of pesticide intoxication”. (2.1)\nmember to ensure person’s safety at all times. »\nIf hospitalization is needed, continue to »\nAttend to mental state and emotional distress. monitor the person closely to prevent suicide. »\n» Provide psychoeducation to the person and\nCare for the person with self-harm. (2.2)\ntheir carers. (2.5)\n»\nOffer and activate psychosocial support. »\nOffer and activate psychosocial support. (2.3)\n(2.3)\n»\nOffer carers support. (2.4) »\nOffer carers support. (2.4)\n»\nConsult a mental health specialist, »\nConsult a mental health specialist, if available. if available. »\n» Maintain regular contact and Follow-Up. Maintain regular contact and Follow-Up."
  },
  {
    "id": 446,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "pport. (2.4)\n»\nConsult a mental health specialist, »\nConsult a mental health specialist, if available. if available. »\n» Maintain regular contact and Follow-Up. Maintain regular contact and Follow-Up. 2.1 Management of pesticide 2.2 Care for the person with self-harm\nintoxication\nPlace the person in a secure and supportive environment Hospitalization in non-psychiatric services of a general\nIf the health care facility has a minimum set of skills and at a health facility ( do not leave them alone). If the hospital is not recommended for the prevention of self-harm."
  },
  {
    "id": 447,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "c services of a general\nIf the health care facility has a minimum set of skills and at a health facility ( do not leave them alone). If the hospital is not recommended for the prevention of self-harm. resources, then treat using the WHO document, “Clinical person must wait for treatment, offer an environment that However, if admission to a general (non-psychiatric) hospital is\nManagement of Acute Pesticide Intoxication” (http://www. minimizes distress; if possible, in a separate, quiet room necessary for the management of the medical consequences\nwho.int/mental_health/publications/9789241596732/en). with constant supervision and contact with a designated of self-harm, monitor the person closely to prevent further\nstaff or family member to ensure safety at all times."
  },
  {
    "id": 448,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ublications/9789241596732/en). with constant supervision and contact with a designated of self-harm, monitor the person closely to prevent further\nstaff or family member to ensure safety at all times. self-harm in the hospital. Otherwise, transfer the person immediately to a health\nfacility that has the following resources: Remove access to means of self-harm. If prescribing medication:\n– Skills and knowledge on how to resuscitate individuals Consult a mental health specialist, if available. – See relevant mhGAP-IG modules for pharmacological\nand assess for clinical features of pesticide poisoning; interventions in the management of concurrent conditions."
  },
  {
    "id": 449,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "health specialist, if available. – See relevant mhGAP-IG modules for pharmacological\nand assess for clinical features of pesticide poisoning; interventions in the management of concurrent conditions. Mobilize family, friends and other concerned individuals or\n– Skills and knowledge to manage the airway; in particular, available community resources to monitor and support the – Use medicines that are the least hazardous, in case\nto intubate and support breathing until a ventilator can person during the imminent risk period (see “Offer and of intentional overdose. be attached; activate psychosocial support”. (2.3)\n– Give prescriptions as short courses (e.g. one week\n– Atropine and means for its intravenous (i.v.) administration Treat people who have self-harmed with the same care, at a time)."
  },
  {
    "id": 450,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "al support”. (2.3)\n– Give prescriptions as short courses (e.g. one week\n– Atropine and means for its intravenous (i.v.) administration Treat people who have self-harmed with the same care, at a time). if signs of cholinergic poisoning develop; respect and privacy given to other people, and be sensitive\nto the emotional distress associated with self-harm. – Diazepam and means for its i.v. administration if the\nperson develops seizures."
  },
  {
    "id": 451,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "elop; respect and privacy given to other people, and be sensitive\nto the emotional distress associated with self-harm. – Diazepam and means for its i.v. administration if the\nperson develops seizures. Include the carers if the person wants their support during\nassessment and treatment; if possible, the psychosocial\nConsider administering activated charcoal if the person\nassessment should include a one-to-one interview\nis conscious, gives informed consent, and presents for care\nbetween the person and the health worker, to explore\nwithin one hour of the poisoning. private issues. Forced vomiting is not recommended. Provide emotional support to carers/family members if they\nneed it. (2.4)\nOral fluids should not be given. Ensure continuity of care."
  },
  {
    "id": 452,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "the poisoning. private issues. Forced vomiting is not recommended. Provide emotional support to carers/family members if they\nneed it. (2.4)\nOral fluids should not be given. Ensure continuity of care. SELF-HARM /SUICIDE 137\n\n138\nSUI 2\nSELF HARM / SUICIDE Management\nPSYCHOSOCIAL INTERVENTIONS\n2.3 Offer and activate psychosocial 2.4 Carers support 2.5 Psychoeducation\nsupport\nInform carers and family members that asking about suicide Key messages to the person and the carers\nOffer support to the person will often help the person feel relieved, less anxious, and better\n– If one has thoughts of self-harm/suicide, seek help\nunderstood. immediately from a trusted family member, friend or health\n– Explore reasons and ways to stay alive."
  },
  {
    "id": 453,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "elieved, less anxious, and better\n– If one has thoughts of self-harm/suicide, seek help\nunderstood. immediately from a trusted family member, friend or health\n– Explore reasons and ways to stay alive. Carers and family members of people at risk of self-harm often care provider. – Focus on the person’s strengths by encouraging them to experience severe stress. Provide emotional support to them if\n– It is okay to talk about suicide. Talking about suicide does\ntalk of how earlier problems have been resolved. they need it. not provoke the act of suicide. – Consider problem-solving therapy to help people with acts Inform carers that even though they may feel frustrated\n– Suicides are preventable."
  },
  {
    "id": 454,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "resolved. they need it. not provoke the act of suicide. – Consider problem-solving therapy to help people with acts Inform carers that even though they may feel frustrated\n– Suicides are preventable. of self-harm within the last year, if sufficient human resources with the person, they should avoid hostility and severe criticism\nare available. Go to Essential care and practice ECP towards the vulnerable person at risk of self-harm/suicide. – Having an episode of self-harm/suicide is an indicator of\nsevere emotional distress. The person does not see an\nActivate psychosocial support\nalternative or a solution. Therefore, it is important to get\nthe person immediate support for emotional problems and\n– Mobilize family, friends, concerned individuals and other\nstressors."
  },
  {
    "id": 455,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "cial support\nalternative or a solution. Therefore, it is important to get\nthe person immediate support for emotional problems and\n– Mobilize family, friends, concerned individuals and other\nstressors. available resources to ensure close monitoring of the\nperson as long as the risk of self-harm/suicide persists. – Means of self-harm (e.g. pesticides, firearms, medications)\nshould be removed from the home. – Advise the person and carers to restrict access to means\nof self-harm/suicide (e.g. pesticides/toxic substances, – The social network, including the family and relevant\nprescription medications, firearms, etc.) when the person others, is important for provision of social support. has thoughts or plans of self-harm/suicide. – Optimize social support from available community\nresources."
  },
  {
    "id": 456,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "cations, firearms, etc.) when the person others, is important for provision of social support. has thoughts or plans of self-harm/suicide. – Optimize social support from available community\nresources. These include informal resources, such as\nrelatives, friends, acquaintances, colleagues and religious\nleaders or formal community resources, if available, such\nas crisis centres, and local mental health centres. SUI 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n1\n»\nMAINTAIN REGULAR CONTACT (via\ntelephone, home visits, letters or contact\nASSESS FOR IMPROVEMENT\ncards) more frequently initially (e.g. daily, weekly) for the first 2 months. » Follow-up for as long as the risk of\nIs the person improving? self-harm/suicide persists. »\nDecrease contact as the person improves."
  },
  {
    "id": 457,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "frequently initially (e.g. daily, weekly) for the first 2 months. » Follow-up for as long as the risk of\nIs the person improving? self-harm/suicide persists. »\nDecrease contact as the person improves. »\nContinue following-up for 2 years, further\ndecreasing contact according to improvement\n(e.g. once every 2-4 weeks after the initial 2 months,\nand twice in the second year). »\nIncrease intensity or duration of contact as necessary. »\nRefer to specialist as needed. 2\nROUTINELY ASSESS FOR THOUGHTS AND\nPLANS OF SELF-HARM/SUICIDE\n»\nAt every contact, routinely assess for suicidal thoughts and plans. Is the risk of self-harm/suicide imminent? See SUI 1 (Assessment)."
  },
  {
    "id": 458,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "2\nROUTINELY ASSESS FOR THOUGHTS AND\nPLANS OF SELF-HARM/SUICIDE\n»\nAt every contact, routinely assess for suicidal thoughts and plans. Is the risk of self-harm/suicide imminent? See SUI 1 (Assessment). SELF-HARM /SUICIDE 139\n\n140\nSELF HARM / SUICIDE\n\nOTHER SIGNIFICANT\nMENTAL HEALTH COMPLAINTS\nThis module aims to provide basic guidance on management Other mental health complaints are considered significant\nof a range of mental health complaints not covered elsewhere in when they impair daily functioning or when the person seeks\nthis guide. Some of these complaints may be similar to depression, help for them. Other mental health complaints can be due\nbut upon closer examination are distinct from the conditions to stress. covered in this guide."
  },
  {
    "id": 459,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "f these complaints may be similar to depression, help for them. Other mental health complaints can be due\nbut upon closer examination are distinct from the conditions to stress. covered in this guide. T his module should not be considered for people who meet the criteria for any of the mhGAP priority conditions (except self-harm). T his module should only be used after explicitly ruling out depression. »\nThis module should be used when helping adults. In case the person is a child or adolescent, go to CMH. OTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS 141\n\n142\nOTH\nOTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS\nOTH Quick Overview\nASSESSMENT MANAGEMENT\nR ule out physical causes that would fully Management Protocols\nexplain the presenting symptoms\n1. Other significant mental health complaints\n2."
  },
  {
    "id": 460,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "LTH COMPLAINTS\nOTH Quick Overview\nASSESSMENT MANAGEMENT\nR ule out physical causes that would fully Management Protocols\nexplain the presenting symptoms\n1. Other significant mental health complaints\n2. Other significant mental health complaints in\nRule out depression or other MNS conditions\npeople exposed to extreme stressors\nAssess if the person is seeking help to\nrelieve symptoms or has considerable\ndifficulty with daily functioning\nAssess if the person has been exposed to FOLLOW-UP\nextreme stressors\nAssess if there is imminent risk of\nself-harm/suicide\n\nAss\nO\ne\nT\nss\nH\nm\n1\ne nt\nAssessment\nCOMMON PRESENTATIONS OF OTHER SIGNIFICANT\nMENTAL HEALTH COMPLAINTS\nF eeling extremely tired, depressed, irritated, anxious or stressed. M edically unexplained somatic complaints (i.e."
  },
  {
    "id": 461,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e nt\nAssessment\nCOMMON PRESENTATIONS OF OTHER SIGNIFICANT\nMENTAL HEALTH COMPLAINTS\nF eeling extremely tired, depressed, irritated, anxious or stressed. M edically unexplained somatic complaints (i.e. somatic symptoms that do not have a\nknown physical cause that fully explains the symptom). 1\nIs there a physical cause that fully explains the presenting symptoms? Manage any physical cause identified and\nrecheck to see if the symptoms persist. 2\nIs this depression or another MNS condition discussed\nin another module of this guide? Go to relevant module."
  },
  {
    "id": 462,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "mptoms? Manage any physical cause identified and\nrecheck to see if the symptoms persist. 2\nIs this depression or another MNS condition discussed\nin another module of this guide? Go to relevant module. OTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS 143\n\n144\nOTH 1\nOTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS Assessment\n3\nIs the person seeking help to relieve symptoms or having considerable\ndifficulty with daily functioning because of their symptoms? No treatment needed. OTHER SIGNIFICANT\nMENTAL HEALTH COMPLAINTS are likely\n4\nHas the person been exposed to extreme stressors? (e.g."
  },
  {
    "id": 463,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "erable\ndifficulty with daily functioning because of their symptoms? No treatment needed. OTHER SIGNIFICANT\nMENTAL HEALTH COMPLAINTS are likely\n4\nHas the person been exposed to extreme stressors? (e.g. physical or sexual violence, major accidents, bereavement\nor other major losses)\nGo to PROTOCOL 1 and 2\nGo to PROTOCOL 1\nIF THERE IS IMMINENT RISK OF SUICIDE,\nASSESS AND MANAGE before continuing\nto Protocol 1 and 2 (Go to » SUI). OTH 2 Management\nPROTOCOL\n1\nOTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS\n»\nDO NOT prescribe anti-anxiety or antidepressant medicines – Inform the person that no serious disease has been identified. Communicate the\n(unless advised by a specialist). normal clinical and test findings."
  },
  {
    "id": 464,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "prescribe anti-anxiety or antidepressant medicines – Inform the person that no serious disease has been identified. Communicate the\n(unless advised by a specialist). normal clinical and test findings. » – If the person insists on further investigations, consider saying that performing\nDO NOT give vitamin injections or other ineffective treatments. unnecessary investigations can be harmful because they can cause unnecessary\n» In all cases, reduce stress and strengthen social supports as worry and side-effects. described in Essential care and practice (ECP). – Acknowledge that the symptoms are not imaginary and that it is still important to\naddress symptoms that cause significant distress. – Address current psychosocial stressors."
  },
  {
    "id": 465,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "care and practice (ECP). – Acknowledge that the symptoms are not imaginary and that it is still important to\naddress symptoms that cause significant distress. – Address current psychosocial stressors. – Ask the person for their own explanation of the cause of their symptoms, and\n– Strengthen supports. ask about their concerns. This may give clues about the source of distress, help build a\n– Teach stress management such as relaxation techniques (see Box 1 at end of module). trusting relationship with the person and increase the person’s adherence to treatment."
  },
  {
    "id": 466,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "of distress, help build a\n– Teach stress management such as relaxation techniques (see Box 1 at end of module). trusting relationship with the person and increase the person’s adherence to treatment. »\nWhen no physical condition is identified that fully explains a presenting – Explain that emotional suffering/stress often involves the experience of bodily\nsomatic symptom, acknowledge the reality of the symptoms and provide sensations, such as stomach aches, muscle tension, etc. Ask for and discuss\npossible explanations. potential links between the person’s emotions/stress and symptoms. – Avoid ordering more laboratory or other investigations unless there is a clear – Encourage continuation of (or gradual return to) daily activities. medical indication, e.g. abnormal vital signs."
  },
  {
    "id": 467,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ms. – Avoid ordering more laboratory or other investigations unless there is a clear – Encourage continuation of (or gradual return to) daily activities. medical indication, e.g. abnormal vital signs. – Remember to apply the practice of reducing stress and strengthening social\n– In case a further investigation is ordered anyway, reduce unrealistic expectations support. Go to » ECP. by telling the person that the expected result is likely to be normal. OTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS 145\n\n146\nOTH 2\nOTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS Management\nPROTOCOL\n2\nOTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS\nIN PEOPLE EXPOSED TO EXTREME STRESSORS\n(e.g."
  },
  {
    "id": 468,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "IFICANT MENTAL HEALTH COMPLAINTS 145\n\n146\nOTH 2\nOTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS Management\nPROTOCOL\n2\nOTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS\nIN PEOPLE EXPOSED TO EXTREME STRESSORS\n(e.g. physical or sexual violence, major accidents, bereavement or other major loss)\n»\nIn all cases, whether or not the person presents with emotional, physical or\n– In most cases, grief will diminish over time. One may think that the sadness, yearning\nbehavioural problems after exposure to an extreme stressor, provide support\nor pain one feels will never go away, but in most cases, these feelings lessen over time. as described in PROTOCOL 1. Listen carefully. Sometimes a person may feel fine for a while, then something reminds them of the\n» loss and they may feel as bad as they did at first."
  },
  {
    "id": 469,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "s lessen over time. as described in PROTOCOL 1. Listen carefully. Sometimes a person may feel fine for a while, then something reminds them of the\n» loss and they may feel as bad as they did at first. There is no right or wrong way to\nDO NOT pressure the person to talk about the event. feel grief. Sometimes one might feel very sad, other times numb, and at other times\n» one might be able to enjoy oneself. These experiences usually become less intense\nAddress the person’s social needs. and less frequent over time. – Ask the person about his/her needs and concerns. »\nIn case of the loss of a loved one, discuss and support culturally appropriate\n– Help the person to address basic needs, access services and connect with family\nadjustment and/or mourning processes. and other social supports."
  },
  {
    "id": 470,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "loved one, discuss and support culturally appropriate\n– Help the person to address basic needs, access services and connect with family\nadjustment and/or mourning processes. and other social supports. – Ask if appropriate mourning ceremonies/rituals have happened or been planned. – Protect the person from (further) harm, if needed. If this is not the case, discuss the obstacles and how to address them. – Encourage the person to return to previous, normal activities, e.g. at school\n»\nor work, at home, and socially, if it is feasible and culturally appropriate. If prolonged grief disorder is suspected, consult a specialist for further\nassessment and management."
  },
  {
    "id": 471,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "es, e.g. at school\n»\nor work, at home, and socially, if it is feasible and culturally appropriate. If prolonged grief disorder is suspected, consult a specialist for further\nassessment and management. »\nIn case of any major loss explain that:\n– The person may have prolonged grief disorder if the symptoms involve\n– It is normal to grieve for any major loss. One can grieve for a person, a place, or\nconsiderable difficulty with daily functioning for at least 6 months and include\nproperty or the loss of one’s own health and wellbeing. Grief has both mental and\nsevere preoccupation with or intense longing for the deceased person\nphysical effects. accompanied by intense emotional pain. – People grieve in different ways. Some people show strong emotions while others do\nnot."
  },
  {
    "id": 472,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "pation with or intense longing for the deceased person\nphysical effects. accompanied by intense emotional pain. – People grieve in different ways. Some people show strong emotions while others do\nnot. Crying does not mean one is weak. People who do not cry may feel the emotional\npain just as deeply but have other ways of expressing it. » »\nIn the case of reactions to recent exposure to a potentially If post-traumatic stress disorder (PTSD) is suspected, consult a specialist\ntraumatic event, explain that: for further assessment and management. – People often have reactions after such events. The reactions may be highly variable – After a potentially traumatic event, the person may have PTSD if the symptoms\nfrom person to person and change over time."
  },
  {
    "id": 473,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "often have reactions after such events. The reactions may be highly variable – After a potentially traumatic event, the person may have PTSD if the symptoms\nfrom person to person and change over time. involve considerable difficulty with daily functioning for at least 1 month and\ninclude recurring frightening dreams, flashbacks or intrusive memories of the\n– They can include somatic symptoms such as palpitations, aches and pains, gastric\nevents accompanied by intense fear or horror; deliberate avoidance of reminders\nupset, and headaches and emotional and behavioural symptoms that include sleep\nof the event; excessive concern and alertness to danger or reacting strongly to\ndisturbance, sadness, anxiety, irritation and aggression. loud noises or unexpected movements."
  },
  {
    "id": 474,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "mptoms that include sleep\nof the event; excessive concern and alertness to danger or reacting strongly to\ndisturbance, sadness, anxiety, irritation and aggression. loud noises or unexpected movements. – Such feelings can be exacerbated or can reappear when reminders of the stressful\nevent or new stressors occur. – In most cases the symptoms are likely to diminish over time, particularly if the\nperson gets rest, social support, and engages in stress reduction. Go to » ECP. Go to Box 1. OTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS 147\n\n148\nOTH 3\nOTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS Follow-up\nOTH 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n»\nAsk the person to return in\n2-4 weeks if their symptoms do\nnot improve or if, at any time,\ntheir symptoms worsen."
  },
  {
    "id": 475,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "HEALTH COMPLAINTS Follow-up\nOTH 3 Follow-up\nRECOMMENDATIONS ON\nFREQUENCY OF CONTACT\n»\nAsk the person to return in\n2-4 weeks if their symptoms do\nnot improve or if, at any time,\ntheir symptoms worsen. ASSESS FOR IMPROVEMENT\nIs the person improving? If the person is not improving or the person or\n»\nContine with treatment plan\nthe carer insists on further investigations and\n»\nFollow-up as needed treatment:\n»\nReview Protocols 1 and 2\n»\nConsider consulting a specialist. BOX 1: RELAXATION TRAINING INSTRUCTIONS\n» »\nExplain what you will be doing. F ocus on breathing techniques. “I am going to teach you how to breathe in a way that will help relax your “Try to breathe from your stomach with me. Remember, we start by\nbody and your mind."
  },
  {
    "id": 476,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e doing. F ocus on breathing techniques. “I am going to teach you how to breathe in a way that will help relax your “Try to breathe from your stomach with me. Remember, we start by\nbody and your mind. It will take some practice before you feel the full breathing out until all the air is out; then breathe in. If you can, breathe in\nbenefits of this breathing technique. The reason this strategy focuses on through your nose and out through your mouth. The second step is to slow\nbreathing is because when we feel stressed our breathing becomes fast and the rate of your breathing down. Take three seconds to breathe in, two\nshallow, making us feel more tense. To begin to relax, you need to start by seconds to hold your breath, and three seconds to breathe out."
  },
  {
    "id": 477,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "of your breathing down. Take three seconds to breathe in, two\nshallow, making us feel more tense. To begin to relax, you need to start by seconds to hold your breath, and three seconds to breathe out. I will count\nchanging your breathing. Before we start, we will relax the body.” with you. You may close your eyes or keep them open. Slowly breathe in, 1,\n2, 3. Hold, 1, 2. Now breathe out, 1, 2, 3.” Repeat this breathing exercise for\n»\nSlowly start relaxation exercises and demonstrate breathing. approximately one minute, rest for one minute then repeat the cycle two\nmore times. “Gently shake and loosen your arms and legs. Let them go floppy and loose. Roll your shoulders back and gently move your head from side to side. »\nE ncourage self-practice."
  },
  {
    "id": 478,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "t the cycle two\nmore times. “Gently shake and loosen your arms and legs. Let them go floppy and loose. Roll your shoulders back and gently move your head from side to side. »\nE ncourage self-practice. Now place one hand on your belly and the other hand on your upper chest. I\nwant you to imagine you have a balloon in your stomach and when you “Try on your own for one minute. This is something you can practice\nbreathe in you are going to blow that balloon up, so your stomach will on your own.”\nexpand. And when you breathe out, the air in the balloon will also go out,\nso your stomach will flatten. Watch me first. I am going to exhale first to\nget all the air out of my stomach.” Demonstrate breathing from the stomach –\ntry to exaggerate the pushing out, and pulling in, of your stomach."
  },
  {
    "id": 479,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "flatten. Watch me first. I am going to exhale first to\nget all the air out of my stomach.” Demonstrate breathing from the stomach –\ntry to exaggerate the pushing out, and pulling in, of your stomach. OTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS 149\n\n150\nOTHER SIGNIFICANT MENTAL HEALTH COMPLAINTS\n\nIMPLEMENTATION OF mhGAP-IG\nIMPLEMENTATION OF mhGAP-IG 151\n\n152\nIMP\nIMPLEMENTATION OF mhGAP-IG\nmhGAP-IG implementation process\nA number of actions are recommended to programme planners to\nimplement this guide in non-specialized health care settings. This can\nbe summarized in the following diagram which includes a number\nof essential actions and continuous activities. This module provides IMPLEMENTATION\nan overview of the mhGAP-IG implementation process."
  },
  {
    "id": 480,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "n\nbe summarized in the following diagram which includes a number\nof essential actions and continuous activities. This module provides IMPLEMENTATION\nan overview of the mhGAP-IG implementation process. PLAN\n3\n3\n4 ADAPTATION\nPROVISION OF\n4\nTREATMENT & CARE\nINTERSECTORAL\nCOLLABORATION\n1 ESTABLISH mhGAP-IG SITUATION 2 2\nIMPLEMENTATION TEAM ANALYSIS ADVOCACY &\nAWARENESS RAISING\n5 TRAINING &\nSUPERVISION\n6\nMONITORING &\nEVALUATION\n\n11."
  },
  {
    "id": 481,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "N OF\n4\nTREATMENT & CARE\nINTERSECTORAL\nCOLLABORATION\n1 ESTABLISH mhGAP-IG SITUATION 2 2\nIMPLEMENTATION TEAM ANALYSIS ADVOCACY &\nAWARENESS RAISING\n5 TRAINING &\nSUPERVISION\n6\nMONITORING &\nEVALUATION\n\n11. Establish mhGAP-IG 2 Situation analysis 3 mhGAP-IG implementation plan\nimplementation team\nThe main objective of the situation analysis is to inform the Based on the situation analysis, develop a plan for mhGAP-IG\nplanning, adaptation and implementation process regarding implementation to answer the following questions:\nIt may be necessary to have one or more teams depending\nresources and needs for MNS conditions. This process involves\nupon the geographical area/regions to be covered. WHERE\ndesk reviews, e.g."
  },
  {
    "id": 482,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "stions:\nIt may be necessary to have one or more teams depending\nresources and needs for MNS conditions. This process involves\nupon the geographical area/regions to be covered. WHERE\ndesk reviews, e.g. checking WHO Mental Health Atlas Country\nClearly delineate the purpose and terms of reference of the Profile, the WHO Assessment Instrument for Mental Health\nWhere will mhGAP-IG be implemented, (e.g. facilities,\nimplementation teams and develop a work plan for each of Systems (AIMS) report or already existing assessments, and\ndistricts, cities)? the team/s members. One of the key functions of this team is interviews and group discussions with multiple stakeholders to\nto oversee the implementation process."
  },
  {
    "id": 483,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "assessments, and\ndistricts, cities)? the team/s members. One of the key functions of this team is interviews and group discussions with multiple stakeholders to\nto oversee the implementation process. answer the following questions: WHEN\nBuild upon any existing body or group rather than What kind of needs and resource assessments must be done When will each of the mhGAP-IG activities be implemented,\nestablishing a new one, for example, a health committee first? What is already known? (e.g. timeline for adaptation, training of trainers, training\nor community advisory group. Sometimes there is more activities, supervision and advocacy activities)? What are the national policies pertaining to mental health,\nthan one group."
  },
  {
    "id": 484,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "of trainers, training\nor community advisory group. Sometimes there is more activities, supervision and advocacy activities)? What are the national policies pertaining to mental health,\nthan one group. Merging groups or establishing a new\nthe staff capacities in the country/region and organizations\ngroup with the participation of members from all of them WHAT\nproviding mental health services? could be a solution. What are the resources needed and available for mhGAP-IG\nWhat are the belief systems and care seeking behaviours\nMembers of the implementation team should include at least implementation, including financial and human resources\naround mental health in the country/region? one member of each of the following categories: civil society and infrastructure, (e.g."
  },
  {
    "id": 485,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ude at least implementation, including financial and human resources\naround mental health in the country/region? one member of each of the following categories: civil society and infrastructure, (e.g. facilities, medication supply)? and service users, policy makers, actual and potential financial What potential barriers exist in relation to implementation\nsupporters or donors, programme managers, service providers of mhGAP-IG exist, for example, stigma and discrimination WHO\nand communication officers. towards people with MNS conditions, national health\nWho will be trained and what knowledge and skills do they\npriorities that supersede MNS conditions, etc. Form smaller action groups or task forces to focus on specific already have, (e.g."
  },
  {
    "id": 486,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ional health\nWho will be trained and what knowledge and skills do they\npriorities that supersede MNS conditions, etc. Form smaller action groups or task forces to focus on specific already have, (e.g. the skills and knowledge that PHC nurses\nactivities, e.g. an action group to implement training and physicians already have), and who will be responsbile for\nactivities and another to implement advocacy & awareness each activity, (e.g. who will train and supervise)? raising activities. Always clearly identify the functions of a\nHOW\ntask force and the role of each of its member. How can you improve communication and referral pathways\nacross different levels of the system, while also introducing\nthe new service?"
  },
  {
    "id": 487,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "functions of a\nHOW\ntask force and the role of each of its member. How can you improve communication and referral pathways\nacross different levels of the system, while also introducing\nthe new service? How can you collect data on mhGAP-IG implementation\nactivities and integrate it into health information system\nindicators? IMPLEMENTATION OF mhGAP-IG 153\n\n154\nIMP\nIMPLEMENTATION OF mhGAP-IG\n14. Adaptation 15."
  },
  {
    "id": 488,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "you collect data on mhGAP-IG implementation\nactivities and integrate it into health information system\nindicators? IMPLEMENTATION OF mhGAP-IG 153\n\n154\nIMP\nIMPLEMENTATION OF mhGAP-IG\n14. Adaptation 15. mhGAP-IG training & supervision\nmhGAP-IG adaptation is the process of deciding on and Method of mhGAP-IG adaptation: An important aspect of mhGAP-IG implementation is the\nproducing the changes needed in the mhGAP-IG, its training training of healthcare providers working in non-specialist\nmaterials, monitoring & evaluation (M&E) tools and other tools Organize a workshop with a group of different stakeholders settings to deliver interventions as front line personnel, along\nto fit a particular country or district context."
  },
  {
    "id": 489,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "(M&E) tools and other tools Organize a workshop with a group of different stakeholders settings to deliver interventions as front line personnel, along\nto fit a particular country or district context. to contextualize and adapt the mhGAP-IG, its training with mechanisms to ensure their continued support and super-\nmaterials and M&E and other tools. vision. Although the intervention guide is to be implemented\nPurpose of mhGAP-IG adaptation: primarily by non-specialists, it requires coordinated effort by\nInclude experts representing relevant disciplines, (e.g. specialists and public health experts to ensure its optimum\npsychiatry, addiction, neurology, paediatrics, social work\nTo make it feasible to implement the guide including its delivery."
  },
  {
    "id": 490,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "iplines, (e.g. specialists and public health experts to ensure its optimum\npsychiatry, addiction, neurology, paediatrics, social work\nTo make it feasible to implement the guide including its delivery. and psychology), people representing different levels of\nassessment and management components through the local\ngeneral health care, (e.g. public health practitioners, primary The objective of mhGAP-IG training is to teach non-specialist\nhealth system. health care providers, family medicine specialists, nurses, healthcare providers the skills and knowledge needed to assess\npharmacists, health information system practitioners), and manage people with priority MNS conditions. The duration\nTo ensure that the guide is acceptable in the local socio-\nservice users and policy makers."
  },
  {
    "id": 491,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ists, health information system practitioners), and manage people with priority MNS conditions. The duration\nTo ensure that the guide is acceptable in the local socio-\nservice users and policy makers. of training depends on the local adaptations made, as well as on\ncultural context. the knowledge and skills that non-specialist healthcare providers\nUse the situation analyses conducted for the regions in\nTo use local terms to improve communication with users already have. Usually this training process takes several full days\nwhich mhGAP-IG will be implemented. and carers. and can be conducted face-to-face or via e-learning, depending\nEnsure that the adaptation process is in line with national on feasibility. To clarify referral pathways. documents, (e.g."
  },
  {
    "id": 492,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "d. and carers. and can be conducted face-to-face or via e-learning, depending\nEnsure that the adaptation process is in line with national on feasibility. To clarify referral pathways. documents, (e.g. the national health policy, legislation and\nThe training structure can follow a cascade plan with two levels:\nTo make materials consistent with relevant national plan, clinical protocols and guidelines used in general/\na master facilitator trains ‘trainers’ who then train the non-\ntreatment guidelines and policies, as appropriate. primary health care and the national medicine list). specialist front-line healthcare providers. To provide a basis for the development of appropriate\ntraining programmes and tools. To ensure M&E indicators are in line with national health\ninformation systems."
  },
  {
    "id": 493,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ist front-line healthcare providers. To provide a basis for the development of appropriate\ntraining programmes and tools. To ensure M&E indicators are in line with national health\ninformation systems. mhGAP-IG train the trainers: mhGAP-IG support & supervison: Ensure that the supply of medicine, medical equipment and\nother support systems for mhGAP-IG implementation are\nThe objective is to ensure that trainers are skilled and confident Participants in the mhGAP-IG training course (mhGAP-IG operational. trainees) are usually non-specialized health care staff working in\nin their ability to train non-specialist healthcare providers and\nDemonstrate and encourage respectful, non-judgmental\nprimary or secondary health care clinics/hospitals."
  },
  {
    "id": 494,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "health care staff working in\nin their ability to train non-specialist healthcare providers and\nDemonstrate and encourage respectful, non-judgmental\nprimary or secondary health care clinics/hospitals. They require\nact as informed resources for these providers. attitudes and ethical treatment that promotes and protects\nongoing help to transfer what they have learned in training to\nthe human rights of individuals with MNS conditions. their clinical practices. Supervision is seen as part of the\nmhGAP-IG trainers/supervisors should have the\nfollowing characteristics: continuum of education required to create competent mhGAP Provide support to healthcare providers experiencing stress. health care providers."
  },
  {
    "id": 495,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ers/supervisors should have the\nfollowing characteristics: continuum of education required to create competent mhGAP Provide support to healthcare providers experiencing stress. health care providers. Support and supervision not only aims\nBe specialists in MNS health care (psychiatrist, psychiatric to assist mhGAP-IG trainees to deliver improved mental health\nnurse, neurologist, etc.), physicians or nurses trained and care (clinical supervision) but also provides support in the work\nexperienced in managing MNS conditions using mhGAP-IG, environment related to mhGAP-IG implementation (administra-\nand/or existing supervisors for the general health system. tive and program supervision). Have clinical skills and experience in mental health and/or\nmanagement of MNS conditions."
  },
  {
    "id": 496,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ntation (administra-\nand/or existing supervisors for the general health system. tive and program supervision). Have clinical skills and experience in mental health and/or\nmanagement of MNS conditions. Specific goals of support & supervision:\nHave skills and experience with administrative aspects\nof managing MNS conditions, including record keeping, Assist in the transfer of skills and knowledge from the\nfollow-up and referral. mhGAP-IG training into clinical practice. Be good facilitators and problem-solvers. Ensure adequate delivery of mental health interventions that\nin line with mhGAP-IG and address areas for further skills\nAvailable for support and supervision, including regular\ndevelopment. supervisory visits."
  },
  {
    "id": 497,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "equate delivery of mental health interventions that\nin line with mhGAP-IG and address areas for further skills\nAvailable for support and supervision, including regular\ndevelopment. supervisory visits. Identify and assist with problems faced by mhGAP-IG\nThe training agenda: trainees in managing complicated clinical situations. The trainers are expected to conduct future mhGAP-IG training\nHelp motivate non-specialized health care workers to provide\ncourses and provide support and supervision to health care\ngood quality care for people with MNS conditions. providers."
  },
  {
    "id": 498,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e mhGAP-IG training\nHelp motivate non-specialized health care workers to provide\ncourses and provide support and supervision to health care\ngood quality care for people with MNS conditions. providers. Apart from training in the assessment and manage-\nment of people with MNS conditions, as described in the Ensure necessary records and administrative procedures\nmhGAP-IG, they will learn about methods of training, planning for MNS conditions, such as referrals and follow-up, are\nof curricula, methods of supervision and quality assurance. established and/or integrated into existing systems at the\nlocal health care facilities. IMPLEMENTATION OF mhGAP-IG 155\n\n156\nIMP\nIMPLEMENTATION OF mhGAP-IG\n16."
  },
  {
    "id": 499,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ds of supervision and quality assurance. established and/or integrated into existing systems at the\nlocal health care facilities. IMPLEMENTATION OF mhGAP-IG 155\n\n156\nIMP\nIMPLEMENTATION OF mhGAP-IG\n16. Monitoring & Evaluation\nMonitoring and Evaluation (M&E) can provide information about Evaluate the mhGAP-IG implementation process, identify There are four main groups of medications that target priority\nwhether a programme is making a difference and for whom; it can successes as well as needs for improvement and update the MNS conditions mentioned in this guide:\nidentify programme areas that are on target or aspects of a pro- situation analysis. antipsychotics for psychotic disorders;\ngramme that need to be adjusted."
  },
  {
    "id": 500,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "he MNS conditions mentioned in this guide:\nidentify programme areas that are on target or aspects of a pro- situation analysis. antipsychotics for psychotic disorders;\ngramme that need to be adjusted. Information gained from M&E\ncan demonstrate to programme implementers and funders that drugs used in mood disorders (depressive or bipolar);\nIn addition to the six actions described above, there are three\ntheir investments are paying off. M&E provides vital information\ncontinuous activities that form an essential part of mhGAP-IG anticonvulsants/antiepileptics;\nfor learning from past experiences, improving service delivery,\nimplementation. These are described in the sections below."
  },
  {
    "id": 501,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ities that form an essential part of mhGAP-IG anticonvulsants/antiepileptics;\nfor learning from past experiences, improving service delivery,\nimplementation. These are described in the sections below. planning, resource allocation and demonstrating results as part medications used for management of substance withdrawal,\nof accountability to key stakeholders. The phrase, “what gets intoxication or dependence . A. PROVISION OF TREATMENT AND CARE:\nmeasured gets done,” summarises the importance of monitoring\nThe experiences of many countries demonstrate that\n& evaluation in programme planning and implementation. The mhGAP-IG recommends a number of pharmacological and\nimprovements in the supply and use of medicines are possible."
  },
  {
    "id": 502,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "countries demonstrate that\n& evaluation in programme planning and implementation. The mhGAP-IG recommends a number of pharmacological and\nimprovements in the supply and use of medicines are possible. psychological interventions be provided by non-specialised health\nAccess of populations to essential medicines are determined by:\nM&E involves planning, coordinating, collecting, analysing care providers. It recommends, for example, problem solving\n(i) a rational selection of medicines; (ii) making prices affordable;\nand using data from national, district and local levels, including therapy (PST) and Interpersonal Therapy (IPT) for adult depression."
  },
  {
    "id": 503,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "a rational selection of medicines; (ii) making prices affordable;\nand using data from national, district and local levels, including therapy (PST) and Interpersonal Therapy (IPT) for adult depression. (iii) ensuring sustainable financing; and (iv) availability of reliable\nhealth facilities and mhGAP-IG facilitators, trainees and super- WHO has developed psychological interventions in simplified\nhealth and supply systems. visors; therefore, it will be helpful if the mhGAP-IG implemen- form. These are scalable interventions and their delivery requires\ntation team appoints a M&E coordinator or sub-committee a less intense level of specialist human resource use. It means\nto plan and carry this out. that the intervention has been modified to use fewer resources B."
  },
  {
    "id": 504,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ppoints a M&E coordinator or sub-committee a less intense level of specialist human resource use. It means\nto plan and carry this out. that the intervention has been modified to use fewer resources B. ADVOCACY AND AWARENESS RAISING:\ncompared with conventional psychological interventions and that\nSome examples of indicators that can be used to monitor people with and without previous training in mental health care Mental health advocacy uses information in deliberate and\nmhGAP-IG implementation are: facility-level indicators, e.g. number can effectively deliver low-intensity versions of PST and IPT as strategic ways to influence others to create change. It involves\nof non-specialist health care providers trained on mhGAP-IG, long as they are trained and supervised."
  },
  {
    "id": 505,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ensity versions of PST and IPT as strategic ways to influence others to create change. It involves\nof non-specialist health care providers trained on mhGAP-IG, long as they are trained and supervised. Examples of WHO the promotion of the needs and rights of people with mental\nnumber of support and supervisory visits to each health facility scalable psychological interventions manuals which are part of disorders, as well as that of the general population. Advocacy is\nimplementing mhGAP-IG; and system-level indicators, e.g. number the mhGAP package include: the WHO Problem Management different from education. Education informs and helps create\nof health facilities using mhGAP-IG to assess and manage persons Therapy PM+ manual, the WHO Interpersonal Therapy manual understanding of an issue."
  },
  {
    "id": 506,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "from education. Education informs and helps create\nof health facilities using mhGAP-IG to assess and manage persons Therapy PM+ manual, the WHO Interpersonal Therapy manual understanding of an issue. Advocacy, on the other hand, aims to\nwith MNS conditions, number of health facilities with an (IPT), the WHO Thinking Healthy manual for maternal depression, persuade. This is done through requests and calls for specific\nuninterrupted supply of essential medicines for MNS conditions. and the WHO Parental Skills training manual. actions. One basic principle is that advocacy is only effective\nwhen the target audience is asked to do something."
  },
  {
    "id": 507,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "essential medicines for MNS conditions. and the WHO Parental Skills training manual. actions. One basic principle is that advocacy is only effective\nwhen the target audience is asked to do something. Mobilizing\nEnsure that the indicators are part of the national health Essential medicines can be used to treat symptoms of MNS people means asking them to become part of the solution. information system. Collecting data using indicators will assist in conditions, to shorten the course of many disorders, reduce\nmonitoring mhGAP-IG. They will also assist in reporting on disability and prevent relapse. Essential medicines are part of the\nnational mental health every two years to the WHO Mental WHO Model Lists of Essential Medicines."
  },
  {
    "id": 508,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ey will also assist in reporting on disability and prevent relapse. Essential medicines are part of the\nnational mental health every two years to the WHO Mental WHO Model Lists of Essential Medicines. Access to essential\nHealth Atlas, to monitor progress on implementation of the medicines is a component of “the right to [the highest attainable\nMental Health Action Plan 2013-2020. standard of] health.”\n\nExamples of advocacy actions C."
  },
  {
    "id": 509,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "monitor progress on implementation of the medicines is a component of “the right to [the highest attainable\nMental Health Action Plan 2013-2020. standard of] health.”\n\nExamples of advocacy actions C. NETWORKING AND INTERSECTORAL To facilitate efficient collaboration between these\nCOLLABORATION: groups, it is important to:\nAdvocacy actions within the general population:\nEnsure that members of the mhGAP-IG implementation\nmhGAP-IG implementation requires collaboration amongst\nInclude and mobilize people with MNS conditions and their team have clear roles and functions. various sectors and stakeholders, such as:\ncarers in the advocacy actions."
  },
  {
    "id": 510,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "requires collaboration amongst\nInclude and mobilize people with MNS conditions and their team have clear roles and functions. various sectors and stakeholders, such as:\ncarers in the advocacy actions. Ensure that the community\nPrepare a list of resources and benefits to help non-\nhas direct and positive social contact with people with\nSpecialist and non-specialist health services and\nspecialized health care staff make meaningful links for those\nMNS conditions. care-providers: e.g. psychologists, community health\nwith mhGAP priority conditions, their carers and other family\nUse the media to increase awareness of mental health issues, workers, social workers,inpatient or outpatient service\nmembers by gathering information from the situational\ne.g."
  },
  {
    "id": 511,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "carers and other family\nUse the media to increase awareness of mental health issues, workers, social workers,inpatient or outpatient service\nmembers by gathering information from the situational\ne.g. through public announcements, magazine features and providers, outreach care workers. analysis and regularly updating the list based on new\nannouncement at health centers, while at same time\nService users: e.g. groups or individuals living with the information. emphasizing the need for responsible reporting, particularly\nsame condition, family members with the same condition or\nregarding suicide. caring for someone with the same condition (after seeking\nProvide education about mental health issues in public consent from all those involved). places (e.g. schools, health care centers)."
  },
  {
    "id": 512,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "suicide. caring for someone with the same condition (after seeking\nProvide education about mental health issues in public consent from all those involved). places (e.g. schools, health care centers). Family and friends: Identify the person’s prior social\nHold public events and lectures around mental health themes. activities that, if reinitiated, would have the potential for\nproviding direct or indirect psychological and social support\nAdvocacy actions with health and mental health workers: (e.g. family gatherings, outings with friends, visiting neighbors,\nsocial activities at work sites, sports, community activities)\nPromote an understanding of the importance of community\nand encourage the person to resume these activities."
  },
  {
    "id": 513,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "friends, visiting neighbors,\nsocial activities at work sites, sports, community activities)\nPromote an understanding of the importance of community\nand encourage the person to resume these activities. care, community participation and human rights of people\naffected with MNS conditions. Informal community supports: e.g. spiritual groups,\nProvide adequate training and support to mental health and saving groups, recreational groups, women groups, youth\ngeneral health workers. support groups, cultural groups, self-help groups, helplines. Education and employment: e.g. schools, education, income\ngenerating or vocational training programmmes."
  },
  {
    "id": 514,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ps, youth\ngeneral health workers. support groups, cultural groups, self-help groups, helplines. Education and employment: e.g. schools, education, income\ngenerating or vocational training programmmes. Specifically,\nsuicide prevention programmes in school settings that include\nmental health awareness training and skills training to reduce\nsuicide attempts and suicide deaths among adolescent students. Non-governmental organizations: e.g. legal aid, child\nprotection services, gender based violence programmes or\npsychosocial support programmes. Government services and benefits: e.g. public justice systems,\nchild welfare, pension, disability, transportation discounts."
  },
  {
    "id": 515,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "vices, gender based violence programmes or\npsychosocial support programmes. Government services and benefits: e.g. public justice systems,\nchild welfare, pension, disability, transportation discounts. IMPLEMENTATION OF mhGAP-IG 157\n\n158\nIMP\nIMPLEMENTATION OF mhGAP-IG\n\nGLOSSARY\n159\n\n160\nGLOSSARY\nTERM DEFINITION TERM DEFINITION\nActivities of daily living A concept of functioning – activities of daily living are basic activities Ataxia Failure of muscular coordination. People with ataxia have problems\n(ADLs) that are necessary for independent living, including eating, bathing and with coordination because parts of the nervous system that control\ntoileting. This concept has several assessment tools to determine an movement and balance are affected."
  },
  {
    "id": 516,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "including eating, bathing and with coordination because parts of the nervous system that control\ntoileting. This concept has several assessment tools to determine an movement and balance are affected. Ataxia may affect the fingers,\nindividual’s ability to perform the activity with or without assistance. hands, arms, legs, body, speech, and eye movements. Agitation Marked restlessness and excessive motor activity, accompanied by Autism spectrum An umbrella term that covers conditions such as autism, childhood\nanxiety. disorders disintegration disorder and Asperger’s syndrome. Agranulocytosis A blood disorder in which there is an absence of granulocytes Autonomy The perceived ability to control, cope with and make personal\n(a type of white blood cell)."
  },
  {
    "id": 517,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Asperger’s syndrome. Agranulocytosis A blood disorder in which there is an absence of granulocytes Autonomy The perceived ability to control, cope with and make personal\n(a type of white blood cell). It is an acute condition involving a severe decisions about how one lives on a daily basis, according to one’s\nand dangerous leukopenia, also known as drug-induced secondary own rules and preferences. agranulocytosis. Behavioural activation Psychological treatment that focuses on improving mood by engaging\nAkathisia A subjective sense of restlessness, often accompanied by observed again in activities that are task-oriented and used to be enjoyable, in\nexcessive movements (e.g. fidgety movements of the legs, rocking spite of current low mood."
  },
  {
    "id": 518,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "sness, often accompanied by observed again in activities that are task-oriented and used to be enjoyable, in\nexcessive movements (e.g. fidgety movements of the legs, rocking spite of current low mood. It may be used as a stand-alone treatment,\nfrom foot to foot, pacing, inability to sit or stand still). and it is also a component of cognitive behavioural therapy. Akinesia The absence or lack of voluntary movement. A state of difficulty in Bereavement A process of loss, grief and recovery, usually associated with death. initiating movements or changing from one motor pattern to another\nCerebrovascular A sudden disturbance of cerebral function attributable to vascular\nthat is associated with Parkinson’s disease. accident disease, principally thrombosis, haemorrhage, or embolism. See stroke."
  },
  {
    "id": 519,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "vascular A sudden disturbance of cerebral function attributable to vascular\nthat is associated with Parkinson’s disease. accident disease, principally thrombosis, haemorrhage, or embolism. See stroke. Altered mental status A changed level of awareness or mental state that falls short of\nCognitive Mental processes associated with thinking. These include reasoning,\nunconsciousness which is often induced by substance intake or other\nremembering, judgement, problem-solving and planning. mental or neurological conditions. Examples include confusion and\ndisorientation. See delirium and confusional state."
  },
  {
    "id": 520,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "by substance intake or other\nremembering, judgement, problem-solving and planning. mental or neurological conditions. Examples include confusion and\ndisorientation. See delirium and confusional state. Cognitive behavioural Psychological treatment that combines cognitive components (aimed at\ntherapy (CBT) thinking differently, for example through identifying and challenging\nAlzheimer's disease A primary degenerative cerebral disease of unknown etiology in\nunrealistic negative thoughts) and behavioural components (aimed at\nthe majority of cases with characteristic neuropathological and\ndoing things differently, for example by helping the person to do more\nneurochemical features. The disorder is usually insidious in onset and\nrewarding activities)."
  },
  {
    "id": 521,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "haracteristic neuropathological and\ndoing things differently, for example by helping the person to do more\nneurochemical features. The disorder is usually insidious in onset and\nrewarding activities). develops slowly but steadily over a period of several years. Comorbid, comorbidity Describing diseases or disorders that exist simultaneously. Anticholinergic side- Anticholinergic medicines block the effects of acetylcholine at\neffects muscarinic receptors. Anticholinergic effects include dryness of the Confidentiality Privacy in the context of privileged communication (such as patient\nmouth, urinary frequency or retention, palpitations and sinus doctor consultations) and medical records is safeguarded. tachycardia."
  },
  {
    "id": 522,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "Privacy in the context of privileged communication (such as patient\nmouth, urinary frequency or retention, palpitations and sinus doctor consultations) and medical records is safeguarded. tachycardia. Confusion, A state of impaired consciousness associated with acute or chronic\nAplastic anaemia A disease characterized by the inability of blood stem cells to confusional state cerebral organic disease. Clinically it is characterized by\ngenerate new mature cells. This disease is also characterised by low disorientation, slowness of mental processes with scanty association\nlevels of red blood cells, white blood cells, and platelets. This disease of ideas, apathy, lack of initiative, fatigue, and poor attention."
  },
  {
    "id": 523,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ation, slowness of mental processes with scanty association\nlevels of red blood cells, white blood cells, and platelets. This disease of ideas, apathy, lack of initiative, fatigue, and poor attention. In mild\nmay present with pallor, fatigue, dizziness, increased risk of infection confusional states, rational responses and behaviour may be\nor increased bruising or bleeding. provoked by examination but more severe degrees of the disorder\nrender the individual unable to retain contact with the environment. TERM DEFINITION TERM DEFINITION\nContingency A structured method of rewarding certain desired behaviours, such Disorganized behaviour Behaviour including posture, gait, and other activity that is unpredictable or\nmanagement therapy as attending treatment and avoiding harmful substance use."
  },
  {
    "id": 524,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "red behaviours, such Disorganized behaviour Behaviour including posture, gait, and other activity that is unpredictable or\nmanagement therapy as attending treatment and avoiding harmful substance use. Rewards not goal-directed (e.g., shouting at strangers on the street). for desired behaviours are reduced over time as the natural rewards\nDistractibility Difficulty concentrating and focusing on tasks; attention is easily\nbecome established. diverted by extraneous stimuli. Convulsion, convulsive Clinical or subclinical disturbances of cortical function due to a\nDystonia Sustained muscle contraction or involuntary movements that can\nmovement sudden, abnormal, excessive, and disorganized discharge of brain\nlead to fixed abnormal postures. See tardive dyskinesia. cells (see seizure)."
  },
  {
    "id": 525,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "le contraction or involuntary movements that can\nmovement sudden, abnormal, excessive, and disorganized discharge of brain\nlead to fixed abnormal postures. See tardive dyskinesia. cells (see seizure). Clinical manifestations include abnormal motor,\nsensory and psychic phenomena. Eclampsia Any condition affecting pregnant women, characterized by seizure or\nconvulsions newly arising in pregnancy."
  },
  {
    "id": 526,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "e). Clinical manifestations include abnormal motor,\nsensory and psychic phenomena. Eclampsia Any condition affecting pregnant women, characterized by seizure or\nconvulsions newly arising in pregnancy. The condition is often associated\nDelirium Transient fluctuating mental state characterized by disturbed\nwith pregnancy-induced hypertension, convulsions, seizure, anxiety,\nattention (i.e., reduced ability to direct, focus, sustain, and shift\nepigastric pain, severe headache, blurred vision, proteinuria, and\nattention) and awareness (i.e., reduced orientation to the\noedema that may occur during pregnancy, labour, or the puerperium. environment) that develops over a short period of time and tends to\nfluctuate during the course of a day."
  },
  {
    "id": 527,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "reduced orientation to the\noedema that may occur during pregnancy, labour, or the puerperium. environment) that develops over a short period of time and tends to\nfluctuate during the course of a day. It is accompanied by (other) Elevated mood A positive mood state typically characterized by increased energy and\ndisturbances of perception, memory, thinking, emotions or self-esteem which may be out of proportion to the individual's life\npsychomotor functions. It may result from acute organic causes such circumstances. as infections, medication, metabolic abnormalities, substance Extrapyramidal Abnormalities in muscle movement, mostly caused by antipsychotic\nintoxication or substance withdrawal. side-effects / symptoms medication."
  },
  {
    "id": 528,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "medication, metabolic abnormalities, substance Extrapyramidal Abnormalities in muscle movement, mostly caused by antipsychotic\nintoxication or substance withdrawal. side-effects / symptoms medication. These include muscle tremors, stiffness, spasms and/or\nDelusion Fixed belief that is contrary to available evidence. It cannot be (EPS) akathisia. changed by rational argument and is not accepted by other members\nFamily therapy Counselling that entails multiple (usually more than six) planned\nof the person’s culture or subculture (i.e., it is not an aspect of\nsessions over a period of months. It should be delivered to individual\nreligious faith)."
  },
  {
    "id": 529,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ls multiple (usually more than six) planned\nof the person’s culture or subculture (i.e., it is not an aspect of\nsessions over a period of months. It should be delivered to individual\nreligious faith). families or groups of families, and should include the person living\nDetoxification The process by which an individual is withdrawn from the effects of a with mental illness, if feasible. It has supportive and educational or\npsychoactive substance. Also referring to a clinical procedure, the treatment functions. It often includes negotiated problem-solving or\nwithdrawal process is carried out in a safe and effective manner, such crisis management work. that withdrawal symptoms are minimized."
  },
  {
    "id": 530,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "atment functions. It often includes negotiated problem-solving or\nwithdrawal process is carried out in a safe and effective manner, such crisis management work. that withdrawal symptoms are minimized. Fetal alcohol syndrome Fetal alcohol syndrome is a malformation syndrome caused by\nDisability Any restriction or lack (resulting from an impairment) of ability to maternal consumption of alcohol during pregnancy. It is characterized\nperform an activity in the manner, or within the range, considered to by prenatal and/or postnatal growth deficiency and a unique cluster\nbe normal for a human being."
  },
  {
    "id": 531,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ng pregnancy. It is characterized\nperform an activity in the manner, or within the range, considered to by prenatal and/or postnatal growth deficiency and a unique cluster\nbe normal for a human being. The term disability reflects the of minor facial anomalies that presents across all ethnic groups, is\nconsequences of impairment in terms of functional performance and identifiable at birth, and does not diminish with age. Affected children\nactivity by the individual."
  },
  {
    "id": 532,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ents across all ethnic groups, is\nconsequences of impairment in terms of functional performance and identifiable at birth, and does not diminish with age. Affected children\nactivity by the individual. present severe central nervous system abnormalities including:\nmicrocephaly, cognitive and behavioural impairment (intellectual\nDisinhibited behaviour, Lack of restraint manifested in disregard for social conventions,\ndisability, deficit in general cognition, learning and language,\ndisinhibition impulsivity and poor risk assessment. It can affect motor, emotional,\nexecutive function, visual-spatial processing, memory, and attention). cognitive and perceptual aspects of a person’s functioning. Fits Colloquial term for convulsions. See convulsion."
  },
  {
    "id": 533,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "tor, emotional,\nexecutive function, visual-spatial processing, memory, and attention). cognitive and perceptual aspects of a person’s functioning. Fits Colloquial term for convulsions. See convulsion. Disorganized / A disturbance in the associative thought process typically manifested\ndisordered thinking in speech in which the person shifts suddenly from Focal deficits Neurological signs that are observable bodily phenomena or\none topic to another that is unrelated or minimally related to the first. responses suggestive of the localization of a relatively circumscribed\nThe individual gives no indication of being aware of the lesion of the nervous system. disconnectedness or illogicality of his or her thinking."
  },
  {
    "id": 534,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "estive of the localization of a relatively circumscribed\nThe individual gives no indication of being aware of the lesion of the nervous system. disconnectedness or illogicality of his or her thinking. GLOSSARY 161\n\n162\nGLOSSARY\nTERM DEFINITION TERM DEFINITION\nHallucination False perception of reality: seeing, hearing, feeling, smelling or Irritability, A mood state characterized by being easily annoyed and provoked to\ntasting things that are not real. irritable mood anger, out of proportion to the circumstances. Hepatic Abnormal mental state including drowsiness, confusion or coma Maculopapular rash A rash that consists of both macules (flat (impalpable), circumscribed\nencephalopathy caused by liver dysfunction. areas of skin or areas of altered skin colour (e.g."
  },
  {
    "id": 535,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "fusion or coma Maculopapular rash A rash that consists of both macules (flat (impalpable), circumscribed\nencephalopathy caused by liver dysfunction. areas of skin or areas of altered skin colour (e.g. freckles)) and\npapules (small raised spots on the skin, often dome-shaped and less\nHerbal products A range of folk medicines, many of them empirically discovered\nthan 5 mm in diameter). hundreds of years ago to be effective, derived from or consisting of\nportions of plants. In many cultures, knowledge about the efficacy of Meningeal irritation Irritation of the layers of tissue that cover the brain and spinal cord,\nherbal remedies is carefully preserved and handed on by oral usually caused by an infection. tradition from one generation to the next."
  },
  {
    "id": 536,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "on of the layers of tissue that cover the brain and spinal cord,\nherbal remedies is carefully preserved and handed on by oral usually caused by an infection. tradition from one generation to the next. Meningitis A disease of the meninges (the membranes covering the brain and\nHyperarousal Intense and prolonged autonomic discharge accompanied by a state spinal cord) usually caused by an infection with a bacterial, viral,\nof frozen watchfulness and alertness to environmental stimuli. Such fungal, or parasitic source. responses are seen most frequently in post-traumatic stress disorders\nMotivational A structured therapy (lasting 4 or less sessions) to help people with\nand often associated with substance use or withdrawal. enhancement therapy substance use disorders."
  },
  {
    "id": 537,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "stress disorders\nMotivational A structured therapy (lasting 4 or less sessions) to help people with\nand often associated with substance use or withdrawal. enhancement therapy substance use disorders. It involves an approach to motivate change\nHypersensitivity Hypersensitivity reactions are the adverse effects of pharmaceutical by using motivational interviewing techniques i.e. engaging the\nreaction formulations (including active drugs and excipients) that clinically person in a discussion about their substance use including perceived\nresemble allergy."
  },
  {
    "id": 538,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "iewing techniques i.e. engaging the\nreaction formulations (including active drugs and excipients) that clinically person in a discussion about their substance use including perceived\nresemble allergy. It belongs to type B adverse drug reactions, which benefits and harms in relation to the persons own values, avoiding\nare defined by the WHO as the dose-independent, unpredictable, arguing with the person if there is resistance, encouraging the person\nnoxious, and unintended response to a medicine taken at a dose to decide for themselves what their goal may be. normally used in humans. It covers many different clinical phenotypes\nMotor twitching See convulsion. with variable onset and severity."
  },
  {
    "id": 539,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "taken at a dose to decide for themselves what their goal may be. normally used in humans. It covers many different clinical phenotypes\nMotor twitching See convulsion. with variable onset and severity. Myasthenia gravis A disorder of neuromuscular transmission characterized by fatigable\nIdiosyncratic reaction Individual, unpredictable, and non-dose-dependent response to any\nweakness of cranial and skeletal muscles. Clinical manifestations may\nsubstance: drowsiness or euphoria, flushing, carpopedal spasms,\ninclude fluctuating diplopia and ptosis, and fatigable weakness of\napnoea, etc. facial, bulbar, respiratory, and proximal limb muscles."
  },
  {
    "id": 540,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "substance: drowsiness or euphoria, flushing, carpopedal spasms,\ninclude fluctuating diplopia and ptosis, and fatigable weakness of\napnoea, etc. facial, bulbar, respiratory, and proximal limb muscles. Informed consent The process by which the health care provider discloses appropriate\nNeonatal abstinence Intrauterine exposure to addictive drugs can lead to neonatal\ninformation to a person who can then make a voluntary choice to accept or\nsyndrome withdrawal symptoms. Withdrawal symptoms are usually\nrefuse treatment. informed consent includes a discussion of the following\nneurological, preventing normal autonomic function."
  },
  {
    "id": 541,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "to accept or\nsyndrome withdrawal symptoms. Withdrawal symptoms are usually\nrefuse treatment. informed consent includes a discussion of the following\nneurological, preventing normal autonomic function. The clinical\nelements: the nature of the decision/procedure; reasonable alternatives to\npresentation of drug withdrawal is variable and dependent on several\nthe proposed intervention; the relevant risks, benefits, and uncertainties\nfactors, such as, the type and dose of drug used, and rate of\nrelated to each alternative; assessment of the person’s understanding, and\nmetabolism and excretion of the mother and infant. the acceptance of the intervention by the person. Neuroinfection Infection involving the brain and/or spinal cord."
  },
  {
    "id": 542,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "of the person’s understanding, and\nmetabolism and excretion of the mother and infant. the acceptance of the intervention by the person. Neuroinfection Infection involving the brain and/or spinal cord. Interpersonal therapy Psychological treatment that focuses on the link between depressive\n(IPT) symptoms and interpersonal problems, especially those involving Neuroleptic malignant A rare but life-threatening condition caused by antipsychotic\ngrief, disputes, life changes and social isolation. It is also known as syndrome (NMS) medications, which is characterised by fever, delirium, muscular\nInterpersonal Psychotherapy. rigidity and high blood pressure."
  },
  {
    "id": 543,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "s, life changes and social isolation. It is also known as syndrome (NMS) medications, which is characterised by fever, delirium, muscular\nInterpersonal Psychotherapy. rigidity and high blood pressure. TERM DEFINITION TERM DEFINITION\nOccupational therapy Therapy designed to help individuals improve their independence in Pruritus Itching; an intense sensation that produces the urge to rub or scratch\ndaily living activities through rehabilitation, exercises and the use of the skin to obtain relief. assistive devices. In addition, such therapy provides activities to\nPseudodementia A disorder resembling dementia but not due to organic brain disease\npromote growth, self-fulfilment and self-esteem."
  },
  {
    "id": 544,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "assistive devices. In addition, such therapy provides activities to\nPseudodementia A disorder resembling dementia but not due to organic brain disease\npromote growth, self-fulfilment and self-esteem. and potentially reversible by treatment; can manifest as symptoms of\nOppositional behaviour Markedly defiant, disobedient, provocative or spiteful behaviour that depression in some older adults. may be manifest in prevailing, persistent angry or irritable mood,\nPsychoeducation The process of teaching people with MNS disorders and their carers/\noften accompanied by severe temper outbursts or in headstrong,\nfamily members about the nature of the illness, including its likely causes,\nargumentative and defiant behaviour. progression, consequences, prognosis, treatment and alternatives."
  },
  {
    "id": 545,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ts or in headstrong,\nfamily members about the nature of the illness, including its likely causes,\nargumentative and defiant behaviour. progression, consequences, prognosis, treatment and alternatives. Orthostatic Sudden drop of blood pressure that can occur when one changes\nQT prolongation A potential medication induced side-effect of ventricular myocardial\nhypotension position from lying to sitting or standing up, usually leading to\nrepolarization characterized by a prolonged QT interval on the\nfeelings of light-headedness or dizziness. It is not life-threatening. electrocardiogram (ECG) that can lead to symptomatic ventricular\nParent Skills Training A family of treatment programs that aims to change parenting beha- arrhythmias and an increased risk of sudden cardiac death."
  },
  {
    "id": 546,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "gram (ECG) that can lead to symptomatic ventricular\nParent Skills Training A family of treatment programs that aims to change parenting beha- arrhythmias and an increased risk of sudden cardiac death. viours and strengthen confidence in adoption of effective parenting\nRacing thoughts Rapid thought pattern with tangential movement from one idea to\nstrategies. It involves teaching parents emotional communication and\nthe next often associated with mania or other mental illnesses. positive parent-child interaction skills, and positive reinforcement\nmethods to improve children/adolescent’s behaviour and functioning. Relapse A return to drinking or other drug use after a period, of abstinence,\noften accompanied by reinstatement of dependence symptoms."
  },
  {
    "id": 547,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ods to improve children/adolescent’s behaviour and functioning. Relapse A return to drinking or other drug use after a period, of abstinence,\noften accompanied by reinstatement of dependence symptoms. The\nPhaeochromocytoma A neuroendocrine tumour of the medulla of the adrenal glands\nterm is also used to indicate return of symptoms of MNS disorder\ncausing symptoms (mainly headaches, palpitations and excess\nafter a period of recovery. sweating) and signs (mainly hypertension, weight loss and diabetes)\nreflecting the effects of epinephrine and norepinephrine on alpha- and Relaxation training Involves training in techniques such as breathing exercises to elicit\nbeta-adrenergic receptors. the relaxation response. Polyneuropathy Disorder and functional disturbance of the peripheral nerves."
  },
  {
    "id": 548,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "g Involves training in techniques such as breathing exercises to elicit\nbeta-adrenergic receptors. the relaxation response. Polyneuropathy Disorder and functional disturbance of the peripheral nerves. This Respiratory depression Inadequate slow breathing rate, resulting in insufficient oxygen. may be manifest as numbness of the extremities, paraesthesia (\"pins Common causes include brain injury and intoxication (e.g. due to\nand needles\" sensations), weakness of the limbs, or wasting of the benzodiazepines). muscles and loss of deep tendon reflexes. Respite care Provision of temporary health-care facilities to a person normally\nPolytherapy Provision of more than one medicine at the same time for the same cared for at home. condition."
  },
  {
    "id": 549,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "on reflexes. Respite care Provision of temporary health-care facilities to a person normally\nPolytherapy Provision of more than one medicine at the same time for the same cared for at home. condition. Rigidity Resistance to the passive movement of a limb that persists\nPorphyria Porphyrias constitute a group of diseases characterized by intermittent throughout its range. It is a symptom of parkinsonism. neuro-visceral manifestations, cutaneous lesions or by the combination of Saving group A saving activity in which the poor can accumulate a large amount of\nboth. Clinical signs of the disease usually appear in adulthood, but some money quickly by pooling their savings in a common fund which can\nporphyrias affect children."
  },
  {
    "id": 550,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "can accumulate a large amount of\nboth. Clinical signs of the disease usually appear in adulthood, but some money quickly by pooling their savings in a common fund which can\nporphyrias affect children. Direct or indirect neurotoxicity may cause then be used by the group or a member of the group for productive\nneurological manifestations. investment. Privacy The state of being free from unsanctioned intrusion. For example, Seizure Episode of brain malfunction due to disturbances of cortical function\npersonal privacy in daily living activities (e.g. for clients in residential resulting in sudden, abnormal, excessive, and disorganized discharge\nfacilities) or confidential health records. of brain cells."
  },
  {
    "id": 551,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "nal privacy in daily living activities (e.g. for clients in residential resulting in sudden, abnormal, excessive, and disorganized discharge\nfacilities) or confidential health records. of brain cells. Clinical manifestations include abnormal motor,\nProblem-solving Psychological treatment that involves the systematic use of problem iden- sensory and psychic phenomena. counselling tification and problem-solving techniques over a number of sessions. Self-harm Intentional self-inflicted poisoning or injury to oneself, which may or\nmay not have a fatal intent or outcome."
  },
  {
    "id": 552,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "unselling tification and problem-solving techniques over a number of sessions. Self-harm Intentional self-inflicted poisoning or injury to oneself, which may or\nmay not have a fatal intent or outcome. GLOSSARY 163\n\n164\nGLOSSARY\nTERM DEFINITION TERM DEFINITION\nSerotonin syndrome Characterised by an excess of serotonin in the central nervous Suicidal thoughts / Thoughts, ideas, or ruminations about the possibility of ending one's\nsystem, associated with the use of various agents, including selective ideation life, ranging from thinking that one would be better off dead to\nserotonin reuptake inhibitors (SSRIs). Serotonin syndrome may result formulation of elaborate plans."
  },
  {
    "id": 553,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ents, including selective ideation life, ranging from thinking that one would be better off dead to\nserotonin reuptake inhibitors (SSRIs). Serotonin syndrome may result formulation of elaborate plans. in muscle rigidity, myoclonus, agitation, confusion, hyperthermia,\nTardive dyskinesia This is dystonia characterized by twisting and sustained muscle\nhyperreflexia as well as dysautonomic symptoms, with a risk of\nspasms that affect regions of the head, neck, and occasionally, the\nshock with low peripheral vascular resistance, seizures, coma,\nback. It may not improve after stopping the antipsychotic medicine. rhabdomyolysis and/or disseminated intravascular coagulation (DIC). Temper tantrum An emotional outburst from a child or those in emotional distress."
  },
  {
    "id": 554,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "improve after stopping the antipsychotic medicine. rhabdomyolysis and/or disseminated intravascular coagulation (DIC). Temper tantrum An emotional outburst from a child or those in emotional distress. Slurred speech Speech with indistinctive pronunciation. Thrombocytopenia Abnormally low number of platelets in the blood. This disease may\nSocial network A construct of analytical sociology referring to the characteristics of\npresent with increased bruising or haemorrhaging. Confirmation is by\nthe social linkages among people as a means of understanding their\nidentification of decreased platelet count in a blood sample. behaviour, rather than focusing on the attributes of individuals."
  },
  {
    "id": 555,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "is by\nthe social linkages among people as a means of understanding their\nidentification of decreased platelet count in a blood sample. behaviour, rather than focusing on the attributes of individuals. Toxic epidermal Life-threatening skin peeling that is usually caused by a reaction to a\nSocial withdrawal Inability of a person to engage in age appropriate activities or\nnecrolysis medicine or infection. It is similar to but more severe than Stevens-\ninteractions with his or her peers or family members. Johnson syndrome. Spider naevus A cluster of minute red blood vessels visible under the skin, occurring\nTraditional Healing A system of treatment modalities based on indigenous knowledge of\ntypically during pregnancy or as a symptom of certain diseases (e.g."
  },
  {
    "id": 556,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ood vessels visible under the skin, occurring\nTraditional Healing A system of treatment modalities based on indigenous knowledge of\ntypically during pregnancy or as a symptom of certain diseases (e.g. different cultures pertaining to healing. cirrhosis or acne rosacea). Transient ischaemic A transient episode of acute focal neurological dysfunction caused by\nSpinal abscess A condition of the spinal cord, caused by an infection with a bacterial,\nattack (TIA) focal ischemia of the brain or retina, without demonstrated acute\nviral, or fungal source. This condition is characterized by a focal accumu-\ninfarction in the clinically relevant area of the brain. Symptoms should\nlation of purulent material within the spinal cord. This condition may\nresolve completely within 24 hours."
  },
  {
    "id": 557,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "d by a focal accumu-\ninfarction in the clinically relevant area of the brain. Symptoms should\nlation of purulent material within the spinal cord. This condition may\nresolve completely within 24 hours. present with fever, back pain and neurological deficits. Transmission is\nthrough haematogenous spread of the infectious agent. Tremor Trembling or shaking movements, usually of the fingers, that is an\ninvoluntary oscillation of a body part. Status epilepticus Defined as 5 min or more of continuous clinical and/or electrographic\nseizure activity or recurrent seizure activity without recovery (returning Vitamin K deficiency Lack of vitamin K can cause severe bleeding in newborn babies\nto baseline) between seizures; it can be convulsive or non-convulsive."
  },
  {
    "id": 558,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "t seizure activity without recovery (returning Vitamin K deficiency Lack of vitamin K can cause severe bleeding in newborn babies\nto baseline) between seizures; it can be convulsive or non-convulsive. disease of the newborn usually immediately after birth but sometimes up to 6 months of age. Bleeding may be cutaneous, gastro-intestinal, intracranial or\nStevens-Johnson Life-threatening skin condition characterized by painful skin peeling,\nmucosal. Maternal intake of antiepiletic medicines is one of its\nsyndrome ulcers, blisters and crusting of mucocutaneous tissues such as mouth,\ncauses. lips, throat, tongue, eyes and genitals, sometimes associated with\nfever."
  },
  {
    "id": 559,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "of antiepiletic medicines is one of its\nsyndrome ulcers, blisters and crusting of mucocutaneous tissues such as mouth,\ncauses. lips, throat, tongue, eyes and genitals, sometimes associated with\nfever. It is most often caused by severe reaction to medications, Wandering People living with dementia feel the urge to walk about and in some\nespecially antiepileptic medicines. cases leave their homes. They can often experience problems with\norientation, which may cause them to become lost. Stigma A distinguishing mark establishing a demarcation between the\nstigmatized person and others attributing negative characteristics to\nthis person. The stigma attached to mental illness often leads to\nsocial exclusion and discrimination and creates an additional burden\nfor the affected individual."
  },
  {
    "id": 560,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "ributing negative characteristics to\nthis person. The stigma attached to mental illness often leads to\nsocial exclusion and discrimination and creates an additional burden\nfor the affected individual. Stroke See cerebrovascular accident (CVA). Mental, neurological and substance use (MNS) disorders are highly prevalent,\naccounting for a substantial burden of disease and disability globally. In order to\nbridge the gap between available resources and the significant need for services, the\nWorld Health Organization launched the Mental Health Gap Action Programme (mhGAP). The objective of mhGAP is to scale-up care and services using evidence-based interventions\nfor prevention and management of priority MNS conditions."
  },
  {
    "id": 561,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "hed the Mental Health Gap Action Programme (mhGAP). The objective of mhGAP is to scale-up care and services using evidence-based interventions\nfor prevention and management of priority MNS conditions. The mhGAP Intervention Guide\nversion 1.0 for MNS disorders for non-specialist health settings was developed in 2010 as\na simple technical tool to allow for integrated management of priority MNS conditions using\nprotocols for clinical decision-making. With uptake in over 90 countries, mhGAP-IG 1.0 version has had widespread success. It is our pleasure to\npresent mhGAP version 2.0, with updates incorporating new evidence-based guidance, enhanced usability,\nand new sections to expand its use by both health care providers as well as programme managers."
  },
  {
    "id": 562,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "o\npresent mhGAP version 2.0, with updates incorporating new evidence-based guidance, enhanced usability,\nand new sections to expand its use by both health care providers as well as programme managers. It is our hope that this guide will continue to provide the road-map to deliver care and services for people with\nMNS disorders around the world and lead us closer to achieving the goal of universal health coverage."
  },
  {
    "id": 563,
    "source": "WHO_mhGAP_doc_2d7811",
    "text": "that this guide will continue to provide the road-map to deliver care and services for people with\nMNS disorders around the world and lead us closer to achieving the goal of universal health coverage. The mhGAP-IG version 2.0 includes the following sections:\nE ssential Care & Practice\nM aster Chart\nDepression\nFor more information,\nPsychoses\nplease contact:\nEpilepsy\nDepartment of Mental Health and Child & Adolescent Mental & Behavioural Disorders\nSubstance Abuse\nDementia\nWorld Health Organization\nAvenue Appia 20 Disorders due to Substance Use\nCH-1211 Geneva 27 Self-harm / Suicide\nSwitzerland\nOther Significant Mental Health Complaints\nEmail: mhgap-info@who.int Implementation of mhGAP-IG\nWebsite: www.who.int/mental_health/mhgap"
  }
]